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ABSTRACT 
 
Development of Portable Diffuse Optical Spectroscopic Systems For Treatment Monitoring 
Christopher J. Fong 
 
 
The goal of this dissertation is to demonstrate the utility of portable, small-scale diffuse optical 
spectroscopic (DOS) systems for the diagnosis and treatment monitoring of various diseases. 
These systems employ near-infrared light (wavelength range of 650nm to 950nm) to probe human 
tissue and are sensitive to changes in scattering and absorption properties of tissues. The absorption 
is mainly influenced by the components of blood, namely oxy- and deoxy-hemoglobin (HbO2 and 
Hb) and parameters that can be derived from them (e.g. total hemoglobin concentration [THb] and 
oxygen saturation, StO2). Therefore, I focused on diseases in which these parameters change, 
which includes vascular diseases such as Peripheral Atrial Disease (PAD) and Infantile 
Hemangiomas (IH) as well as musculoskeletal autoimmune diseases such as Rheumatoid Arthritis 
(RA). In each of these specific diseases, current monitoring techniques are limited by their 
sensitivity to disease progression or simply do not exist as a quantitative metric.  
As part of this project, I first designed and built a wireless handheld DOS device (WHDD) that 
can perform DOS measurements at various tissue depths. This device was used in a 15-patient 
pilot study for infantile hemangiomas (IH) to differentiate diseased skin from normal skin and 
monitor the vascular changes during intervention. In another study, I compare the ultra-small form-
factor WHDD’s ability to monitor synovitis and disease progression during a patient’s treatment 
of RA against the capabilities of a proven frequency domain optical tomographic (FDOT) system 
that has shown to differentiate patients with and without RA. Learning from clinical utility of the 
WHDD from these two studies, I adapted the WHDD technology to develop a compact multi-
channel DOS measurement system to monitor perfusion changes in the lower extremities before 
and after surgical intervention for patients with peripheral artery disease (PAD). Using this multi-
channel system, which we called the vascular optical spectroscopic measurement (VOSM) system, 
our group conducted a 20-subject pilot study to quantify its ability to monitor blood perfusion 
before and after revascularization of stenotic arteries in the lower extremities. This proof-of-
concept study demonstrated how DOS may help vascular surgeons perform revascularization 
procedures in the operating room and assists in post-operative treatment monitoring of vascular 
diseases.
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For Aunt Linda 
  1 
1 Background and Motivation 
1.1 Overall Goal and Thesis Outline 
The overall goal of the dissertation is to demonstrate the clinical utility of portable, small-scale 
diffuse optical spectroscopy (DOS) systems for the diagnosis and treatment monitoring of various 
diseases. DOS is an optical imaging technique that uses infrared laser light to investigate functional 
changes (i.e. oxygenation and metabolism) in the body. The physical principles of DOS allows 
this by having the near-infrared (NIR) light penetrate biological tissue such as skin, fat, and 
underlying muscle and is absorbed and scattered within the tissue. The attenuation of NIR light in 
tissue is due to chromophores such as oxy- and deoxy-hemoglobin, or by light scattering from 
cellular structures. Since these chromophores are biological markers that can be affected during 
the progression of various diseases, it provides an opportunity to use DOS to diagnose and monitor 
diseases. Unfortunately, many investigational DOS systems lack the portability and ease of use to 
be implemented in a clinical setting.  
Development of a low-cost wireless handheld DOS device (WHDD) with a small form factor, 
portable enough to be utilized in various clinical settings offers a solution to these shortcomings 
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with its ability to measure hemodynamic and optical changes without ionizing radiation or contrast 
injection. To test this hypothesis, I pursued the following four specific aims: 
SPECIFIC AIM 1: Design a wireless handheld DOS device (WHDD) to perform optical 
measurements on patients with medical condition that lead to a change in tissue optical properties.  
SPECIFIC AIM 2: Use the WHDD in a longitudinal pilot study to assess optical changes during 
treatment and natural history of infantile hemangiomas (IH), to determine the clinical utility of the 
WHDD. 
SPECIFIC AIM 3: Compare the sensitivity of optical measurements of the WHDD to the proven 
capabilities of a frequency domain optical tomographic (FDOT) system for a clinical study 
monitoring the affects of treatments for patients with RA. 
SPECIFIC AIM 4: Based on the findings and experiences in clinical studies performed under 
specific aims 2 and 3, design, build, and verify within a clinical study a compact multi-channel 
DOS system to monitor perfusion changes in leg extremities before and after intraoperative 
intervention for patients with peripheral artery disease (PAD). 
Current diffuse optical imaging systems are mostly large scale, making them difficult to transport 
and use in exam and operating rooms. The new technology presented in this thesis demonstrates 
the potential of how use-of-use DOS systems can provide sensitive measurements for monitor and 
diagnosis to various diseases without the use of contrast agents or ionizing radiation. Furthermore, 
the evaluation of this technology to monitor multiple diseases demonstrates the breadth of this 
technology. 
The dissertation is organized as follows: In Chapter 1, I provide an overview of DOS technology 
and its use to measure tissue chromophores such as oxy- and deoxy-hemoglobin along with other 
functional blood parameters. I also explain the signal detection techniques that were implemented 
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within the instrumentation of my thesis work. Lastly within this chapter, I provide a short 
introduction of three medical applications that are currently studied with DOS technology to 
provide a foundation of the work in this thesis. 
In Chapter 2, I introduce the previous work of a WHDD that was built for verification of a DOS 
reconstruction algorithm to compute hemodynamic parameters such as oxy- and deoxy-
hemoglobin (HbO2 and Hb). I will then discuss the design of an updated WHDD that can easily 
and reliably be used in a clinical setting. I will also describe the how I verified the WHDD ability 
to reconstruct optical properties with phantom measurement as well as its ability to make 
repeatable measurements. 
In Chapter 3, I describe how the updated WHDD has the potential to be used to help physicians 
manage treatment of infantile hemangiomas (IHs) in a 15-subject longitudinal pilot study. This 
will include study population, cohort selection and imaging imaging protocol. I explain the 
statistical analysis for evaluating WHDD ability to track IH progression within its treatment and 
natural history. Finally, I describe how the two-layer discrimination of optical properties can be 
applied to this application. I will describe a new reconstruction algorithm that has the ability to 
compute optical properties in two layers and I demonstrate its ability by presenting a numerical 
simulation study in which I evaluate the accuracy of the algorithm with dozens of different 
simulations. A two-layer phantom study is also presented to show the ability of the algorithm with 
physical experiments. 
In Chapter 4, I compare the sensitivity of the DOS-WHDD probe in monitoring the treatment 
efficacy in patients with rheumatoid arthritis (RA) to that of a more proven method in frequency-
domain optical tomographic (fDOT) imaging. I will describe an fDOT system and it’s capabilities 
that our lab has used in a previous study and how the fDOT and the WHDD probe was used in a 
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20-subject longitudinal study. This will include the study protocol, which includes several different 
clinical modalities for comparison, along with the optical imaging protocol. With only a single 
patient enrolled over a 4-year recruitment period, I will present a case study and demonstrate how 
fDOT and WHDD optical measures performed compared to that of the other clinical modalities. 
In Chapter 5, I discuss the expansion of the WHDD design into a new multi-channel DOS system, 
which we call Using this multi-channel system, which we called the vascular optical spectroscopic 
measurement (VOSM) system, that can be used to monitor revascularization treatments for 
patients with PAD. I will explain the design details of VOSM and how the multiple channels 
interface to the measurement subject’s foot. I will describe how the system was characterized by 
presenting results from noise and repeatability experiments. In addition, I will describe the initial 
results of a 100-patient clinical study that uses VOSM to monitor perfusion in patients before and 
after their revascularization treatment. Furthermore, I describe the methods for handling the data 
sets as well as feature extraction and analysis techniques. I explain the statistical analysis for 
evaluating VOSM ability to monitor and assess severity as well as localize PAD in the foot using 
angiosome theory. 
Finally, I will conclude my thesis by addressing future directions for my thesis work within the 
three of the clinical studies to improve the efficacy and other limitations that were observed in my 
work. I will introduce current research that is being done to improve the instrumentation and 
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methods on how to improve the instrumentations use in clinical settings and improvements that 
could be made on interfacing to the subject.  
1.2 Diffuse Optical Spectroscopy and Tomography 
1.2.1 Introduction 
When light interacts with tissue it can be absorbed and scattered. The amount of absorption and 
scattering is dependent on the tissue’s optical properties. These properties are represented by the 
wavelength-dependent absorption coefficient (µa), scattering coefficient (µs) and anisotorpy factor 
(g). The µa represents the probability of a photon being absorbed per unit length. It is proportional 
to the number of chromophores that absorb the light as it propagates through the tissue. The µs 
represents the probability of a photon being scattered per unit length and the anisotropy factor 
represents the direction at which light scatters within the medium. The value of g ranges between 
positive and negative one. A value of g=-1 implies a completely backward scattering medium, g=0 
an isotropic medium and g=1 is a completely forward scattering. Most biological tissues are highly 
forward scattering with a g > 0.9. Also widely used is the term reduced scattering coefficient, 
which is defined as µs’= µs(1-g). 
In diffuse optical spectroscopy (DOS) red and near-infrared light (650nm < λ < 900nm) are used 
to probe biological tissues. This wavelength range is used because light absorption is relatively 
low, enabling the light to penetrate deep into the tissue. The absorption coefficient increases 
rapidly as the wavelength of light deviates from the NIR as can be observed in Figure 1.1.  
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Figure 1.1 This image shows the absorption spectrum of major intrinsic chromophores in tissue, within the 
NIR wavelength range. 
 
 
In DOS, non-radiative energy (~1 to 2.5 eV) is delivered to one or more locations on the surface 
of the body part under investigation and back-reflected light intensities are measured at distances 
up to 10 cm. Using multiple wavelengths, we are able to extract the effect of certain chromophores 
within the body. Of special interest are the blood constituents oxy-hemoglobin (HbO2) and deoxy-
hemoglobin (Hb), which have distinctly different absorption spectra in the visible and near-
infrared wavelengths (Fig. 1.1). By performing measurements at multiple wavelengths, 
concentration of these chromophores as well as derived parameters such as total hemoglobin 
([HbT] = [HbO2] + [Hb]) and oxygen saturation ([HbO2]/[HbT]) can be obtained [1]. By gathering 
data at different wavelengths and using multi-wavelength reconstruction codes, measurements of 
these parameters can be generated.  
Using a reflectance geometry between the source and the detector, a banana-shaped curve 
describes the most-likely path of photons between the source and detector (Figure 1.2); therefore, 
the effective path length is greater than the geometric distance between the source and a detector. 
It is generally accepted that, for a source-detector separation of 3 cm, the region of maximum 
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brain/muscle sensitivity will be found between the source and detector fiber tip location, and 
roughly 1.5 cm below the surface of the skin, though a banana-shaped region of sensitivity extends 
both above and below this depth [2]. For our studies, we have assumed that our light penetration 
is about d/2 for a d source-detector distance. 
In diffuse optical tomography (DOT), the NIR light is also delivered to one or more locations on 
the surface of the body part under investigation and transmitted and/or back- reflected light 
intensities are measured [3-6], just as in DOS. If the spatial geometry of the imaging medium is 
know, illuminating the tissue from various spatially distributed source positions and measuring the 
transmitted and reflected light at a number of detector positions surrounding the sample, DOT 
generates 3D spatial maps of the absorption (ua, typically 0.01-1 cm-1) and scattering (us’, 
typically 10-100cm-1) of tissue back onto the 2D or 3D volume that is known.  
This makes DOT similar to X-ray computed tomography in terms of using electromagnetic 
radiation for generating imaging contrast, but they are different in several aspects. First, X-ray uses 
shorter wavelengths with higher ionizing energy (~5 to 150 keV), whereas DOT uses longer 
wavelengths with lower, non-ionizing energy (approximately 1 to 2.5 eV). As a result, DOT 
imaging, and its counterpart DOS, can be used more safely than X-ray imaging in applications and 
longitudinal studies. Secondly, while X-ray uses Beer-Lambert law and the inverse radon 
transform for the image reconstruction, direct inversion schemes cannot be used in DOT imaging. 
Unlike X-ray imaging DOT has to deal with multiple scattering events by cellular and sub-cellular 
tissue structures. Such scattering effects inside the tissue are taken into account by employing 
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appropriate light propagation model [7-11]. The reconstructed images of optical properties are 
obtained by solving the associated inverse problems. 
By gathering data at different wavelengths and using multi-wavelength image reconstruction 
codes, 2 and 3-dimensional maps of these and other parameters, such as blood volume, can be 
generated [12-20]. The DOT imagers in this thesis will be referred to as frequency-domain optical 
tomography (fDOT) imaging system that is used in Chapter 4 to study RA and DOS systems in 
this thesis will be referred to as wireless handheld DOS device (WHDD) and the vascular optical 
spectroscopy measurement (VOSM) system.  
 
Figure 1.2 Penetration depth of NIR light depends on adipose tissue thickness. In particular, the light goes 
deeper in the muscle tissue in the case of low subcutaneous fat (AT1) and reaches the shallow region of the 
muscle tissue in the case of high subcutaneous fat (AT2). 
 
1.2.2 Signal Detection Techniques for Differentiating Optical Properties 
While spectroscopy measures optical properties of within one- or two-dimensions, tomography 
makes the same measurements two- or three-dimensional space with a known spatial geometry. 
Thus, in optical tomography, anatomic shaped images of optical maps are produced, providing 
information of absorption and scattering properties within tissue. As with spectroscopy, when 
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multiple wavelengths are used for illumination, chromophore concentrations of Hb and HbO2 can 
be computed. 
There are several methods in which to perform optical imaging through tissue. Generally, the 
instrumentation operates in one of three possible modes: steady-state domain ︎also known as 
continuous wave ︎(CW) domain ︎, frequency domain (FD), or time domain (TD) (Figure 1.1). The 
CW mode uses a constant intensity light as a source and solely measures the attenuation of light 
intensity passing through tissues. This attenuation is usually wavelength dependent. This approach 
allows for simple low-cost instrumentation with high signal-to-noise-ratio (SNR) and faster data 
acquisition for dynamic signal detection. The disadvantage of this signal detection technique is 
that relatively low information can be derived from the detected signal, which makes it difficult to 
differentiate between the absorption and the scattering effects in tissues [21]. The Wireless 
Handheld DOS device (WHDD) that will be presented in Chapter 1 and the Vascular Optical 
Spectroscopic Measurement (VOSM) system in Chapter 5 both operate in CW mode, in which the 
light impinges on the tissue surface with a constant intensity and the intensity of the light 
transmitted through different sections of the tissue is detected. 
In TD systems, pico-second light pulses illuminate tissues and high speed detectors record 
temporal profiles of light (Temporal Point Spread Function (TPSP)) at different photon arrival 
times [22]. This approach yields much more information and helps to differentiate absorption and 
scattering properties in tissues. As a result, the TD mode can improve spatial resolution and 
sensitivity compared with the CW imaging mode. However, due to the very short time-gated 
detection, SNR is low and long data acquisition times are required. These characteristics also 
prevent the use of TD systems for studying sub-second hemodynamic effects. In addition, these 
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systems are rather expensive compared to CW and FD imaging modes, because of the fast time-
gated detection technology and high-speed pulse laser components that are required for imaging. 
FD systems constitute a compromise between CW and TD systems [23-25]. In FD mode, the 
incident light is modulated in the megahertz to gigahertz range, which causes so-called “photon 
density waves” (PDWs) to be generated and travel through the tissue [24]. Detection of amplitude 
and phase of those PDWs provides information about the damping and the time delay of the wave. 
The intensity attenuation and the phase shift of PDWs can be measured. FD systems are less 
expensive and offer higher SNR than TD system. In addition, FD systems can differentiate 
absorption and scattering more precisely and show better spatial resolution than the CW system. 
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However, the FD system is somewhat more expensive and has lower SNR than the CW system 
[26]. The FD mode of imaging is used in the fDOT finger imaging system discussed in Chapter 4. 
 
 
Figure 1.3 Diagram representing signal detection modes (a) time domain (TD), (b) frequency domain (FD), and 
(c) continuous wave (CW) modes 
  
Going from steady-state domain over frequency domain to time domain, the imaging systems 
become increasingly complex and, hence, the cost for these systems increases. However, with 
increasing complexity the amount of information available increases too. For example, absorption 
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and scattering properties can be better separated using frequency-domain data when compare to 
CW data. 
 
1.2.3 Applications of Diffuse Optical Imaging 
Diffuse optical imaging (DOI), which includes DOS and DOT, has various applications due to its 
high sensitivity to blood-dependent parameters. Medical problems that involve changes in the 
blood-related parameters could benefit from the use of DOI. Especially, cancerous tumors often 
exhibit higher vascularity and higher blood volume than normal tissues; blood oxygenation levels 
are often used to monitor the status of tumor progression. Currently, DOI imaging for cancer 
detection has been primarily focused on breast imaging. DOI is a safe, noninvasive and 
inexpensive imaging method compared to traditional X-ray mammography and MRI [27-30]. In 
many research studies, high total hemoglobin concentrations (THb) and oxygen saturation level 
have been used for diagnosis and monitoring the efficacy of cancer treatments [31, 32].  
The ability to monitor blood parameters such as [Hb] and [HbO2] in cancerous tumors also makes 
DOI a research tool to analyze vascular skin diseases such as melanoma [33-35]. Current studies 
examine hypoxia, hemoglobin absorption, and the spectral features in the NIR range. Current 
studies have found success in classifying between malignant and benign tumors using spectral 
features and separation in oxygenation levels between melanoma and normal skin. This research 
in melanoma makes the study of IH with DOS a good extension of vascular skin diseases, such as 
infantile hemangioma (IH). 
DOI has also been used to study exercise physiology by examining oxygenation of calf muscles 
before, during, and after exercise [36-38]. Exercise studies have provided insight to how oxidative 
metabolism increases and decrease during plantar flexion and exercise. These studies have also 
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provided information about the regional changes in oxygen availability during dynamic exercise. 
Such studies provide a foundation to study perfusion in the lower extremities for diseases such as 
peripheral artery disease (PAD).  
Another application is joint disease monitoring. Scattering coefficient changes are observed in the 
synovial fluid of joints affected by arthritis and inside the bones of patients with osteoarthritis. 
Hence several groups have focused their efforts on developing DOI systems for joint and bone 
imaging [39, 40].  
 
1.3 Review of Existing Portable Diffuse Optical Imaging Systems 
With the emergence of high-tech wearable devices over the past several, medical device 
technology has also miniaturized, including in the field of biomedical optics.  Portable and wireless 
optical imaging platforms have recently been developed for wearable technologies [41-45], 
endoscopy [46, 47], and breast cancer [48-50]. In addition, cell phone based technologies have 
been employed for general hemodynamic or spectrometer measurements [51-53]. 
A wearable patch-like device designed by Muehlemann et al. uses 4 CW sources and 4 detectors 
with 2 wavelengths [45]. Similarly, a larger, but still portable wearable brain-imaging system 
developed by Atsumori et al. [44] uses 8 CW sources and 8 detectors with 2 wavelengths for 
imaging the frontal cortex. Along with a portable pack that attaches to the subject's waist, the 
wireless system allows the subject to move around during imaging. Both of these systems focus 
on differential imaging and use the modified Beer-Lambert law to look at relative changes in the 
concentration of [HbO2] and [Hb].  A flexible printed circuit board holds the illumination, 
detection, and wireless transmission electronics. A wearable fNIRS system was developed by 
Piper et al uses 8 dual wavelength LEDs and 8 SiPDs that are embedded onto a stretch fabric cap.  
Ribbon cables sending and receiving signals for acquisition connect to the components on the cap 
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and the system electronics. The system electronics and a notebook used for acquisition are placed 
in a backpack, which the user carries during acquisition. Functional brain measurements are made 
while the user is on a bicycle.  
A miniature Bluetooth enabled NIRS system with 2 LEDs with separate wavelengths and 2 SiPD 
used to measure hemoglobin changes in the brain of rats was designed by Kuo et al [42]. The probe 
has LEDs and PDs in direct contact with the rat’s head with source-detector distances of 16mm to 
measure oxygenation changes while subjected to a traumatic brain injury.  
An ambulatory diffuse optical tomographic and multimodality physiological monitoring system 
was designed by Hu et al [54]. This handheld system is capable of recording 64-channels of NIRS 
imaging data, as well as EMG or ECG data. The “NINscan-M” contains 8 laser diode sources and 
8 photodetectors that can be employed on a limb, head, or abdomen for NIRS scanning while the 
EMG/ECG module contains 8 channels. The device can sample at 250Hz and runs on 2 AA 
batteries. Data is either stored on flash memory or can be streamed a smartphone via Bluetooth. 
Portable and wireless tissue oxygenation monitoring systems were produced by Watanabe et al 
[51]. for the use of analyzing brain hemodynamics and sports medicine. The PocketNIRS Duo 
consists of 2 channels, with each channel consisting of 3 NIR LEDs and a single photodiode. This 
device is controlled by a smartphone or a PC with Bluetooth communication. In addition, the group 
developed the PocketNIRS HM specifically for brain oxygenation, where the device is embedded 
in a plastic helmet. Evaluation of these devices were done with a solid phantom, an arm cuff 
occlusion test related to exercise monitoring, and a breath-hold test for brain oxygenation 
monitoring. 
Within breast cancer research, Jung et al. developed a compact wide-field NIR scanner has been 
developed towards contact as well as no-contact based real-time imaging in both reflectance and 
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transmission mode for the use of breast cancer imaging and functional brain mapping [48]. 
Phantom experiments have been conducted to estimate the feasibility of diffuse optical imaging 
by using Indian-Ink as absorption-based contrast agents and preliminary in-vivo studies 
demonstrated the feasibility of real-time monitoring of blood flow changes. The use of this device 
was continued by Rodriguez et al. as a potential use of breast cancer screening [49]. In this study, 
10 healthy females were scanned with an India ink marker on the breast to mimic a region of 
increased absorption. 
An ultra-compact wireless NIRS imaging system for breast tumor detection was implemented by 
Cheng et al., where an image reconstruction algorithm was implemented of a custom-made system-
on-chip (SoC) using VLSI technology [50]. Transmission of data is performed via Bluetooth to a 
tablet or PC. 
In endoscopy, capsule-like wireless devices have been designed for spectral, fluorescent, and 
bright field imaging of the gastrointestinal tract [46, 47]. These devices use small complementary 
metal-oxide semiconductor (CMOS) or charged couple device (CCD) sensors to perform 
qualitative imaging for identifying suspicious regions at the surface of the tissue.  
Incorporations of NIR imaging to smartphones have also emerged in various designs. A 
smartphone-based spectrometer was designed by Das et al to carry out measurements in a range 
of studies in the optics field [52]. The device has a dedicated app interface on the smartphone to 
communicate, receive, plot and analyze spectral data. Validations of the device were carried out 
by demonstrating non-destructive ripeness testing in fruit samples.  
Smith et al. developed a microscope attached to a smartphone that transformed the phone’s 
integrated lens to a 350um microscope and visible-light spectrometer [53]. The microscope has a 
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resolution of 1.5 um and a usable FOV of 150 x 150 um without image processing and 
approximately 350 x 350 um with post-processing. 
Despite this progress, there are currently no wireless optical imaging devices that perform diffuse 
optical tissue measurements with absolute reconstruction of the concentrations of tissue 
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2 Hardware Design for a Diffuse Optical Spectroscopy Device 
2.1  Device Background 
A first prototype of a portable wireless handheld DOS device (WHDD) was previously developed 
[55] in our biophotonics and optical radiology laboratory for the purpose of breast cancers 
hemodynamic measurements. The original WHDD was a Bluetooth enabled device that contained 
four near-infrared lasers and two photodetectors that operate in continuous-wave mode. The light 
passes through the sample and is absorbed and scattered as it travels to two detectors configured 
in reflectance geometry and located 1.8–2.4 cm and 2.7–3.3 cm away from the sources. The laser 
power was modulated at 3-5kHz and uses digital detection techniques to perform measurements 
at 2.3 Hz. The average laser power was 5mW. The device is enclosed by a plastic case measuring 
11.5 cm × 16 cm × 2.5 cm. A Labview program on a laptop computer was created to acquire data. 
Using a multispectral evolution algorithm for chromophore reconstruction, the device can measure 
absolute oxygenated and deoxygenated hemoglobin concentration as well as scattering in tissue.  
 
Figure 2.1 Photograph of (a) the 1st iteration of the WHDD device and (b) with the enclosure opened to expose 
the electronics. 
  18 
 
This first prototype was used as a proof-of-concept and its performance was evaluated using a 
series of liquid phantoms comprised of Intralipid, ink, and other dyes. While these tests on tissue 
phantoms were successful, its use in clinical settings was problematic as the device was not as 
robust as required in a demanding clinical situation. For example, upon turning on, the device 
would begin its acquisition, before pairing with a host device (Labview). This makes it dangerous 
in a clinical setting as the lasers could illuminate at the subject’s eye if not careful. This method of 
acquisition also is wasteful for the battery. The plastic case was also unstable, as it was made of a 
soft plastic, with the electronics inside was Velcro’d to the plastic casing. This made it difficult to 
make repeatable measurements as the lasing interface and electronics would slide or move 
depending on the pressure put on the casing. Additionally, the hardware acquisition performance 
suffered, as features such as laser modulation and signal conditioning had to be physically set on 
board manually. Because of these limitations, the development of second-generation portable 
WHDD was pursued. This chapter discusses the instrument design and improvements made to the 
first-generation device.  
 
2.2  Design and Creation of a Second-Generation WHDD 
The new design is a similar DOS system configured in reflectance geometry that is similar to the 
previous design. The new WHDD is composed of four near-infrared wavelengths of light to 
illuminate tissue. The light passes through the tissue and is absorbed and scattered as it travels to 
two detectors configured in reflectance geometry. At this separation, the effective light depth will 
be about 40% of the source detector distance [56], or 2-10mm. The light is detected by a silicon 
photodiode where the signal is conditioned by a 16-bit analogue-digital converter (ADC) 
controlled by a microcontroller. The new WHDD contains a more powerful microcontroller that 
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demodulates the signal and passes the result back to the host controller via Bluetooth® or through 




Figure 2.2 System for performing DOS measurements for infantile hemangiomas. (A) Smartphone with a 
custom-built phone application for system control. (B) Wireless handheld diffuse optical spectroscopy (WHDD) 
device with measurement head circled in yellow. (C) Diagram of measurement head with dimensions. S1-S4 
represents light sources at 780, 905, 850, and 808nm. D1 and D2 represent the two detectors with a sensing area 
of 5.7mm2 used to capture back-reflected light from skin tissue. 
 
Use of haywires and breadboards from the previous design were replaced by a two-part 4-layer 
PCB design that consisted of a main board that consisted of backend and digital components and 
an imaging head where laser and detector components are placed. Multiple PCB designs of the 
imaging head were made to not only be optimized of superficial imaging, but deeper tissue imaging 
for applications such as breast cancer and peripheral arterial disease. These imaging heads can be 
easily swapped out for another by use of a sliding connector. For each imaging head design, 
components were accurately positioned on the PCB. The board corners were filed to fit the 
enclosure of the device. The laser and detector components that protrude out were fit into a cover 
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slip that was made from laser cut Delrin pieces so that both the components and cover would be 
flush with the sample. The imaging head was re-designed and optimized for infantile hemangiomas 
(IHs) because the tissue medium require more superficial measurements. For the application of 
imaging IHs, the detectors are located 0.6-1.4 cm and 1.25–2.0 cm away from the sources as shown 
in Figure 2.2C.  
 In this section, the design of the probe will be described. A block diagram of the device is shown 




Figure 2.3 System block diagram for the handheld wireless device. 
 
2.2.1 Light Illumination 
The input light is generated by 5 mW 5.6 mm-diameter laser diodes at wavelengths l of 780 nm, 
808 nm, 850 nm, and 904 nm (L780P010, L808P010, L850P010, L904P005, Thorlabs). The 
wavelengths are selected to provide a range of spectral information to reconstruct µa, µs’, and the 
concentrations of oxygenated hemoglobin ([HbO2]), and deoxygenated hemoglobin ([Hb]).  
The laser source for each wavelength is modulated programmatically using a combination of a 1 
kHz–33 MHz Oscillator (LTC69034, Linear Technology), a binary counter (M74HC4820, 
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STMicroelectronics) and a low-pass filter (LTC1067, Linear Technology). This constitutes and 
improvement over the previous system where the modulation frequency was set by a 
potentiometer. The potentiometer had to be carefully set and was susceptible to changes when the 
device was subject to vibrations. The modulation of the input light provides several advantages 
including superior noise rejection (including ambient light) as well as the ability to illuminate the 
tissue simultaneously with multiple wavelengths. 
The laser diodes are driven by the 15 V Laser Diode Driver (iC-WKN, iC Haus). The power of the 
laser diode can be controlled using a 20kOhm potentiometer that regulates the current to the laser 
driver. The modulation of the input light provides several advantages including superior noise 
rejection (including ambient light) as well as the ability to illuminate the tissue simultaneously 
with multiple wavelengths.  
 
2.2.2 Light Detection 
The light is absorbed and scattered as light passes through the sample to two silicon photodiodes 
(SiPD) (Hamamatsu S1337-33BR) on an interface adapter board configured 0.6-1.4 cm and 1.25–
2.0 cm away from the sources. Current from the two SiPD is converted to voltage using a 
transimpedance amplifier that utilizes a bandwidth-extension technique previously implemented 
in [57]. Unlike in the first prototype, the transimpedance amplifier (TIA) no longer uses jumpers 
to manually change the gain settings and instead uses carefully laid out components to minimize 
noise. Additionally, a 3-bit programmable gain amplifier (PGA) stage is used to optimize the signal 
to the scale range of the ADC (LTC6910, Linear Technology). Filtering of the signal prior to the 
ADC has been upgraded from a first-order passive low-pass filter to a 10th order programmable 
filter stage (LTC1569-7, Linear Technology). This stage improves the signal remarkably as 
demodulation of the signal can be noise dependent. Gain control of the PGA are digitally set  using 
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I/O pins from the microcontroller. The cutoff frequency of the filter stage is set via the 
microcontroller by its pulse-width modulation module (PWM) which can create clock speeds up 
to 20MHz. For our purpose, the cutoff frequency was set to 7kHz by creating a 224kHz clock from 
the PWM to the LTC1569-7 chip.  Their values can be adjusted through the user interface settings. 
The result is an increase in SNR by 30dB from the previous hardware revision. Once the signals 
on both channels are well conditioned, they are multiplexed into a level shifter and quantized using 
a 16-bit ADC (LTC1865, Linear Technology) that provides speeds up to 150kps.  
 
2.2.3 Processing and Communication 
At the heart of the design improvements is a 32-bit pic microcontroller (PIC32MX695F512H, 
Microchip Technologies) that provides USB connectivity and DSP functionality. This upgrade 
gives the device complete digital control of the source and detector stages as well as the addition 
peripherals. Additionally, this controller provides high speed and increased memory that addresses 
the issues as mentioned in [55]. As before, the signals are demodulated using our digital lock-in 
detection scheme [58] by the microcontroller. The microcontroller has the ability to demodulate 
all four wavelengths in one imaging cycle, providing the ability to illuminate at source lasers at 
once. This dramatically increases the scan rate of the system. As previously reported, the scan rate 
of the previous system is 2.3Hz, with no combined source laser illumination provided. With the 
speed and DSP functionality of the new microcontroller, the speed of the system is increased to 
~12Hz for no combination of illumination, ~18Hz for two combined wavelengths, and ~24Hz 
when all sources are illuminated. Once demodulated, the resulting data is then passes the result 
back via Bluetooth or USB to the host controller. 
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2.2.4 Firmware  
The firmware of the WHDD commands the system to perform tasks requested by the user. The 
PIC32 microcontroller firmware was developed using the Microchip MPLAB 8 IDE with 
additional bug fixes done in MPLAB X IDE and the C32X compiler. The configuration bits for 
the chip were hardcoded such that the PIC32 was computing from the internal oscillator, with the 
speed set to SYSCLK=80MHz and PBCLK=40MHz.  
The device then performed initialization of the controller modules and the peripheral chips. These 
modules include the timer, interrupts, Universal asynchronous receiver/transmitter (UART), Serial 
Peripheral Interface (SPI) Bus, and the Output Compare (OC) modules. After the initialization of 
the modules, the following peripherals are setup: 
1. The I/O pins shut off the lasers, set gain settings to –inf dB, disable MUX leading to 
the ADC 
2. Initialize the Bluetooth chip via the UART module 
3. Initialize the ADC via the SPI module 
4. The modulation frequencies of the laser sources are set to the SPI controlled oscillator 
chips. 
5. The cutoff frequency of the anti-aliasing filter is set by creating a square wave with a 
computed frequency based on the filter chip 
After the system setup is completed, the firmware will go into its imaging subroutine, where the 
device waits on an instruction from the user. When a command is sent to the device from the user, 
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the UART interrupt is initiated and a task to performed. The flow chart in Figure 2.4 provides 
details of the firmware processing.  
 
Figure 2.4 Flow chart of WHDD firmware processing to set gain, calibrate gain, start, and stop acquisition.  
  25 
The commands from the user are strings of ASCII code that is parsed by the device. For most 
commands, only the first ASCII character is needed for the command. Only the gain settings 
contain a payload more the 0. Table 2.1 shows the header command structure needed for the device 
to perform tasks. 
Command Header Command Payload Example 
Start Y 0 'Y000' 
Stop S 0 'S000' 
Calibrate Gain Settings C 0 'C000' 
Configure Gain G (# of SD pairs) * 2 'G020 1 2 3 4 5 6 7 7' 
Initialize Device N 0 'N000' 
Table 2.1 Commands excepted by the WHDD to perform imaging and control tasks. 
  
2.2.5 Gain Optimization and Calibration 
A firmware routine in the device measures the optimal gain setting for the PGA for a given sample. 
While the probe is at the sample, the gain optimization routine illuminates all of the lasers at all of 
the gain settings. The best gain is chosen for each source detector pair by computing the highest 
amplitude of the signal that does not exceed the threshold set by the user. Although the threshold 
is user controllable, the threshold is nominally set at 2.8V. This is because the ADC can only 
sample voltages from 0-3.3V and 2.8V provides a 15% buffer from the maximum computable 
amplitude. 
Once in the calibration routine, the device acquires frames and computes the amplitude for all gain 
settings. This creates a matrix with size (# of gain settings) by (# of SD pairs). The best gain 
selection is determined by picking the gain setting where the corresponding amplitude is the largest 
gain setting under the threshold. The best combination of gain settings is loaded to the device and 
the single frame of data is acquired and is sent back to the user interface. 
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2.2.6 Reconstruction Algorithm 
A brief description of the reconstruction algorithm previously described is presented here [55]. 
The algorithm computes the special distributions of µa, µs’, and the concentrations of oxygenated 
hemoglobin ([HbO2]), and deoxygenated hemoglobin ([Hb]).  The diffuse spectroscopic technique 
is based on the reflectance measured at multiple locations on the surface of the medium, where the 
diffuse reflectance depends solely on the absorption coefficient µa and the reduced scattering 
coefficient µ′s and the source- detector separation d. Under the assumption of a semi-infinite 
homogeneous medium, the closed-form analytic solution for the spatially resolved reflectance is 
given by Farrell et al. [59] as 
 
𝑅(𝑑)%& = 14𝜋𝜇,- 𝜇.// + 1𝑟23 𝑒𝑥𝑝 −𝜇.//𝑟2𝑟23





 𝑟2 = 1𝜇,- 3 + 𝑑3,								𝑟3 = 34 𝐴 + 1𝜇,-
3 + 𝑑3 (2.2) 
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Here µeff is the effective attenuation coefficient 𝜇.// = 3𝜇<𝜇=- 	, µ′t is the total transport 
coefficient (µ′t = µa + µ′s ) and A is the internal reflection parameter [60] that takes into account 
the refractive index mismatch at air-tissue interface.  
We employed a multispectral direct method that exploits the following relations that describe the 
tissue absorption, chromophore concentration, and scattering as  
 𝜇< 𝜆 = 𝜀@(𝜆)𝐶@BC@D2  (2.3) 
and, 
 𝜇=- = 𝐴𝜆EF (2.4) 
 
where εi(λ) and Ci are the absorption extinction coefficient and the concentration for the ith 
chromophore in tissue. Nc is the number of tissue chromophores that contribute to the absorption 
at wavelength λ. The scattering parameters A and b are the scattering amplitude and the scattering 
power, respectively. The multispectral direct method reconstructs Ci, A. The scattering power, b, 
is kept constant and is set by the user. The scattering power should be decided by the medium of 
the measurement. For example, phantom measurements typically assume a flat scattering across 
the NIR range, but muscle or fat will have a scattering profile that is more linear, and decreases 
with the increase in wavelength [61].  
The SRS problem with the direct approach can be formulated as the following inverse problem 
where the optimal solution can be found by minimizing the misfit between predictions Rd and 
measurements zd of the reflectance on the tissue surface  
 𝐹 𝑥 = 𝑅%H − 𝑧%H 3H,%  (2.5) 
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where x is the vector of all unknowns, e.g., x = (Cj, A). Although this algorithm can solve many 
several different variables at once, the algorithm developed will only reconstruct chromophores 
[HbO2] and [Hb], alongside the scattering amplitude A. To minimize this equation, an evolution 
strategy algorithm was implemented.  
The general structure of the ES algorithm used here can be described as follows. Consider a 
population of individuals Pk = (x1, ..., xn)k at iteration k, where each individual xj represents a 
potential solution to the inverse problem under investigation. Each individual xj is evaluated using 
the objective function (Eq. (4)). Next individuals are randomly recombined and mutated to give 
more than n individuals and then each individual is evaluated again with the objective function, 
and the n fittest individuals are selected to generate the new population Pk+1 = (x1, ..., xn)k+1. This 
process is repeated until the fittest individual is selected. Table 2.2 shows the pseudo-code of the 
ES algorithm. 
		 		
1 Set k = 0  
2 Initialize Pk =(x1,...,xn) with xj =(CHbO2,CHb,A,b)j  
3 Evaluate Pk  
4 Repeat while (not converged)  
a Recombine P ̃k =(x ̃1,...,x ̃m)(m>n)  
b Mutate Pk = P ̃k + Zk 
c Evaluate Pk  
d Select n best individuals 
e k = k + 1 
5 End 
Table 2.2 Pseudo-code of the evolution strategy algorithm. 
 
 
2.2.7 User Interfaces 
The host controllers we have developed include a MATLAB interface and an Android mobile 
application. The WHDD mobile application we developed controls the hardware and receives and 
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stores the transmitted data. Currently, the most popular operating environments on mobile devices 
are Android and iOS. However, with the iOS environment having significant limitations on the 
Bluetooth standard and protocols, we decided to develop the application for the Android operating 
system so that we could utilize the Bluetooth 2.1+EDR standard with the RFCOMM protocol. The 
Android SDK provided the tools and API's necessary to communicate with the hardware via 
Bluetooth. The application was developed based off the open-source application BlueTerm, which 
is a terminal emulator for communicating with devices using a Bluetooth serial adapter. Our 
application allows the user to control the hardware (initialize or connect to the device, calibrate 
gain settings, start recording, and stop recording) using buttons in the interface that send unique 
commands to the device (Figure 2.5). The application also allows the user to connect and 
disconnect to a paired Bluetooth device through a menu.  In separate threads, the data is parsed, 
stored on the devices removable SD storage, and plotted in real-time to on-screen graphs. Once 
acquisition is complete, the acquired data can be uploaded to our data servers via the Dropbox 
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phone application which is also stored on the Android phone. The phone used for data acquisition 
is a Samsung Galaxy SIII.  
 
 
Figure 2.5 Screenshot of the user interface from the Android application to control and collect data from the 
wireless handheld probe.  
 
A MATLAB Graphical User Interface (GUI) (Figure 2.6) was developed as a tool where long 
experimentation times make USB connectivity more suitable. The GUI can connect to the probing 
device using a virtual COM port, making connectivity to both Bluetooth and USB available. The 
GUI was developed using MATLABs Graphical User Interface Design Environment (GUIDE). 
The GUIDE module allows the user to create point-and-click control of software applications, 
eliminating the need to learn a language or type commands in order to run the application. It 
integrates the two primary tasks of app building―laying out the visual components and 
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programming app behavior―and allows you to quickly move between visual design in the canvas 
and code development in an integrated version of the MATLAB Editor.  
The GUI that was created has the ability to control the WHDD probe, save the data to a specified 
location, load previous gain settings, and display incoming data from the WHDD in real time. The 
GUI controls the device using the same command signals as the Android application and can 
control the device with functions: connect, stop, start, and calibration of gain. The data received 
by the GUI is saved to a text file at a user specified location. The interface also has the ability to 
manually adjust and send individual gain settings to the device using sliders for each source 
detector pair by pressing the “Send Configuration” button. With 4 sources and 2 detectors, there 
are a total of 8 source-detector pairs that can have their gain adjusted.  
The user can load previous gain information by clicking on the “Browse” button on the “Open 
Config. File” section and selecting a “*_config.txt” file and pressing the “Load” button. Once 
loaded, the sliders for the gain configuration will update accordingly. The user must then press the 
“Send Configuration” button to send the loaded gain settings to the device.   
Once the gain configuration is sent, the user can press the “Start” button to begin acquiring data. 
The start data will send a command to the device to begin imaging. Once the imaging is initiated, 
the WHDD will continually collect frames of SD pair data. Each frame of data is sent in a packet 
via USB or Bluetooth. Each packet contains a header with the packet size, the SD pair data with 
an adjustable size of significant digits of raw (voltage) data, and the gain of the SD pair. For each 
frame, the GUI parses the packet by computing the size of the packet from the header. The GUI 
then separates the data from the packet and writes the frame to the text file. In addition, the frame 
of data is displayed on the GUI screen for real-time visualization of the data acquisition. The 
displayed data is a rotating buffer of incoming data, with up to 500 frames allowed to be viewed 
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at once. This rotating buffer scheme was used to improve the performance of the acquisition since 
displaying data is computationally taxing. 
If the computer used for data acquisition is Bluetooth enabled, a virtualized COM port can be 
created for it to be used as a connection pathway to acquire data instead of using USB. Although 
this GUI can be natively used with a Windows PC, this GUI has the ability to be used with the 





Figure 2.6 Screenshot of the user interface from the MATLAB to control and collect data from the wireless 
handheld probe. 
 
2.3 System Characterization 
For monitoring applications where the location of the diseased tissue is known, the WHDD may 
provide a simplified diagnostic solution for easier clinical use. In ensure that the system can be 
used appropriately for a given application, characterization of the device capabilities must be 
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performed.  Here we discuss the characterization of the system with the following parameters: 
Speed, Sensitivity and Dynamic Range, Linearity, Stability, Size.  
2.3.1 Speed 
The speed of acquisition is an essential parameter for making point measurements where motion 
artifacts may play a role during acquisition. The temporal response of the WHDD system is limited 
by the digital lock-in detection scheme applied in microcontroller of the acquisition board. 
However, the method of performing the digital lock-in detection can be adjusted to performing the 
task with 1, 2 or all 4 lasing wavelengths at a time. As previously reported, the scan rate of the 
previous system is 2.3Hz, with no combined source laser illumination provided. With the speed 
and DSP functionality of the new microcontroller, the speed of the system is increased to ~12Hz 
for no combination of illumination, ~18Hz for two combined wavelengths, and ~24Hz when all 
sources are illuminated. 
2.3.2 Sensitivity and Dynamic Range 
The dark noise represents the smallest measurement that can be reliably performed with the 
system, occurring when no incident light is present while measuring. Figure 2.7 shows the average 
dark noise measured for each gain setting with the error bars representing the standard deviation   
across wavelength measurements. By increasing amplification in the PGA stage, we see an 
increase of noise, with a large increase in noise at gain 64x (101uV). However, at the gain stages 
1-16, we see noise levels below 75 µV. Although the highest gain settings results in a much higher 
dark noise measurement compared to the lowest, the RMS dark noise only results in a noise of less 
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the 1% of the optimal return for a foot measurement, which is 2.7V. That is 101uV/2.7V = 0.004%, 
or 88dB of SNR.  
The largest light signal that can be detected uses the full detector range for the lowest gain setting, 
which in this case is to detect a 3V peak-to-peak voltage on the 20kV/V gain setting. Using these 
values, we can calculate the dynamic range of the system to be 89.5 dB. 
 
Figure 2.7 Plot of the root mean squared (RMS) dark noise for each detector gain setting. Error bars represent 
the standard deviation of all detectors. 
 
2.3.3 Linearity 
System linearity was examined by measuring the detected voltage from the solid block phantom 
across all possible PGA chip gain settings (LTC6910-2, Linear Technology). The PGA chip used 
in the detector channels are 3-bit controlled with gain settings (0, -1, -2, -4, -8, -16, -32, -64V/V). 
The results are plotted in Figure 2.8, where it is demonstrated that a linear relationship across the 
  35 
gain settings is generally maintained. For the curves below, linearity with R-squared measures of 
R=0.975.  
 




Repeatability measurements tests were performed to ensure that the device can be reliably be used 
for repeated measurements, such as in a longitudinal study. In order to quantify the repeatability 
of the WHDD, two types of experiments were performed. The first test was to use the WHDD to 
scan a solid phantom with a homogeneous medium as shown in Figure 2.9.  The solid phantom is 
a Biomimic Optical Phantom (INO, Canada) which has optical properties shown in Table 2.3. The 
optical properties requested by our group is the requested values, and the measured values are the 
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values from the characteristic report supplied by INO. The optical properties of the phantom made 
by INO are advertised to have a flat spectrum and have a reliable reduced scattering coefficient.  
 
  Optical Properties of Solid Phantom  
WL (nm) 670 780 808 850 
Predicted (ua) 0.15 0.15 0.15 0.15 
Predicted (us') 8.5 8.5 8.5 8.5 
Measured (ua) 0.214 0.179 0.173 0.168 
Measured (us') 9.31 8.93 8.97 8.72 
Table 2.3 Optical properties of solid phantom used for repeatability study. 
 
 
Figure 2.9 The Wireless Handheld DOS Device imaging the INO solid phantom block. 
 
 
The protocol of the repeatability measure on the phantom was to scan the solid phantom on one 
location at two different orientations, such that the WHDD interface is rotated 180 degrees. This 
measurement was repeated another two times, in 1 hour intervals, totaling in 6 measurements. A 
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Bland-Altman diagram was created to demonstrate repeatability (Figure 2.10). This figure 
demonstrates that the percent change in reflectance between repeated measures is achievable to 
99.7% accuracy with a standard deviation of 1.00% 
In addition, a repeated-measure ANOVA was performed to compare the repeated scans of the 
phantom. Using this method, it was found that the mean temperature difference between the 
repeated measures were not significant (P = 0.475). Because repeatability requires that 
measurements not change between trials, accepting the null hypothesis is desired. 
 
Figure 2.10 Bland-Altman plot demonstrating repeatability on a phantom block. A total of 3 independent tests 
were performed from WHDD’s 8 source-detector pairs. 
 
A similar protocol was also repeated on human skin. For this repeatability test, the wrist of 5 
subjects were scanned with the WHDD with 2 repeated measurements. For each repeated 
measurement, the probe was placed onto the wrist for 5 seconds, released from skin contact for 5 
seconds, and then placed back onto the wrist for another 5 seconds. A Bland-Altman plot was 
created for all subjects and source-detector pairs (Figure 2.11). The mean percentage change 
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between these measurements was 4.35% with a standard deviation of 5.05%. It is important to note 
that repeatability accuracy increases when the reflectance measurements increases. For example, 
reflectance measurements above 2.1V result in a repeatability change of 1.8% with a standard 
deviation of 2.1%. In addition, a repeated-measure ANOVA was performed to compare the means 
of the initial scan and the repeated scan of the wrists of subjects and differences between these 
scans were not significant (P = 0.429).   
 
Figure 2.11 Bland-Altman plot demonstrating repeatability on human subjects. Measurements were taken 
from the wrists of 5 subjects with the WHDD’s 8 available source-detector pairs. 
 
2.4 System Summary 
We have presented a new hand-held wireless device for diffuse optical tissue spectroscopy. The 
prototype was created for less than $500 and presents an inexpensive, portable, and user-friendly 
device for clinical optical measurements. The size of the device is currently suited for hand-held 
operation, but could be further scaled down in size to a device pen sized, by selecting smaller 
component footprints, a smaller battery, and denser board layout. Table 2.4Error! Reference 
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source not found. presents a comparison between the new wireless handheld DOS device and the 
previous version presented by Flexman et al. [55]. The most important difference between the 
WHDD system described in this thesis and previous version lies in the digital control of peripheral 
signal processing of illumination and detection. This results in a 10-fold increase in system speed, 
from 2.4 to 24 Hz. In addition, the detection section has more gain control that is can be more 
easily manipulated by the user. This gain feature allows for a great dynamic range, allowing for a 
wider range of absorbing and scattering tissues than the previous hardware version. Finally, 
although the gain of the system has higher control, the system dark noise is similar to the previous 
version (<50µV for most gain settings). This is due to the fact that the front end of the detection 
circuit has the same transimpedance topology as before. 
Features First Generation Second Generation 
Scanrate 2.4Hz 24Hz 




Detection Gain Manual Jumpers Digitally 
Programmable 
Accelerometer No Yes 
USB Option No Yes 
Rechargeable No Yes 
DSP Functionality No Yes 
Sampling 12-bit MCU  16-bit ADC 
Table 2.4 Comparison of 1st and 2nd generation handheld wireless DOS probe 
 
This device can facilitate future clinical studies exploring the optical signatures of various medical 
applications such as vascular anomalies, skin cancers, as well as subcutaneous cancers such as 
breast cancer. Indeed, this device provides a fast and easy way to make static and dynamic 
measurements on many other tissues, including, for example, brain, limbs, and breast, without the 
need for specific interfaces for each application. The ease of use, portability, and low cost of this 
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device will complement many existing clinical optical studies by providing real-time 
measurements, and will create opportunities for new clinical applications. 
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3 Diffuse Optical Spectroscopic Assessment of Infantile Hemangiomas 
3.1 Infantile Hemangiomas 
Infantile hemangiomas (IHs) are the most common benign vascular neoplasms in infants, affecting 
~5% of all infants born [62, 63]. Females are more likely to develop IH with a sex ratio ranging 
from 3:1 to 5:1 and even until 9:1 in case of PHACES syndrome. (PHACE Syndrome is the 
association between large infantile hemangiomas, usually of the face, and birth defects of the brain, 
heart, eyes, skin and/or arteries. It is an acronym that stands for the medical names of the parts of 
the body it often impacts.) Other identified risk factors are: race (Caucasian), prematurity, and low 
birth weight (less than 1500 g) [64].  
The natural history of these lesions, with initial rapid proliferation followed by gradual involution 
and regression, has not been completely elucidated. At birth the lesions are either absent or barely 
evident. It has been suggested that the onset of IH is caused by hypoxic stress [62, 65]. The 
proliferative stage involves the proliferation of benign endothelial cells and mast cells in the first 
few weeks to months of life. This results in an increase of blood vessels and vasculature within the 
area. After 5 to 10 months, the growth curve flattens, followed by an involution phase over several 
months to years [62-64, 66]. Within this involution stage, histological examination reveals a 
diminishing endothelial cellularity and an increase in fibrofatty tissue [62, 64, 65, 67]. At the age 
of 5 years, 50 percent of the hemangiomas have involuted, and at the age of 9 years 90 percent 
have [67].  
Their clinical presentation can vary significantly, from nodular lesions several millimeters in 
diameter to plaque-like tumors covering the entire face or a quadrant of the body [67]. Larger 
tumors can interfere with vital organ function and/or cause permanent disfigurement. 
Complications include ulceration, threat to vision, airway obstruction, and congestive heart failure 
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[68]. Fig. 2.1 shows a mixed hemangioma that contains a superficial feature and a subcutaneous 
feature.  
 
Figure 2.3.1. An example of infantile hemangioma. This particular hemangioma has a deep component that 
can be seen as a large bulge, and a red, blotchy superficial component 
 
 
3.2 Clinical Measures 
IH progression is documented using relatively subjective techniques relying upon physical 
examination findings, visual analog scale (VAS), and review of photographs [69-75]. Subjective 
clinical diagnostics typically include a visual assessment of the hemangiomas by photography of 
the lesions to analyze size, color, and anatomical distortion [70, 72, 73, 75]. Measurements of 
lesion are also taken to determine area and volume of the lesion [75]. These assessments give 
insight of which stage the lesions are in and whether treatment or its natural course is effective in 
its involution. Although it has been common practice to use subjective assessments to determine 
the status of the lesions, it has been of interest to validate and exercise necessary means for 
evidence based diagnostics [63, 76, 77]. It has also been noted that there has been a lack of 
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characteristics can be hard to predict early in infancy, as they are not present as fully formed tumors 
at birth [75].   
Surgical biopsies are performed in atypical cases and are done if the history, physical examination, 
and imaging studies do not clearly define the pathologic process. It is suggested that invasive 
measures are not to be used otherwise [64].  
3.3 Imaging Techniques 
Current evaluation consists of diagnostic imaging of the IH lesions by means of Doppler 
ultrasound (US), MRI, CT, and in rare cases angiography [64]. Doppler US is a non-invasive tool 
to measure IH thickness, as well as blood flow and vessel density to follow IH regression [79-81]. 
However, everyday clinical use is further limited by the need for an experienced ultrasonographer 
and operator variability. MRI is a noninvasive effective tool for imaging and classification of 
vascular malformations based on the presence of lobulated masses, signal voids, and hemodynamic 
flow characteristics. MRI also provides details about anatomic extent of the lesion, proximity to 
vital structures, and involvement of multiple tissue planes [82]. CT scan images examine for 
density before contrast medium enhancement, the presence of calcification(s), the limits of the 
lesion, the fat stranding and the type of enhancement [83]. Although these imaging techniques are 
well suited to measure hemangiomas in three dimensions, they are not immediately available and 
costly, and in the case of CT or MR, may require sedation or general anesthesia in young infants 
[75]. Additionally in the case of US, there are limitations by its small field-of-view, restricted 
penetration and operator dependency [82]. Moreover, imaging is reserved to evaluate the depth 
and extent of the lesion, usually underestimated by physical examination especially for 
symptomatic lesions when treatment is contemplated [82]. These methods make it unviable for 
early detection and diagnosis, where proliferation is barely evident. The temperature difference 
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between IH and surrounding or contralateral skin commonly observed makes infrared 
thermography (IRT) a viable solution for monitoring IH [84]. However, results showed that IRT 
observed a much faster months to zero-temperature difference between the deep IH and the 
contralateral normal skin site than that of the mixed or superficial IH subtypes. This shows that 
IRT is less sensitive to deep IH because deep IH have a much longer involution stage than 
superficial IH, but due to the lack of heat from the more subcutaneous deep IH, the temperature 
difference is closer to that of normal skin. False temperature elevations may also result from 
ulcerated IH by use of IRT. 
Optical imaging techniques have shown the potential to monitor treatment and give an early 
diagnosis to vascular skin lesions, most notably melanoma. Studies of this nature have been 
reported previously [85-88]. Kuzmina, et. al. reported results using diffuse reflectance 
spectroscopy (DRS) and a multi-spectral imaging (MSI) analysis to image various vascular skin 
lesions in adults, before and after laser treatment [86]. Their results showed that the optical density 
spectrum, color parameters, and the spectral ratio of diseased and healthy skin changed before, 
immediately after, and 2-3 weeks after laser treatment. Kokolakis et al. presented an optical 
computed tomography (optical-CT) system as a tool for three-dimensional (3-D) imaging of 
biopsy samples of melanocytic lesions and its ability to discriminate benign from malignant 
melanocytic lesions while simultaneously determining the thickness of invasive melanoma [87]. 
In a less invasive approach, Konig et al. used two OCT modalities and dermoscopy to image 
various dermatological disorders. It was concluded that the combination of the three could be a 
useful tool in early skin cancer diagnostic and the evaluation of treatment [85]. However, these 
presented modalities consist of a several large components and control cables where the size and 
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weight complicate the handling in demanding environments. This makes it difficult to image 
lesions on all locations of the body or to image multiple localized lesions that may be evident.  
 
3.4 Assess Optical Changes in IH During Treatment and Natural History  
Recently, it has been suggested that IHs are brought on by hypoxic stress of local skin tissue [62, 
65]. However, the lack of objective and quantifiable tools to measure IH biology and severity can 
hamper understanding of pathophysiological processes, such as hypoxia or other mechanisms that 
may contribute to risk for ulceration, that may be involved [63, 66], and make it difficult to quantify 
and compare efficacies of different treatments. Thus, it is of great interest to clinicians to develop 
and validate means for evidence based diagnostics [76, 77].  
One appropriate solution for measuring vascular and hypoxic changes in human tissue is by diffuse 
optical imaging, whether by DOS or DOT. Optical imaging has been widely utilized for diagnostic 
imaging for brain oxygenation in newborn infants suffering from cerebral hypoxic-ischemic injury 
[89-92]. In addition, DOS has also been utilized to measure chromophore concentrations of the 
skin, as well as vascular lesions [93-99]. For example, work performed by Lim et al [93] showed 
that Raman spectroscopy was the best imaging modality for discriminating Melanoma from non-
Melanoma lesions. A study was performed by Tsang et al in which chromophore concentrations 
of human skin was measured in-vivo from absorption and scattering coefficients. These results 
suggested that diffuse reflectance techniques with the visible and near infrared light sources can 
be employed to investigate the hemodynamics and optical properties of upper dermis and lower 
dermis. Although DOS has been shown to be a viable tool for skin and vascular lesion 
measurements, the technology has not been utilized to measure infantile hemangiomas. Given the 
extensive background in imaging oxygenation in tissue, a small form factor DOS measurement 
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device could provide clinicians with a tool that can be easy to use and non-intimidating for children 
and parents while being used in a clinical setting.  
To address this clinical need, we employed our WHDD system in a longitudinal pilot study to 
evaluate its utility in IH vascularity assessment.  We monitored changes in [THb] and StO2 over 
several time-points up to 18 months in patients that were untreated or treated with propranolol or 
topical timolol. The DOS characteristics of IH in different stages (proliferation, plateau and 
involuting) and IH receiving treatment was correlated with clinical features. 
3.4.1  Clinical Examination 
IRB approval was obtained from Columbia University Medical Center (CUMC) Investigational 
Review Board (Protocol# IRB-AAAJ1201), and patients were recruited from the Pediatric 
Dermatology practices at CUMC. Infants were eligible if they were younger than 9 months at the 
time of initial visit and had at least one cutaneous IH greater than 2 cm in diameter in an area 
accessible by our probe’s 3x1cm measurement head. Frontal facial lesions were excluded. 
Patient’s eyes were shielded from the light using an NIR light absorbing material. Infants were 
scheduled to be assessed with the WHDD at the initial visit, at 2-4 months, and at 1 to 2 year 
follow-up visits. Parents of eligible patients were informed of the investigational nature of the 
study protocol and were required to read, agree to, and sign a statement of informed consent prior 
to participation. 
Patients were assigned to the “natural history” cohort if no medical intervention was clinically 
indicated. Patients were enrolled in a “treatment” cohort when medical intervention was indicated 
with either oral propranolol or topical timolol. Prior to DOS measurements, subjects underwent 
clinical examination and photographic documentation. IH staging (proliferating, plateau, or 
involuting) and classification, in which the IH lesion is deep (subcutaneous), superficial, or mixed 
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(both) was determined based on parental history of IH appearance Figure 3.2, clinical and parental 
photos, patient age, and IH characteristics (e.g. color, texture) on physical exam at the time of 




Figure 3.2 Examples of different IH classification. Left: Superficial IH. Center: Deep IH. Right: Mixed deep 
and superficial IH. 
 
3.4.2 Study Device 
All patients were scanned with our enhanced WHDD system (Figure 3.3A,B), which is an 
optimized version of a previously presented device (11). The WHDD (Figure 3.3C) is composed 
of four near-infrared wavelengths of light to illuminate tissue to provide a range of spectral 
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information to determine the concentrations of [HbO2], [Hb], [THb], and StO2. The measurement 
probe was controlled via Bluetooth by a custom designed Android phone application.  
 
 
Figure 3.3 System for performing DOS measurements for infantile hemangiomas. (A) Smartphone with a 
custom-built phone application for system control. (B) Wireless handheld diffuse optical spectroscopy (WHDD) 
device with measurement head circled in yellow. (C) Diagram of measurement head with dimensions. S1-S4 
represents light sources at 780, 905, 850, and 808nm. D1 and D2 represent the two detectors with a sensing area 
of 5.7mm2 used to capture back-reflected light from skin tissue. 
 
The WHDD probe head was placed on top of the IH or contralateral normal skin for measurements. 
If the IH lay in the center of the body, a normal skin measurement would be performed a minimum 
of 5cm above or below the IH. Multiple measurements at different probe orientations were taken 
to ensure consistency of the measurement area. Individual measurements take only seconds; and 
the entire measurement procedure, including placement of the probe at multiple sites, can be 
performed in less than a minute. Once the infant had been scanned, the detected light intensities 
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were entered into a reconstruction algorithm (11) to compute [HbO2], [Hb], [THb] and StO2. 
These functional parameters from the multiple measurements were averaged prior to analysis. 
 
3.4.3 Data Analysis 
Since [THb] and StO2 may differ at different skin sites around the body, each IH measurement was 
normalized to the measurement performed at the contralateral normal tissue site to produce [THb] 
and %StO2 ratios: 
 𝑟𝑇𝐻𝑏 = 	 MNFOPMNFQRSTUV , 																	𝑟𝑆𝑡𝑂3 = %[,\]OP%[,\]QRSTUV			. (3.1) 
  
The ratio rTHb provides a metric for volume measurement based on overall vascularity observed. 
For example, in bulkier, deep IHs compared to superficial IHs, one would expect higher values of 
rTHb. The ratio rStO2 provides a relative measure of the oxygen supply within the 
microvasculature between involved and uninvolved tissue.  
The rTHb and rStO2 features may vary greatly depending on the subtype and staging, which could 
make it difficult to interpret the overall state of the IH. To quantify the overall state of the IH, we 
derived a third index that combines the two features with equal weight, which we call the 
Normalized Hypoxia Fraction (NHF): 
 𝑁𝐻𝐹 = 	 𝑟𝑇𝐻𝑏 + 1𝑟𝑆t𝑂32  (3.2) 
 
This unitless index equally combines information about [THb] and StO2 into one number, since 
rTHb and rStO2 may change independently over time. This index, as we found, provides the best 
distinction between the proliferation, plateau, and involuting stages. As the IH evolves through 
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these stages, rTHb and rStO2 will trend towards 1— suggesting that the vascular properties of the 
IH site is equivalent to that of the normal skin site. The three DOS derived parameters (rTHb, 
rStO2, and NHF) were correlated to the results of the clinical examination. 
3.4.4 Statistical Analysis 
Comparisons between patients in different stages of IH were made using a one-way analysis of 
variance (ANOVA). The Holm-Sidak t-test was used to determine individual inter-group 
significance. Boxplots were generated for visualization of the range, shape, and skewness of data. 
Scatterplots showing normalization of NHF over time were produced. Repeatability of the system 
measurements was computed by measuring the coefficient of variance of [THb] and StO2 for each 
patient.  
3.4.5 Study Demographics  
Thirteen infants with fifteen hemangiomas were enrolled. All subjects were female. A summary 
of the enrolled patients is found in Table 3.1. 
	 Age (Months) Classification Location 
   Superficial Deep Mixed Trunk Extremities Head 
All IH (N=15) 5.8 ± 2 N=8 2 5 10 3 2 
Untreated IH (N=11) 6 ± 1.9 5 2 4 8 1 2 
Treated IH (N=4)   3 0 1 2 2 0 
Table 3.1 Demographic features and clinical classifications for all subjects. 
3.4.6 Untreated Infants with IH 
We performed a total of 23 measurements on 13 untreated IHs including two pre-treatment 
measurements from two of the four treated infants for our analysis of untreated patients. Three IHs 
were scanned three times, five were scanned twice, and four were scanned once. At time of 
measurements, the IHs were classified as being in the proliferation (N=6), plateau (N=12), or 
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involuting stage (N=5) and correlated with patient age: the mean (SD) ages of subjects were 5.1 
(±2.2), 9.1 (±2.3), and 14.0 (±7.9) months respectively.  
 
Table 3.2 Scatterplot of Normalized Hypoxia Fraction measurements of untreated subjects 
The NHF index peaked at 6 months of age (±2.9) (Figure 2). NHF index decreased and trended 
towards normal skin over time. IHs with a deep component (deep or mixed IH) reached a minimum 
value of 1.46, while the superficial IH reached a minimum value of 1.03, showing that no deep or 
mixed IH was fully involuted before the age of 23 months. 
Overall, mean NHF indices decreased significantly as IHs progressed from proliferative to 
involuting (Figure 3, ANOVA, p = 0.002). Using the Holm-Sidak t-test, the NHF index during the 
proliferative stage was significantly higher than during the plateau and involuting stages (p=0.020, 
p=0.001 respectively). There was no significant difference in the NHF index between plateau and 
involuting stage IHs (p=0.121). A summary of the statistical results can be found in Table 3.3, 
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which shows that NHF yields a better distinction than the measures of vascularity or oxygenation 
by themselves.  
 
 
Table 3.3 P-values of features comparing the three stages of IH (Proliferative, Plateau, and Involuting). 
 
Figure 3.4 Boxplots show the distribution of NHF measurements according to the stage classification: 
Proliferation (N=6), Plateau (N=12), and Involuting (N=5). One star (*) indicates statistical significance based 
on the Holm-Sidak t-test. 
 
 
3.4.7 Treated Infants with IH 
Within the treatment subjects (N=4), 3 IHs were classified superficial and 1 as mixed. All subjects 
demonstrated response to propranolol treatment according to clinical criteria or size, volume, and 
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color. Of the four infants, two did not have complete measurement data and were omitted from the 
analysis. From the remaining two subjects, one showed an improvement in NHF by 39.2% over a 
3-month span of treatment with topical timolol.  
The final subject (Figure 3.5) presented at 1 month of age with a large segmental superficial 
proliferative IH of the left lower extremity and was started on oral propranolol. Pre-treatment (1 
month) and post-treatment (3 and 13 months) measurements were obtained from the IH and the 
contralateral, unaffected leg.  
 
Figure 3.5 Photographs of a subject classified with a large segmental superficial IH. Top, subject at 1 month of 
age, just prior to treatment. Middle, subject after 2 months of treatment. Bottom, subject after 12 months of 
treatment. 
 
The baseline DOS measurements demonstrated hypoxia in the IH (NHF 2.38), which normalized 
to normal skin oxygenation (NHF 0.96) after 2 months of propranolol treatment. This correlated 
to clinical observations of decreased red discoloration and papules (Figure 3.5, Table 3.4). After 
propranolol discontinuation at 13 months, NHF continued to be normal (0.97). These parameters 
suggest that total hemoglobin content was reduced while oxygen saturation in the IH increased 
towards normal skin values during propranolol treatment. 
 
Response to Propranolol: DOS Measurements 
 1 month 3 months 13 months 
rTHb 3.22 0.85 0.98 
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rStO2 0.65 0.94 1.04 
NHF 2.38 0.96 0.97 
Table 3.4 Normalized [THb] StO2 and NHF results from the treated case subject. Measurements were made at 
1 month of age just prior to treatment, and at 3 month and 13 months of age where propranolol was 
administered. 
 
3.4.8 Study Discussion 
IHs are the most common tumor of infancy and have phenotypic heterogeneity that can complicate 
management decisions and objective monitoring for natural progression or response to treatment. 
Accepted standards use subjective visual assessments of the IHs such as clinical examination, 
visual analog scale (VAS), and photography to analyze size, color, and anatomical distortion [70, 
72, 73, 75]. Methods to measure IHs to determine area and volume of the lesion have been 
proposed [70, 72, 75]. Haggstrom, et. al. developed a comprehensive severity score that that 
attempts to account for size, complications, and location, and disfigurement [71]. Although the 
results are promising, the scale does not provide information with regard to IH volume and extent, 
and subjective measures integrated in the calculation made is operator- dependent. In summary, 
assessments are largely subjective and operator-dependent thus may not be easily replicable and 
compared. 
Furthermore, the lack of objective and quantifiable tools to measure IH biology and severity can 
hamper understanding of pathophysiological processes, such as hypoxia, that may be involved [63, 
80], and make it difficult to quantify and compare efficacies of different treatment modalities. 
Thus, it is of great interest to clinicians to develop and validate means for evidence based 
diagnostics [63, 76, 77]. 
We have developed a WHDD device that provides an objective, reproducible, non-ionizing, non-
invasive and portable tool to measure hemoglobin content and oxygen saturation in IHs of all 
stages without the need for sedation. By using these measures, DOS can tell us more about IH in 
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its different stages and how the vascular information could be applicable towards understanding 
the pathophysiology. 
Employing the WHDD, we have defined NHF as a measure of tissue hypoxia and vascularity that 
correlates well to clinical appearances and stages of IHs. NHF peaks at 6 months of age, correlating 
with the end of the most active proliferative period. By 13 months of age, a period of plateau phase, 
the NHF is steadily decreasing. This demonstrates the IH become more like normal skin as they 
mature and become less hypoxic. This might explain why IH become more likely to ulcerate during 
rapid growth periods [100]. Furthermore, propranolol treatment normalized NHF at time points 
earlier than untreated IHs, suggesting that propranolol may target IHs in part by correction of the 
hypoxic state. This demonstrates that with successful treatment of IH, DOS may be able to track 
accelerating involution or movement towards normalization.  
There are limits to this study. Although this system can be used for facial IH, we decided to take a 
conservative approach for ease of recruiting subjects given that greater ocular protection would be 
required to use the device on lesions closer to the eye. Use of protective goggles caused infants to 
become more active, and a result, repeatability measures faltered for these measurements. We did 
not use a formal visual analog scale (VAS) to assess patients at time points. US was only performed 
as clinically indicated and we do not have data for all patients. In cases in which US was performed 
the clinical classification (superficial versus having a deeper component) correlated with our 
clinical impression. Ulcerated IHs were excluded because the WH-DOS interface requires contact 
with the skin. Future versions of the WH-DOS could have a non-contact interface for measuring 
ulcerated lesions and improving repeatability.  
In conclusion, we demonstrate that DOS has the potential to aid in monitoring IH growth and 
involuting stages, which may aid in management decision and quantify treatment efficacy. The 
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high variability in the size and classification of IHs require more subjects for a more complete 
analysis. The treatment cohort was small and anecdotal and our findings need to be confirmed in 
a larger study. Future studies are required to evaluate DOS in relation to other objective measures 
of IH growth such as VAS and US, as well as to assess its applicability in complicated IHs. 
 
3.5  Two-Layer Discrimination of Optical Properties 
Using the reconstruction technique described in section 2.2.6, a semi-infinite target medium is 
assumed of our measurement area. Thus, the optical properties of that medium are assumed to be 
uniform throughout the medium. For infantile hemangiomas (IH), the lesion is largely cutaneous 
and the normal tissue lies underneath. Because of this, our DOS measurements is largely an 
integration of the IH and normal tissue, depending on the depth of the IH and the distance of the 
source-detector (SD) pair. For example, if the SD distance is 20mm, as is the case with two of the 
pairs from the WHDD system, the measured tissue within a 10mm depth will be integrated as one 
semi-infinite medium with the light prorogation model described in section 2.2.6. Therefore, it 
would be advantageous to have the ability to discriminate the optical properties of the IH and the 
normal skin underneath. For example, an IH that is located on the scalp will not have the optical 
properties of the skull or brain integrated into the reconstruction. This not only provides a more 
accurate depiction of the optical properties of the IH, but also allows the IH to be measured without 
interference of the various tissue types that the IH may be located. 
The end objective for the use of two-layer discrimination of optical properties is to use the data 
obtained during the clinical trial and the calculated depth from Ultrasound images against the two-
layer model to estimate the optical properties of the IH and the normal tissue layer beneath it. 
Unfortunately, US was only performed as clinically indicated and we do not have data for all 
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patients. In addition, US imaging was taken place weeks before or after the DOS measurements, 
and therefore cannot be combine in this research. 
In this section, work towards discriminating the IH and normal tissue layers are presented. To 
discriminate the optical properties of the two tissue types, a two-layer reconstruction was 
developed that can more accurately compute the optical properties of the two different layers 
(Figure 3.6). To test the two-layer reconstruction, several numerical simulations were performed 
to test the theoretical viability of the algorithm. Optical properties of the two layers will be 
computed with the developed two-layer reconstruction model while varying the number of 
variables the algorithm can compute. For example, results with and without the depth information 
will be compared, as well reconstructing the scattering parameter, or setting the scattering 
parameter to a fixed value. To test the algorithm experimentally, a two-layer liquid phantom model 
was created. 
 
Figure 3.6 A schematic drawing of a two-layer system with a semi-infinite bulk medium. The parameter z is 
taken in the vertical direction and the interface is at z=0. The parameter L is the depth of the first layer, which 
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3.5.1 Ultrasound Guided Optical Imaging 
Optical imaging based on diffusive near-infrared NIR light has the great potential to differentiate 
tumors from normal tissues through determination of tissue parameters, such as blood volume, 
blood O2 saturation, tissue light scattering, and water concentration. As a potential diagnostic tool, 
however, NIR diffusive light imaging suffers from low spatial resolution and lesion location 
uncertainties because of intense light scattering in tissue.  
Reconstruction of tissue optical properties in general is underdetermined and ill-posed because the 
total number of unknown optical properties always exceeds the number of measurements, and the 
perturbations produced by the heterogeneities are much smaller than the background signals. In 
addition, the inversion reconstruction algorithms are sensitive to measurement noise and model 
errors. Current instruments can distinguish simple structures approximately 1 cm in size, but sharp 
edges are typically blurred by a few millimeters. 
Other groups have developed hybrid imaging methods that combines ultrasound and NIR diffusive 
light imaging [101-103]. The hybrid imaging obtains coregistered ultrasound and NIR diffusive 
light images through simultaneous deployment of an ultrasound array and NIR source–detector 
fibers on the same probe. Coregistration permits joint evaluation of acoustic and optical properties 
of different tissue types (i.e. tumor and normal tissue) and enables use of lesion morphology 
provided by high-resolution ultrasound to improve the lesion optical property estimate. With the a 
priori knowledge of lesion location and shape provided by coregistered ultrasound, NIR imaging 
reconstruction can be localized within specified regions. As a result, the reconstruction is 
overdetermined because the total number of unknown optical properties is reduced significantly. 
For our application, the two-layer reconstruction of optical properties between the IH and normal 
skin can be better resolved if the number of unknown are reduced, particularly if the depth 
information is known in order to only obtain the optical properties. To this point, it is possible to 
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use Doppler ultrasound as a high spatial resolution imaging modality to compute the depth of the 
IH as a priori information that can be used in the two-layer optical reconstruction algorithm. 
 
3.5.2 Reconstruction Algorithm 
Many different parts of the human body exhibit a layered structure, e.g., skin layer, the head or the 
extremities. Specifically for IH, a highly vascular diseased layer of tissue overlays a much thicker 
normal layer of tissue. To this end, the semi-infinite reconstruction algorithm described in section 
2.2.6 is expanded such that he SRS equation is solved for the 2-layered turbid media in the steady-
state. With the semi-infinite model, there were three unknown variables to solve for using the ES 
optimization technique (HbO2, Hb, reduced scattering, µs’). For the two-layer model, the number 
of variables have increased to seven variables. These consist of the previous three, (HbO2, Hb, 
µs’), but both are independent for the two layers, in which case there is HbO2top, Hop, µs’top, 
HbO2bottom, Hbbottom, µs’bottom. The seventh variable is the thickness of the top layer, L (Figure 3.6). 
If more chromophores are within the tissue medium, then any additional variables must be added 
to the model. 
 The solutions were derived for a semi-infinite layered and for a finite layered geometry, i.e., the 
bottom layer has an infinite and finite thickness, respectively. For simplicity of presentation, only 
two spatial dimensions are considered. Hereafter, z denotes depth and x the transverse spatial 
variable. For simplicity, we assume index-matched boundaries. The optical properties in one layer 
may be different from the other layer. To acknowledge this difference, we denote the optical 
  60 
properties in the top layer by (HbO2top, Hbtop, µs1’) and those in the lower layer by (HbO2bottom, 
Hbbottom, µs2’), as shown in Figure 3.7.  
 
Figure 3.7 Ultrasound image of a deep IH from a patient in our IH-DOS measurement clinical study. 
Radiologist measurements of the length and depth (L) are in dotted yellow. Labels show how the two-layer 
model separates the optical properties of the IH and the underlying layer.  
 
 
3.5.3 Numerical Simulations 
Numerical simulation experiments were conducted to evaluate the capabilities of the 
reconstruction algorithm to accurately measure the different absorbers in a two-layer medium. This 
algorithm is capable of reconstructing optical properties of human tissue, specifically 
chromophores of [Hb], [HbO2], lipid, and water concentrations. In addition, the algorithm can also 
reconstruct optical properties for phantom experiments, namely ink and water concentrations. For 
purposes of characterizing the algorithm’s capabilities, numerical simulations were done for both 
cases of human tissue and phantom measurements. 
The numerical simulation experiments are done in two parts. First, simulated data must be created 
by the reconstruction’s forward model, and second, using the simulated data, reconstructions of 
the tissue or phantom’s medium properties are computed. In order to create simulated data, a 
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forward calculation is made with known properties of the simulated two-layer medium. These 
forward calculations provide the theoretical reflectance data acquired at the detector of the 
experimental setup. This simulated reflectance data sets were then used in the two-layer 
reconstruction algorithm to compute the optical properties of the two layers. 
To simplify the numerical simulation experiments, parameters were either assumed to be known 
or assumed to be equal between the two layers. Specifically, the depth (L) was assumed to be 
known, since the depth of an IH lesion is commonly computed using US imaging, particularly with 
IH that can affect the functionality of surrounding organs. In addition, the scattering amplitude and 
power is assumed to be equal between the two layers. This is due to the limitation of continuous 
wave DOS imaging, which makes it difficult to accurately separate scattering from absorption 
coefficients when reconstructing optical properties. It is expected that the number of potential 
unknowns (N=7) is too great for the number of source-detector pairs (N=8) and that not enough 
information is provided for the reconstruction algorithm making the problem largely ill-posed 
compared the semi-infinite based model. 
When reconstructing the optical properties of the simulated two-layer medium, an initial guess of 
the optical properties of the medium must be provided to be used as a starting point for the 
algorithm to reconstruct the actual properties. If the starting point is the exact properties of the 
medium, then obviously, the reconstruction algorithm will immediately reconstruct the medium 
with accurate results. Because of this, the initial guess made for each unknown parameter was 
randomly made with a starting point within the mean of the provided range for the particular 
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chromophore. For example, if the range for reconstructing [Hb] is from 5 to 250uM, then the initial 
guess for the chromophore is 127.5uM. 
For numerical simulations based on simulating different IH lesions with different depths and 
optical properties for the “top”, or IH layer, while keeping the “bottom”, or normal tissue layer 
constant for different experiments. Because IH lesions will have a much higher absorption than 
the bottom layer, due to the higher concentration of HbO2 and Hb in the lesion, the parameters 
will be such that the total hemoglobin concentration ([HbT]) will always be higher than that of the 
normal, “bottom”, layer. In addition, the IH lesions are proposed to be hypoxic compare to the 
normal tissue, and as such the concentrations of [HbO2] and [Hb] will vary such that the %Sto2 
will be lower than that of the bottom layer. The SNR of the reconstructions were set to 20 to 
simulate noise acquired during acquisition. Table 3.5 contains the values of the simulated tissue 






Table 3.5 Values for simulated properties of IH diseased and normal tissue layers.   
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Figure 3.8 Computed error of reconstruction results that simulate IH diseased and normal tissue layers. (TOP): 
shows the total hemoglobin concentration error for top layers, given 3 different simulations. The bar graphs 
on the bottom layer show the accuracy of the properties of the bottom layer provided the depth and the 
concentration of the top layer. L1 denotes “layer 1” or top layer. (BOTTOM): error of the reconstructions of 
StO2%. This demonstrates the algorithms ability to discriminate different chromophores. 
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The optical and physical parameters chosen for the numerical study was derived from the results 
of our clinical study, based on the semi-infinite medium based reconstruction algorithm. Our 
clinical results showed IH depths of 0.1cm to 1.5cm and a range of THb from 120 to 400uM for 
the first layer. The simulations created had a linear profile of depth to THb concentrations. The 
StO2 was also varied for each THb and depth profile. The StO2 in these simulations were 30%, 
60% and 70%. This simulates a highly hypoxic, moderately hypoxic, and non-hypoxic tissue. The 
second layer, simulating normal tissue, assumed a THb of 65uM and a StO2 of 77%. Scattering 
power was assumed to be equal in both layers. To evaluate the improvement in accuracy using a 
priori or assumed information, experiments were done using a known depth. This would simulate 
the use of a high spatial resolution imaging such as US to determine the depth of the lesion.  
The results for the first layer show that the reconstructions fall within 5% of the actual value of 
HbT and StO2. The measured results of the optical properties from the second layer is not as 
accurate as the top layer and the accuracy varies greatly for different first layer depths. This is due 
to the fact that the larger the depth of the top or diseased tissue, the less amount of light is 
penetrated to the bottom layer, and consequently, the amount of light reflected back to the detector 
is even lower. This makes for an inaccurate measurement for the bottom layer, but fortunately, the 
optical properties of the top or diseased layer are most important and it may be assumed that for a 
certain thickness of IH tissue, the medium can to modelled as semi-infinite. Results from the 
second layer show that the properties are accurate within 5% up to depths to 10mm. Beyond 10mm, 
the properties of the bottom layer reconstruct with an error up to 52%. 
In addition to simulating optical properties of tissue, I evaluated the algorithms ability to 
reconstruct simulated phantom data. Simulating phantom data was done to help design a physical 
phantom study. This way, the actual phantom results can be compared to the theoretical results. In 
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this simulation, I created two profiles for a two-layer phantom. The first profile consists of a high 
absorbing top layer, simulating the high absorption of an IH lesion. The second profile is a lower 
absorbing layer than the first, simulating an IH lesion that is in its plateau or involuting stage. The 
second bottom layer has a lower absorption than the top layers two profiles. The scattering 
coefficient for this simulation is equal for all layers. Table 3.6 contains the absorption and reduced 
scattering coefficients for the simulated phantom, and Figure 3.9 shows the error of the 
reconstructed values against the actual values. 






Absorption	(cm^-1)		 0.537	 0.895	 0.179	
Scattering	(cm^-1)	 8.93	 8.93	 8.93	
Table 3.6 Optical properties of a simulated phantom design. Two profiles are shown: a lower absorbing top 
layer profile and a higher absorbing top layer profile. The bottom layer properties are the same for both 
profiles. 
 
Results of this phantom simulations show that the lower absorbing profile can be accurately 
resolved even at depths of 12mm for both top and bottom layers. However, for the higher absorbing 
profile, the results are only accurate within 99% for the top layer. For the bottom layer of the higher 
absorbing profile, the accuracy is within 99% up until a top layer depth of 9mm, at which point 
the optical properties of the bottom layer cannot be accurately resolved. In the next two sections, 
I will describe a physical phantom and report experimental results based on the two profiles 
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Figure 3.9 Reconstruction results of simulated phantom data. (TOP): This figure shows the error of the 
reconstruction for the higher absorbing profile, in which the top layer absorption coefficient is ua=0.895(cm-1). 
(BOTTOM): This figure shows the results for the lower absorbing profile, which demonstrates that the 
properties can be accurately resolved at this lower absorbing coefficient of ua=0.537(cm-1). 
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3.5.4  Two-layer Phantom Design 
To verify the use of the two-layer algorithm experimentally and to demonstrate the viability of the 
reconstruction algorithm, the numerical study was translated into phantom experiments to simulate 
real tissue. Various groups have created two layer optical phantoms to simulate skin and skin 
lesions such as melanoma [104-108]. Although there were several designs to utilize as a baseline 
for a two-layer phantom, I choose the design from Bianco et. al., in which a phantom was produced 
that used U-shaped spacers of different thicknesses and mylar sheets as a clear separator to create 
multiple wells to hold liquid solutions to simulate multiple layers of tissues with different optical 
properties [109].  Since this design was the most applicable for simulating an IH lesion while using 
liquid solutions to simulate tissue, I used this design as the backbone for my phantom design.  
Implementation of the design however was not a robust solution for reproducibility, and the 
making of a two-layer phantom while using liquid solutions took many iterations of design for a 
successful phantom design. The initial two-layer phantom design that was be created was a two-
well box that can hold liquid solutions that simulate optical properties of that of human tissue. As 
with Bianco et al, I used U-shaped spacers that were made from laser cut acrylic that were 4mm 
thick. The spacers were stacked to make up the proper volume of the two wells, which was 1 to 
15mm thick for the “top” or IH diseased layer and 100mm for the “bottom” or normal tissue layer. 
The large depth of the second well is due to the assumption that the second layer is a semi-infinite 
medium.  The two wells will be separated by mylar film that is only 20um thick. This mylar film 
also is used as a window to the outer box so that the WHDD can make as close a contact to the 
liquid solution as possible. Each layer of spacer and mylar window separator were sealed using 
RTV silicone to prevent leaking.  In order to hold the phantom wells together and to prevent 
leaking, seven 15cm long socket caps are pushed through the entire phantom with wing nuts 
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screwed into the other end to secure all phantom parts together. A photo of the design is shown in 
Figure 3.10. 
 
Figure 3.10 Photo of the first two layer phantom design. A prototype of the WHDD is shown imaging the 
phantom at the mylar window. 
 
Two major issues with the design of the phantoms was securing a leak-free enclosure for the liquid 
phantom solutions and designing the wells such that inserting and removing the liquid solution. 
With two different absorbing and scattering solutions, it was important that the solutions do not 
interact with each other. In addition, leaks from individual wells was also an issue, as the liquid 
solution is costly and difficult to make. As such it was important for us to preserve the solution.  
To solved the problem of leaking and repeated use, silicone spacers were used instead of using the 
combination of acrylic spacers and RTV silicone. These silicone spacers were designed similarly 
to the acrylic spacers but was implemented differently. In order to create the spacers, an aluminum 
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sheet of 30mm thickness was milled to create moldings for the two-part silicone mixture (Dragon 
Skin 20). Four moldings with different depths (1, 3, 6, and 10mm) were milled into the aluminium 
sheet (Figure 3.11).  
 
Figure 3.11 This aluminum sheet was milled to create a molding for the silicone spacers.  
Once the silicone mixture cured (About 24hr cure time), the spacers were stacked in the same way 
as the acrylic spacers. Mylar sheets were used to separate the wells, and screws were used to tighten 
and hold the phantom in place (). This design of using silicone made the spacers double as a spacer 
for the well and a gasket to prevent leaking. The silicone design also was easier to use and reuse, 
as RTV silicone did not have to be replaced when modifying the phantom for a different well 
thickness. Unfortunately, the use of silicone spacers with the screw tightening caused the silicone 
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to compress much more than expected, and with the use of the mylar windows, the thickness of 
the “top” layer well could not be accurately measured. 
 
Figure 3.12 Phantom design with silicone spacers. The silicone in this design made a tight seal to prevent leaks 
but was not rigid enough to accurately measure the thickness of the “top” well. 
 
Due to the difficulty of using liquid solutions for a multi-layer phantom, a half solid, half liquid 
solution phantom design was implemented. In this final design, a single well with dimensions of 
10cm x 10cm by 12cm was created, where a 10x10x10cm solid phantom (Biomimic, INO Québec, 
Canada) was used as the lower absorbing bottom layer and a high absorbing liquid solution was 
used as the top layer. The properties of the solid phantom are shown in Table 3.7. A clear Mylar 
window at one end was used so that the DOS probe could be placed and the phantom could be 
imaged with minimal interference from the clear window. A Solidworks image of the design, as 
shown in Figure 3.13 shows the single well phantom for two-layer measurements. 
		 INO	Phantom	Block	Optical	Properties	(1/cm)	
WL	(nm)	 670	 780	 808	 850	
Predicted	(ua)	 0.15	 0.15	 0.15	 0.15	
Predicted	(us')	 8.5	 8.5	 8.5	 8.5	
Measured	(ua)	 0.214	 0.179	 0.173	 0.168	
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Measured	(us')	 9.31	 8.93	 8.97	 8.72	
Table 3.7 Optical properties of the INO solid phantom block. Predicted values are the values submitted to INO. 
Measure values are the actual optical properties.  
 
 
Figure 3.13 Solidworks design of a two-layer phantom mold that contains two wells to hold tissue-simulating 
solutions for optical spectroscopic measurements. The front well will simulate the IH lesion while the larger 
second well will simulate normal tissue. The spacers can be changed and adjusted by unscrewing the container. 
 
In this design, the solid phantom was wrapped tightly with one layer of Saran wrap and placed into 
the well such that there was 1 to 15mm of space between the solid phantom block. In the space 
between the solid phantom block and the mylar window, the liquid solution that consisted of water, 
ink and Intralipid was inserted. To adjust the depth of the layer of liquid solution, the solid phantom 
block could be place back and forth to a set distance from the mylar window. A small metric ruler 
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was placed onto the edge of the phantom well to accurately adjust the depth of the first layer. A 
photo of the final phantom design is shown in Figure 3.14. 
 
Figure 3.14 Photos of phantom well with modified front window with increased tension for more accurate two-
layer measurements.  
3.5.5 Discussion 
Infantile hemangiomas (IH) are vascular plaques that proliferate during early stages of life. Its 
presentation consists of a nodular tumor of varying classification (Deep, superficial, mixed) with 
normal tissue surrounding it. In section 3.4, I describe a clinical study in which IH optical 
properties were measured using a reconstruction algorithm that assumes a semi-infinite medium. 
Although the results were promising, a two-layer model better represents the IH overlaying normal 
tissue. To this end a two-layer reconstruction model was developed. The reconstruction algorithm 
was characterized using various numerical simulations that varied the absorption of the “top” IH 
layer while keeping the absorption from the “bottom” layer constant. The scattering coefficient 
was assumed to be constant and equal for both tissue layers. The depth of the top layer was 
assumed to be known, corresponding to the use of Ultrasound imaging to determine the thickness 
and size of the IH. The theoretical experiments modelled both tissue and phantom based mediums 
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accurately within 95% for most cases. It was observed that at “top” layer depths of 9mm and 
greater, the error of the reconstructions exceeded 10% and reached as high as 50%.  
To characterize the two-layer model even further, the numerical simulations were translated into 
a phantom study, in which a large phantom well that contained a solid phantom with well 
characterized optical properties and a liquid solution that was optically absorbing and scattering 
were used simulate the two-layer IH-normal tissue layers.  
Future work would consist of imaging IH subjects on the same day as the Ultrasound imaging to 
ensure that the depth of the lesion is accurate to the measurements time of DOS. US was only 
performed as clinically indicated and we do not have data for all patients. Unfortunately, US was 
never perform on the same day of the DOS measurements. To expand on the two-layer 
measurement study, it will be important that US and DOS imaging be done at the same time. In 
addition, there are groups that have implemented a US-DOS probe to perform the measurement 
simultaneously [110-112]. A system as such would be beneficial to hemodynamic research of IH 
lesions as it can provide accurate a prioi data for DOS reconstructions. 
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4 Optical Imaging Techniques for Monitoring Treatment of Rheumatoid 
Arthritis 
The content for this chapter focuses on the effort towards achieving Aim 3 of this dissertation, 
where the objective is to compare the sensitivity of optical measurements of the WHDD to the 
proven capabilities of a frequency domain optical tomographic (fDOT) system for a clinical study 
monitoring the effects of treatments for patients with RA. In this chapter, I will first provide an 
overview of RA and its prevalence, the current treatment strategy, and the clinical and radiological 
imaging measures used to characterize the severity of the disease. Next, I will describe the current 
optical imaging techniques used for imaging RA and the outcomes. This will include the previous 
work from our research lab. I will also describe the system and techniques used by our lab’s fDOT 
imaging system used to diagnose RA. Finally, I will describe a longitudinal treatment study for 
patients suffering from RA. I will provide fDOT and WHDD results and compare them both to 
each other as well as the clinical measures. 
4.1 Rheumatoid Arthritis 
Rheumatoid arthritis (RA) is a systemic, chronic, inflammatory autoimmune disorder that causes 
chronic inflammation of the synovial membrane of small and large joints [113, 114]. RA is 
characterized by the persistent synovial inflammation and damage to the associated articular 
cartilage and underlying bone, typically in the peripheral joints and their surrounding tendons and 
ligaments [115]. While RA can be mild, it can also be severe and can be associated with significant 
pain and disability, with studies showing that up to 10% of individuals suffering from RA can 
experience total disability [116]. 
RA affects 1% of the population worldwide, with approximately 1.3-2.1 million people in the US 
[117-119]. The disease also leads to 5–50 per 100,000 new cases annually [120] and leads to 9 
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million physician visits per year in the US [121]. Women are about three to four times as likely as 
men to develop RA [120]. RA can occur at any age, although it is more likely to occur among 
those aged 40-70 years and its incidence rate increases with age. Fifty percent of the risk for 
development of rheumatoid arthritis is attributable to genetic factors. Smoking is the main 
environmental risk.  
Subjects with RA can suffer from severe pain, joint stiffness, swelling of multiple joints, and lack 
of joint mobility. Symptoms primarily affect the peripheral joints, with common joints being the 
wrists, proximal interphalangeal (PIP), and the metatarsophalangeal joints [115, 121]. 
Uncontrolled, the symptoms can lead to self-limiting arthritis or rapidly progressing multi-system 
inflammation with significant morbidity and mortality (including cardiac, neurological, and 
hematological complications) [115]. These symptoms can eventually lead to severe disabilities and 
loss in quality of life. The severity of RA has been classified by different authors have providing 
classifications of the disease progression into different stages [118, 122]. 
 
Figure 4.1 (a) Example of symmetric synovitis affecting the hands, highlighting the location of a PIP joint. (b) 
X-ray images with radiographic evidence of RA, highlighting the location of a PIP joint. (c) Illustration of a 
typical healthy joint. (d) Illustration of a typical joint exhibiting symptoms of RA. (c,d) Schematic of a typical 
synovial joint. 
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The pathophysiology of RA is not completely known, but in the past 10 years there has been 
several key advances into the pathophysiology of RA [123, 124]. At its onset, the synovium 
sublining undergoes alterations, resulting in prominent infiltration of mononuclear cells such as T-
cells, B-cells, macrophages, and plasma cells. Overproduction and over-expression of TNF is one 
of several key inflammatory forces in RA, and is known to drive synovial inflammation (Synovitis) 
and joint destruction [115]. The handicaps associated with RA can result in large financial costs 
due to health care expenses and loss of productivity at work. Despite recent advances in therapeutic 
intervention including biological therapies, there is currently no cure for RA. Early treatment of 
RA, however, has been shown to significantly improve clinical outcome and management of the 
disease. It is, therefore, important to diagnose a subject with RA as early as possible. 
4.2 Treatment of RA 
There is currently no cure for RA [124]. Disease-modifying anti-rheumatic drugs (DMARDs), the 
key therapeutic agents, reduce synovitis and systemic inflammation and improve function. The 
leading DMARD is methotrexate, which can be combined with other drugs of this type, such as 
hydroxychloroquine, or sulfasalazine. Because of the poor prognosis of RA and the effectiveness 
of early treatment, it has become important to diagnose RA as early as possible [121]. 
Many pro-inflammatory cytokines, chemokines and growth factors are expressed in diseased 
joints, and the recognition of the key role of TNF led to the development of highly effective new 
therapies. It was shown that anti-TNF agents may inhibit joint damage. Recent pharmacological 
advances saw the introduction of the first set of biological agents that target TNF and are approved 
for use by subjects with RA. These agents include etanercept (Enbrel), infliximab (Remicade), and 
adalimumab (Humira). However, approximately only 50% of patients treated with the most 
commonly used non-biologic DMARD (methotrexate) adequately respond to treatment. Among 
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patients not responding to treatment with methotrexate or another type non-biologic DMARD, up 
to 20% are eventually placed on therapy with biologic therapy, typically a TNF inhibitor. 
4.3 Clinical Measures 
4.3.1 Laboratory Measures 
Laboratory tests are commonly used in helping diagnose RA, however, they are not specific to 
RA. The presence of biological markers, such as rheumatoid factor (RF) and anti-cyclic 
citrullinated peptide (anti-CCP) antibodies, are used in diagnosis of RA. The presence of elevated 
titers of RF has been associated with a more severe disease course [125]. The erythrocyte 
sedimentation rate (ESR), a measure of the rate at which red blood cells settle, is generally a useful 
measure for following the course of inflammatory activity in an individual subject. Concentration 
levels of the C-reactive protein (CRP), an acute-phase reactant, may also be used to monitor the 
level of inflammation.  
4.3.2 Clinical Imaging 
Frequently, rheumatologists seek imaging evaluation of the joints in order to further support a 
decision to advance treatment or monitor response to treatment. Numerous imaging modalities are 
available to evaluate joint involvement in RA. Radiography (X-ray) can document bone damage 
(erosion) that results from RA and visualize the narrowing of cartilage spaces. Although effective, 
X-rays use ionizing radiation to generate images in the body that can potentially cause damage to 
DNA. In addition, although X-ray is a standard diagnostic tool for RA, it has long been recognized 
that x-ray imaging is insensitive to the early manifestations of RA, namely effusion and 
hypertrophy of the synovial membrane. To evaluate X-ray images, the Sharp method is a well-
established and used widely in many studies. In this method, erosions and joint space narrowing 
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are scored in 17 and 18 areas in each hand respectively. The maximum score per single joint for 
erosions is 5, and for joint space narrow, 4 [126, 127]. 
Magnetic resonance imaging (MRI) is a highly sensitive and accurate imaging technique that does 
not require radiation and can evaluate synovial inflammation, as well as damage to non-bony 
articular structures. MRI is most useful in assessing soft tissue problems, avascular necrosis, 
degree of cartilage erosion, osteonecrosis and carpal tunnel syndrome [128-131]. Cumbersome 
use, large costs, and the need for contrast agents (e.g. gadolinium to detect increase blood volume 
caused by neovascularization in the hypertrophic synovial membrane) have prevented MRI from 
becoming a widely used imaging modality for detection of RA. Scoring of synovitis and erosions 
will be performed according to the EULAR OMERACT criteria using a semi-quantitative scoring 
system as previously described by Schirmer [132]. 
Ultrasound is used for the detection of synovial changes in RA and has been validated as a measure 
of hyperemia in RA inflammation. Previous studies have shown that Doppler US can detect 
synovitis in the small joints [133-135], and a quantitative estimate of the degree of inflammation 
can be obtained. The degree of joint effusion and hypertrophy will be evaluated and classified on 
a 4-grade semi-quantitative ultrasound examination score (USS) according to Szkudlarek et al. 
[136]. 
4.3.3 Clinical Assessment  
Disease activity in RA is estimated using tools that take into account swollen and tender joint 
counts, patient assessment of pain, patient and evaluator global assessment of disease activity, 
measurement of acute phase reactants and evaluation of functionality. These assessments help the 
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clinician decide how to adjust the medication regimen making it essential to managing the disease. 
The following are three commonly used scoring indices. 
Clinical Disease Activity Index (CDAI): The calculation of CDAI is based on four measures. The 
first two summates the number of swollen and tender joints (swollen joint count [SJC] and tender 
joint count [TJC]) using a 28-joint count (Scored 0-28). Next, a patient global assessment (PTGA) 
score is made and finally, a provider global assessment (PRGA) score is made. The final score for 
CDAI is given by the equation CDAI = SJC + TJC + PTGA + PRGA. As part of the joint count 
assessment, basic lab results such as RA related antibodies and levels of inflammatory markers 
will be collected if they have been obtained for the participants as part of their routine care [137]. 
Health Assessment Questionnaire (HAQ): The HAQ is a generic measure of functional disability 
and is the most widely used measure of functional disability in RA. This self-assessment 
questionnaire comprises a functional disability index (DI), a visual analogue scale (VAS) that 
measures pain, and a patient global VAS [138].  
Short Form 36 (SF-36): The SF-36 is a self-assessment questionnaire designed for use in clinical 
practice and research, health policy evaluations, and general population surveys. The SF-36 
includes one multi-item scale that assesses eight health concepts for both physical and 
psychological distress [139]. Table 4.1 Interpretation and scoring ranges for the five non-imaging 
clinical scores. provides an interpretation for the various scoring methods. 
	 Disease	Activity	Range	
Measure	 Remission	 Low	 Moderate	 High	





Table 4.1 Interpretation and scoring ranges for the five non-imaging clinical scores. 
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4.4 History of Diffuse Optical Imaging for RA Diagnostics and Motivation for Utilizing 
the Wireless Handheld DOS Device 
Optical techniques for imaging peripheral joints for the purpose of diagnosing the presence of RA 
occurred as a result of studies in the 1990s, when researchers first reported on differences in optical 
properties between finger joints with and without rheumatic disorders [140]. It was found that in 
the early stages of RA, changes in the optical properties could be expected in the synovium and 
the synovial fluid.  
The number of leukocytes, or white blood cells, increases from 100/mL to 200/mL in healthy joints 
to 1,000/mL to 100,000/mL during stages 1 and 2, respectively. This is particularly important for 
optical techniques, as leukocytes have a diameter of approximately 7-21um and therefore have a 
considerable effect on the scattering coefficient. In regards to optical imaging of finger joints, the 
differences in optical signals between healthy joints and joints of subjects affected by RA were 
strongest at wavelengths between 600 and 700 nm [141]. 
These indications lead to the development of several optical imaging systems and some pilot 
studies [140, 142]. In these studies, light from one or more wavelengths were focused onto the 
back of the finger and transillumination intensity profiles were recorded by a CCD camera. Some 
of the limitations of pure transillumination imaging of finger joints were overcome with DOT 
imaging studies. Our research team has focused in the past on application of DOT imaging for 
detecting and characterizing inflammation in RA. Our research team has focused in the past on 
application of DOT imaging for detecting and characterizing inflammation in RA. Analysis of 
reconstructed DOT images of absorption and scattering coefficients in the proximal 
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interphalangeal (PIP) joints 2-4 has allowed classification of PIP joints with and without RA with 
sensitivity and specificity of 78% and 76%, respectively [143, 144].  
Our research team’s most recent work involved a 56 subject clinical study in which we used fDOT 
to image finger joints 36 RA affected and 20 healthy volunteers in an effort to detect RA [145]. 
This is accomplished by deriving multiple optical parameters from the optical tomographic images 
and combining them for the statistical analysis. Parameters derived from the scattering coefficient 
perform slightly better than absorption derived parameters. Furthermore, it was found that data 
obtained at 600 MHz leads to better classification results than data obtained at 0 or 300 MHz. 
Using fDOT techniques we showed that sensitivities and specificities of 0.85 and higher can be 
achieved in detecting RA when comparing to healthy volunteers without RA. The features that 
provided that best classification between healthy and RA affected joints were max us’, and stdev 
ua. Other features that provided a good classification between healthy subjects and those affected 
with RA are stdev us’ and max ua. The fDOT imaging in this study was performed using a custom 
built system used for finger imaging [146].  
Interpretation of features stdev us’ and max ua has not been fully established. It is known through 
our previous work that a large stdev (ua, us’) from the ROI likely demonstrates that the patient 
does not have synovitis in that joint. It is my hypothesis that while synovitis will create an 
accumulation of white blood cells, which is highly absorbing and scattering, optical properties are 
similar to that of the cartilage on the bone, making the optical properties uniform across of the 
joint. In addition, a large max (ua, us’) may show that bone edema and erosion is not present at 
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articular cartilage or bone ends. In a longitudinal study, we can expect that these two features will 
change according to the drug response of the patient. 
Furthermore, the use of fluorescence contrast imaging has also been shown to provide a good 
diagnostic measure of RA inflammation and disease progression [20, 147-150]. For example, 
Werner er al. [147] utilized indocyanine green (ICG)-enhanced fluorescence optical imaging (FOI) 
to assess inflammation in RA patients and found that FOI correlated significantly with Disease 
Activity Score 28, US, and the Rheumatoid Arthritis MRI Score while showing normal results in 
97.8% of joints of controls.  
Continuous wave DOT has been employed in a previous study [151], where a dual-wavelength 
tomographic imaging system DOT was used to measure hemodynamic differences in normal and 
RA affected joints. Based on 8 RA cases studies and 6 healthy volunteers, differences in the 
vascular reactivity exist between affected and unaffected joints. Analysis of the images have 
shown an enhanced vascular supply feeding the rheumatoid joint. Additionally, the dynamic 
hemoglobin characteristics support existing works that show a rise in oxygen consumption and 
metabolic activity in RA. 
Unfortunately, the current optical imaging instrumentation used for RA research thus far contains 
large components that are difficult to transport, which may prevent it use in a clinical exam setting, 
or is not feasible for screening purposes. Similar instrumentation scaled to have a smaller form 
factor of the technology used in these studies may provide diagnostic capabilities appropriate for 
screening use, or treatment monitoring. To test this hypothesis, the WHDD was employed 
alongside the fDOT in a clinical study monitoring the treatment efficacy for RA patients. It is 
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predicted that the use of the WHDD would provide information of rheumatically affected joints 
compared to non-affected or normal joints. 
4.5 fDOT Instrumentation and Imaging Protocol for Monitoring the Treatment of RA 
To evaluate RA progression under treatment, I will compare two optical imaging modalities, 
diffuse optical spectroscopy (DOS) and frequency-domain diffuse optical tomography (FDOT). 
As explained in section 1.2.2, frequency-domain (FD) optical tomography provides more accurate 
information about mediums optical properties than continuous-wave (CW) methods. With a 
sensitivity and specificity about 0.85 from the fDOT system used by our research group in our 
diagnostic study [145], we employed this system as a study device in the longitudinal study 
attempting to reliably detect optical changes from synovitis in the PIP finger joints to determine 
the efficacy of the drug therapy. In addition, the WHDD presented in Chapter 1 will be used to 
determine if the sensitivity of the device can concurrently detect the same optical changes as the 
fDOT system.  
4.5.1 fDOT System for Imaging RA 
The fDOT imaging system that will be used as a benchmark for optical changes in the finger joints 
has been described in previous literature [40, 146]. The system is made up of two units: a 
tomographic unit that performs FD based transillumination measurements and a topographic 
scanning unit, that is used to create 3D renderings of the finger joints that will be imaged. The two 
units together provide transillumination and structural information that is required to reconstruct 
3D absorption and scattering mappings of finger joints.  
The tomographic system employed is a frequency-domain system that allows for source-
modulation frequencies up to 1 GHz. As described in section 1.2.2, incident light that is modulated 
in the megahertz to gigahertz range, causes photon density waves (PDWs) to travel through the 
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finger [152]. Detection of amplitude and phase of those PDWs provides information about the 
damping and the time delay of the wave, which is valuable information for reconstructing the 
absorption and scattering properties of the finger imaged. The light source is a thermoelectric 
controlled laser diode (LDH-M-C-670, PicoQuant GmbH, Germany) with an average optical 
power of 8mW at the wavelength = 670 nm. The transillumination from the incident light is 
captured using an ultrafast gateable ICCD camera that provides RF modulated light amplification 
up to 1 GHz (PicoStar HR12, LaVision GmbH, Germany). Specific directions on how to operate 
the tomographic imaging unit can be found in “Operation Instructions 3D-TopoScan 2010-06-
02.pdf” and “Operation Instructions TomoScan 2010-11-01.pdf”. 
In addition to the transmission measurements, accurate surface coordinates of the finger can be 
generated by a topographic laser scanner unit. Using this unit, the finger is scanned by two red 
laser lines at the back and the palm. The shapes of the deformed laser lines on the finger surface 
are imaged with a fast video camera (SPC 900 NC, Philips, The Netherlands), which is controlled 
by the DAVID laser-scanner software (ver. 1.6b, TU-Braunschweig, Germany). Using a 
combination of the DAVID laser scanning software, a custom-made program for mesh fusion, and 
FEM filtering software (MeshLab) a surface mesh of the finger is acquired. Finally, the surface 
mesh is used to generate a volumetric discretization of the surface encapsulated by the surface 
mesh, often referred to as a finite-element method (FEM) mesh. 
Specific directions on how to operate the topographic imaging unit, including information on how 
to fuse the mesh data, can be found in “Operation Instructions 3D-TopoScan 2010-06-02.pdf” A 
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surface mesh of the scanned part of the finger can be created and a 3D finite volume mesh can be 
generated using GMsh software (v2.16 http://gmsh.info/).  
4.5.2 fDOT Imaging Protocol 
Before fDOT imaging, each finger is marked with a small black dot on the dorsal surface of the 
finger, 17 mm distal from the PIP joint. This mark is used to position the finger identically in both 
the fDOT imager and in the laser scanner unit. Then, the finger is place inside the FDOT scanner 
using the hand rest to hold the hand. The laser beam is then moved to the marked position. The 
finger axis (along the length of the finger) aligns with the scanning plane of the laser. Finally, 
scanning begins by moving the laser to the first source position, located approximately 10 mm 
distal from the PIP joint. The laser is then scanned over a range of 20 mm, from proximal to distal 
end of the finger (Figure 4.2). Each position represents a unique “source.” 
 
Figure 4.2 Positions of 11 laser sources on the dorsal side of the finger.   
Transillumination (on the palmar surface) is recorded for each source position with the intensified 
CCD camera. The scan is performed twice, first in the forward direction with modulation 
frequency of 600 MHz, and then in the reverse direction at 300 MHz. Two examples of 
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transillumination obtained from a single surface source, as captured by the ICCD-based detector 
system, on the posterior (or palmar) surface of the finger are presented in Figure 4.3. 
 
Figure 4.3 Transillumination captured by the ICCD detector unit on the palmar surface of a PIP joint from a 
subject with RA 
Three fingers were scanned from the predominant hand of each subjects with RA and on both 
hands of control subjects; the index, middle, and the ring finger (PIP 2 to PIP 4). To avoid 
movement artifacts in the image reconstruction, the examiner controls the correct position of the 
finger again after the tomographic scan is finished. The complete tomographic scanning time 
needed for six fingers and two modulation frequencies was about 15 minutes, or about 7 minutes 
when using only one frequency. 
4.5.3 Processing Prior to Reconstruction 
As mentioned in the previous chapter, prior to imaging the finger joints, each finger is marked 
with a small black dot on the dorsal surface of the finger, 17 mm distal from the PIP joint. This 
mark is used to position the finger identically in both the fDOT imager and in the laser scanner 
unit. Although this solution is can be feasible for imaging patients, it can also be time consuming, 
as even subtle shifts left and right may occur and can go unnoticed until after the imaging 
procedure is complete. In addition, patients suffering with RA may have significant structural 
damage to the joint, which may cause the patient unable to straighten the PIP joint. This prevents 
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the tomo- and topo-scans from aligning correctly. That is, when source and positions are selected 
on the finger mesh, the corresponding pixel location of the CCD could be in another location due 
to the misalignment. To correct for these potential inconsistencies, an effort was put into place to 
programmatically align the joints utilizing the CCD camera images to locate the center of the joint 
and to be able to map the joint center of the CCD image to the finger mesh. In this section I will 
explain how X and Y axis offsets is computed to improve the mapping of the source and detector 
positions and pixel selection from the CCD images. 
The acquisition of the CCD images produce the amplitude and phase of the laser transillumination 
from the finger. During the tomoscan, there are 11 positions along the sagittal plane of the finger 
that is illuminated for which the CCD acquires images (Figure 4.2). Along these 11 positions, it is 
expected that the source positions over the phalanx bones will have less light transmitted through 
the finger compared to the finger joint. From visual inspection from Figure 4.4, it is observed that 
the part of the finger with the highest amplitude also has the laser source directly over that location. 
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Once all 11 CCD images are acquired, the mean of these images is computed to create one image 
that produces the entire transillumination profile of the finger (Figure 4.5a).  
 
Figure 4.4 Amplitude measurements from the transillumination CCD images. Each subplot represents the 
amplitude image from the 11 source positions. From visual inspection, it is observed that the part of the finger 
with the highest amplitude also has the laser source directly over that location.  
In addition to utilizing the amplitude images, the phase of the CCD images is used to locate the 
edges of the finger joint. Here, the phase conveniently creates a pseudo-mask in which the finger 
joint is distinguishable from the background of the CCD image (Figure 4.4b). Then, by using edge 
detection and median filters, a mask of the joint from the CCD image is created (Figure 4.5c). To 
account for images that may be noisy, a user input function is used so that the user can crop the 
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image before applying the edge and mask filters. Because user input can be a long and tedious task 
for multiple fingers and subjects, the CCD finger mask data is saved for later use.  
 
Figure 4.5 Using the CCD camera images of the finger joint to create a mask for the joint of the CCD image. 
(TOP) the average of the amplitude from 11 source positions. (MIDDLE) the median of the phase from the 11 
source positions. (BOTTOM) a mask used to extract the detector positions from the CCD images.  
With the amplitude profile and finger mask used to separate the finger from the CCD, the 
amplitude line profile in the X direction can be computed. The line profile can be represented as a 
second order Gaussian (guass2 in Matlab), and along with the amplitude line profile, the fitting for 
the profile is computed (Figure 4.6). This profile is used to determine the location of the center of 
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the joint. The center of the joint in the sagittal plane can be determined by computing the location 
of the pixel where the peak of the fitting is located. The pixel position where the peak is located is 
assumed to be the center of the finger joint. Using the finger mesh to determine the position of the 
center of the joint, the X offset can be determined. 
 
Figure 4.6 Amplitude profile across the sagittal plane of the finger. (Blue) The actual amplitude profile of the 
finger joint. (Red) The fitting of the CCD amplitude profile using a second-order Gaussian fitting. 
To compute the offset in the Y direction for the CCD images, a combination of the CCD finger 
mask and the laser spot location is used. First, the laser spot location is predetermined prior to 
imaging. The position of the laser spot of the CCD images is determined by acquiring images 
without a finger or any object in the scanner. With a ND filter to reduce the laser intensity, the 
beam spot can be acquired without saturating the camera. The positions of the beam spots 
determine where the center of the finger (Y-axis) should ideally be located. Second, the mask of 
the finger from the CCD phase image can determine the actual center of the finger. The y-offset is 
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then computed by subtracting the y-axis location of the laser spot by the y-position of the center 
of the finger (Figure 4.7).  
 
Figure 4.7 Alignment correction for mapping source positions and detector locations from the CCD image 
(Right) and the mesh projection on a 2D plane (Left). The blue crossing denotes the actual center of the joint 
as determined on the mesh projection and the CCD image. The green crosses in both images show the laser 
source positions and the magenta cross show the detector positions. 
 
With the X and Y offsets determined, the mapping of the detector positions from the CCD to the 
source and detector positions on the mesh can simply be determined.  
4.5.4 3D Reconstructions of Optical Properties from fDOT 
Finally, 3D image reconstructions of absorption and scattering maps can be performed using the 
PDE-constrained reduced-Hessian SQP method [153], that solves the forward and inverse 
problems simultaneously. As a forward model, this code employs the frequency-domain equation 
  92 
of radiative transfer [154, 155]. To be able to consider the refractive index mismatch at air-tissue 
interface [156], we implemented a partially-reflective boundary condition.  
Given the spatial distribution of optical properties inside the medium, we solve the radiative 
transfer equation with a discrete ordinates method [156], which provides the prediction of 
measurements obtained on the surface of the medium. While reconstructing, the algorithm runs 
through multiple iterations to improve the estimate of the optical properties. For a given estimate 
of forward and inverse variables, the rSQP scheme makes the new iterate for both forward and 
inverse variables. Typically, the total reconstruction time was approximately 2-3 hours on a 
MacPro tower with an Intel Xeon 3.3 GHz processor. 
4.5.5 Data Processing to Obtain 3D Reconstructions 
Instructions on how to properly create FEM meshes from the toposcan, coregistering the toposcan 
to the tomoscan, and reconstruction of the finger data can be found in Appendix A. 
 
4.6 Pilot Study to Evaluate Optical Imaging Techniques in Assessment of Joint 
Inflammation and Its Response to Treatment in Patients with Rheumatoid Arthritis 
In this section, I will describe a clinical pilot study we employed to evaluate optical imaging 
techniques for the assessment of joint inflammation and response to treatment with patients with 
RA. From the previous results from our research group’s diagnostic study on differentiating 
patients with and without RA, I used the same optical parameters that distinguished healthy and 
RA affect patients to characterize the effects of drug therapy during a 36-week longitudinal study. 
From our previous work, it was found that the features that provided that best classification 
between healthy and RA affected joints were max us’, and stdev ua. 
In investigating fDOT in this longitudinal study, I hypothesize that we can differentiate the 
severely affected from the non- or marginally affected joints at baseline. In addition, I predict that 
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a response to treatment will observe a higher standard deviation of ua and higher max us’ over 
time in affected joints. Finally, I hypothesize that non- or marginally affected joints will not 
respond as highly to treatment than severely affected joints. To evaluate these hypotheses, I will 
compare optical trends to that of the clinical information provided. This will include self-
assessment questionnaires, standard laboratory tests, and radiographic imaging.  
4.6.1 Study Design 
IRB approval was obtained from Columbia University Medical Center (CUMC) Investigational 
Review Board (Protocol# IRB-AAAI0501), and patients were to be recruited from the 
rheumatology practices at CUMC. A pilot study was employed in which patients with active 
disease were to be evaluated using optical imaging techniques of fDOT and DOS using the WHDD 
probe to study and track treatment response for RA patients. PIP joints 2-4 were measured (Figure 
4.8) using these two optical imaging techniques to provide an assessment of the progression of RA 
throughout the trial. 
 
Figure 4.8 Bones of the human hand, highlighting in red the PIP joints 2-4 that were measured using fDOT and 
DOS using the WHDD probe. The PIP 1 joint denotes the thumb. 
No investigational agents were tested as study participants received only FDA-approved therapies 
for RA following the current standard of care, with all treatment choices and/or changes made by 
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the subject’s primary rheumatologist. RA adult patients with active disease (defined by CDAI >10) 
despite current methotrexate therapy who were being considered for treatment escalation were 
eligible for participation in this study. According to standard of care for patients with active disease 
despite methotrexate, study participant received either a second non-biologic DMARD (Disease-
modifying anti-rheumatic drug) versus a biologic such as Humira in addition to methotrexate.  
To assess and monitor disease progression while under therapy, several clinical scoring criteria 
were used at baseline (before initiation of treatment, or additional treatment) and at subsequently 
regular intervals of 2, 6, 12, 24, and 36 weeks. A list of the criteria is shown in Table 4.2. Under 
this criterion, patients were to be evaluated with optical imaging techniques, undergo a clinical 
assessment of their disease activity, and complete questionnaires regarding functional status. First, 
we compared changes in optical measures to changes in three clinical outcome measures: CDAI, 
SF36 and HAQ. Next, imaging modalities MRI, X-Ray and Ultrasound was used to assess the 
involvement of individual joints. Because MRI and X-ray are either expensive, time consuming, 
or radiative, these two imaging modalities were only used at baseline and at the end of the study, 
at 36 weeks. Ultrasound imaging was performed at all time points. Scoring guidelines from 
radiographic images as described in section Error! Reference source not found.. Finally, as part 
f their clinical assessment, standard of care laboratory studies such as RA related antibodies (anti-
CCP, RF) and levels of inflammatory markers (CRP, ESR) would be collected if they have been 
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obtained for the participants as part of their routine care. In addition, we will also collect 
information from the subject regarding their RA and medication history. 
 
Table 4.2 Timeline and criteria for monitoring progression of RA during drug therapy. 
 
The aim of this study was to show that the tomographic algorithms and instrumentation developed 
are capable of detecting changes in optical imaging parameters in the finger joints with treatment. 
To this end, the results of the optical measurements were compared with changes in clinical disease 
activity measures of RA.  
4.6.2 Study Subject 
Over a three-year recruitment period, only one RA patient was enrolled into this study. Although 
we initially intended to enroll up to 20 subjects for this study, I will present the results as a case 




















Table 4.3 Clinical profile for this case study for RA treatment monitoring 
 
This subject, a 42-year-old female, non-smoker, initially was taking 20mg Methotrexate once a 
week for treatment of RA. At enrolment, the subject was given additional treatment of 2000mg 
Sulfasalazine seven days a week, and 400mg of Hydroxychlorquine once a week. Both 
Sulfasalazine and Hydroxychloroquine are DMARDs that has shown to slow the progression of 
erosion, and have shown to inhibit TNF antibodies [113, 157-159]. Studies have also shown that 
the combination of Methotrexate, Sulfasalazine, and Hydroxychlorquine perform better together 
than each taken alone [160-162]. 
4.6.3 Non-Imaging Clinical Results 
To assess and monitor disease progression while under therapy, several clinical scoring criteria 
were used, as mentioned in section 4.6.1. Within this criterion, there were several non-imaging 











Table 4.4 Table of non-imaging clinical scores and self-assessment measurement tool to assess the progression 
of RA. 
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Within the non-imaging clinical scores, the CRP and ESR are measures derived from standard 
laboratory blood tests. The scores for these tests will decrease if the progression of RA improves 
for the patient. Conversely, the CDAI measure, which is derived from a combination of a joint 
count assessment and self-assessment from the patient, will have it score increase if the progression 
of RA improves.  
Figure 4.9 shows the results from the non-imaging clinical score measures. The CRP and ESR 
measures show that there was an overall improvement in the progression of RA. However, at 
weeks 6, 12, and 24, there was a fluctuation in the scores, suggesting that RA continued to 
progressed negatively. There was no data available at two weeks.  
 
Figure 4.9 Laboratory blood test results for our case study. 
 
While assessing joint count information using the CDAI scoring measure (Figure 4.10), the results 
showed an overall improvement of RA progression. As with the case with the blood test measures, 
there was fluctuation in the CDAI score over the course of the 36-week period. At the 2-week 
mark, CDAI score results more than doubled, which suggests that the subject had high disease 
activity just 2 weeks after the new treatment was administered. At 6 weeks however, the results 
dropped dramatically to its lowest point during the entire trial, but increased slowly for the 
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CDAI, the medication took weeks to become effective. The CDAI score at 6 weeks suggested a 
low disease activity. 
 
Figure 4.10 Results from the Clinical Disease Activity Index (CDAI)  
Self-assessment questionnaires were used to evaluate the subjects’ ability to do everyday activities 
such as opening a door and difficulty getting up in the morning. In addition, the questionnaires 
provide an assessment of mental health, since it is possible that even though the pathology and 
radiological scores of monitoring RA is not improving, the feeling of pain may subside. Figure 
4.11 shows the results of the SF-36 self-assessment scores. The SF-36 results imply that the subject 
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score nearly doubled from 2 weeks and held steady until the end of the trial. This jump at 6 weeks 
suggests that the therapy was most effective at this timepoint.  
 
Figure 4.11 Results from the short form 36 (SF-36) assessment tests. Scores are out of 100, with a larger score 
corresponding to improvement to RA progression. 
 
Finally, the Health Assessment Questionnaire – Disability Index (HAQ-DI), is a questionnaire to 
measure functional disability and is the most widely used measure of functional disability in RA 
(Figure 4.12). The HAQ-DI is a measure that decreases as RA reaches closer to remission. These 
results show that the drug therapy made a strong improvement to the disease activity at 2 weeks 
and stayed steady throughout the trial. 
 
Figure 4.12 Results of the Health Assessment Questionnaire – Disability Index (HAQ-DI). Results suggest a 
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Although there were fluctuations within the non-imaging clinical scores, all scores suggested that 
there was a reduction in the disease activity, showing that the drug therapy was improving the state 







Table 4.5 Summary of the non-imaging clinical results. 
 
4.6.4 Radiological Imaging Results 
In addition to using self-assessment questionnaires, joint assessment, and laboratory measures, RA 
severity assessments to monitor disease progression while under therapy using radiological 
imaging scoring methods, as mentioned in section 4.3.2. These imaging modalities include X-Ray, 
MRI, and Doppler Ultrasound (US). Within each of these imaging modalities has multiple scoring 
criterion to assess structural damage and fluid assessment. A list of all of the imaging scores can 
be found in Error! Reference source not found..  
X-Ray Imaging: Traditional radiological imaging is used in RA to assess the structural changes 
that RA manifests to a subject. For this study, X-Ray’s were only performed at 0 and 36 weeks.  
The two measures from X-Ray imaging are joint space narrowing and erosion (Figure 4.13). The 
x-ray results indicate that the right PIP 3 and left PIP 4 are the most affected joints that were scored. 
These joints did not exhibit a change during the 36 weeks. The joints that did observe a change are 
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the right PIP 2 and 4. During the course of the study, the joint space narrowing improved while 
the erosion in those same fingers worsened. 
 
Figure 4.13 Quantitative scores for X-Ray imaging performed on our subject. (TOP): Joint space narrowing. 
(BOTTOM): Joint erosion from cartilage damage. 
MRI Imaging: Imaging performed by MRI produces high resolution images which can provide 
detailed information of the soft tissues that may be affected by RA. MRI imaging is expensive, 
and requires long acquisition times.  Because of these reasons, we only used MRI at 0 and 36 
weeks. In addition, only the dominate hand (left hand) was imaged. The MRI scoring criterion 
include synovitis, erosion, and bone marrow (BM) edema (Figure 4.14). Results for MRI scoring 
present that left PIP 2 and 3 had marginal changes over the 36-week period for synovitis and BM 
edema. However, it was shown that erosion did not change in score. The joint with the highest 
severity of RA in the left hand was left PIP 4. Although joints left PIP 2 and 3 did observe a 
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worsening in severity, both joints were marginally worse and were not shown to be affected at 
baseline. The severity level of left PIP 4 corresponds to the severity level observed in the X-Ray 
scores.  
 
Figure 4.14 Quantitative scores for MRI imaging performed on our subject. (TOP): Synovitis score. 
(MIDDLE): Joint erosion from cartilage damage. (BOTTOM): Bone Marrow Edema. 
Doppler Ultrasound Imaging: Doppler Ultrasound (US) was performed on the 6 PIP joints at all 
timepoints over the 36-week trial. Within the US scoring criterion, there are four measures: Joint 
effusion, synovitis, joint changes (erosion), and power doppler (vessel flow). A summary of the 
US results is shown in Figure 4.15. Most PIP joints analyzed showed that joint effusion worsened, 
with left PIP 2 initial showing improvement before worsening. Bone changes, or erosions largely 
remained constant at 1, with exceptions to left PIP 3 (improved 2 to 1). Synovial thickening largely 
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varied, with improvements in left and right PIP 3, worsening in right PIP 2, and constant at severity 
score 1 or 2 in all others PIP joints.  
 
Figure 4.15 Quantitative scores for Doppler ultrasound imaging performed on our subject. (TOP LEFT): Joint 
Effusion. (TOP RIGHT): Synovitis score. (BOTTOM LEFT): Joint erosion from cartilage damage. (BOTTOM 
RIGHT): Doppler (vessel) flow. 
 
As a global assessment of the US scoring, it was found that the right PIP 3 joint exhibited that 
most severity out of the six joints. Right PIP 4 and left PIP 4 showed the least severity, which for 
left PIP 4, counters the MRI and X-ray scores that left PIP 4 is one of the more severe cases. The 
fluctuations for US imaging scores being between 1 and 2 shows that the severity is mild but was 
difficult to strongly classify. 
Combining Imaging Scores: With a large number of scoring criteria from three different imaging 
modalities, it may be difficult to determine treatment success. For this reason, I have simplified 
the nine imaging scores into three scores, one for each imaging modality. For this analysis, I have 
taken the summation of each subcategory for each imaging method. The purpose of performing 
this analysis is to demonstrate which fingers are the most affected by RA at baseline, which fingers 
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are not or marginally affected, and which fingers observed the most improvement from the new 
treatment therapy.   
X-Ray Total Score: By combining the X-Ray subcategory scores, the scoring range is 0 to 9, with 
highly affected joints receiving a 9. The combined scoring for X-Ray produced findings that the 
left PIP 4 and right PIP 3 joints observed the highest severity of RA (Figure 4.16). In addition, the 
results also showed the left PIP 2 was not affected, and that the remaining joints were mildly 
affected. Right PIP 2 and 4 observed a reduction in severity by 1. 
 
Figure 4.16 Total severity score for X-Ray, combining erosion and joint space narrowing. 
MRI Total Score: The MRI subcategory scores were combined into one total score, with the score 
ranging from 0 to 29, with highly affected joints receiving a 29. The combined scoring for MRI 
produced findings that the left PIP 4 had the highest severity of RA for the left hand. At 36 weeks, 
the left PIP 2 and 3 joints had a score more than half of that of the left PIP 4 joint. This total score 
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the highest affected joint in the left hand (Figure 4.17). The high severity score of the left PIP 4 
also coincides with the x-ray total scoring results. 
 
Figure 4.17 Total severity score for MRI, combining synovitis, erosion, and bone marrow edema. The MRI 
total severity score ranges from 0 to 29. 
Doppler Ultrasound Total Score: Finally, the Doppler US subcategory scores were combines to 
have a total range of 0-12. These subcategories include joint effusion, synovitis thickening, bone 
changes, and Doppler flow. The combined scoring for US demonstrated that the right PIP 3 joint 
exhibited the highest severity of RA amongst the six joints analyzed at baseline (Figure 4.18). At 
36 weeks, the right PIP 3 joint showed a dramatic improvement, decreasing from a score of 6 to 
3. Conversely, right PIP 2 demonstrated an increase in RA severity over the trial. For this joint, 
the severity increased from 2 to 5. It was also shown from the total US score that the right PIP 4 










  106 
The PIP joints from the left hand were unchanged during the trial, except left PIP 3, which 
observed a drop in severity from 5 to 3.  
 
Figure 4.18 Total severity score for Doppler ultrasound, combining scores for joint effusion, synovitis score, 
joint erosion, Doppler (vessel) flow. The summation of the subcategories created a scoring range from 0-12. 
 
Summary of Clinical Imaging Scores: In summary, all three imaging modalities demonstrated that 
the right PIP 3 joint was the most affected joint with RA. Only from the US total score did the 
right PIP 3 show improvement over the trial as oppose to x-ray, which showed that there was no 
change during that period. The left PIP 4 joint also showed a high severity of RA in MRI and x-
ray, but not in the scoring in US. Conversely, the right PIP 4 joint demonstrated the lowest RA 
severity across x-ray and US. With these imaging modalities, the right PIP 4 did not change during 
this trial.  
Assessment of US was found to largely have a contradictory score from the x-ray and MRI. The 
scores for the left PIP joints under US scoring found to have a similar score to that of the most 
severe joint, the right PIP 3. In this case, left PIP 2 and 3 observed a score of 5 during multiple 
imaging sessions, while the highest observed score for right PIP 3 was 6. This is contradictory to 
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out of the analyzed joints. Based on all of the imaging scoring criterion, Table 4.6 provides a 








Table 4.6 Summary of PIP joint severity and the overall progression over the course of the trial 
4.6.5 FDOT Reconstruction Results 
We start our optical results by showing example of two-dimensional cross-sections through the 
three-dimensional tomographic reconstructions of optical properties from the fDOT imaging 
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system. Figure 4.19 shows the transverse slices from the absorption coefficient while Error! 
Reference source not found. shows the transverse slices from the reduced scattering coefficient.  
 
Figure 4.19 Transverse slices from the absorption coefficient of the fDOT reconstruction images. The column 
of images are from the 3 RIGHT PIP joints imaged, while the rows of images represent the timepoints in which 
these joints were imaged (0, 2, 6, 12, 24, and 36 weeks). 
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Figure 4.20 Transverse slices from the absorption coefficient of the fDOT reconstruction images. The column 
of images are from the 3 LEFT PIP joints imaged, while the rows of images represent the timepoints in which 
these joints were imaged (0, 2, 6, 12, 24, and 36 weeks). 
The most pronounced differences between joints of subjects affected by RA and of subjects not 
affected by RA occur at the center of the images, where the joint cavity is located. For a subject 
responding to treatment, it is expected that both ua and us’ would lower in the joint cavity region 
as the effects of the treatment begins to take shape. It has been shown in our research groups 
previous work that a lower ua	and	us’ of the synovial fluid that fills the joint cavity and a higher 
ua and us’ in the surrounding tissues (Cartilage, bone marrow). This profile of low 
absorbing/scattering of the joint cavity, and a high absorption/scattering in the surrounding areas 
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is indicative of a healthy joint [20, 40, 143, 145, 163, 164]. Joints affected by RA typically do not 
show a strong drop in optical properties in these regions. 
However, diagnosis on the basis of visual inspection alone may mislead false positive or missed 
diagnose. In the following section, I explore feature extraction to assist in quantifying the accuracy 
of monitoring treatment. 
 
Figure 4.21 Transverse slices from the reduced scattering coefficient of the fDOT reconstruction images. The 
column of images is from the 3 RIGHT PIP joints imaged, while the rows of images represent the timepoints in 
which these joints were imaged (0, 2, 6, 12, 24, and 36 weeks). 
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Figure 4.22 Transverse slices from the reduced scattering coefficient of the fDOT reconstruction images. The 
column of images is from the 3 LEFT PIP joints imaged, while the rows of images represent the timepoints in 
which these joints were imaged (0, 2, 6, 12, 24, and 36 weeks). 
 
4.6.6  FDOT Feature Extraction 
Each 3D reconstruction of the finger joints is unique, even for the same finger measured 
longitudinally, making it impossible to compare joints using all reconstruction data for two 
reasons. First, each mesh is unique to each joint, and as such, comparisons between joints on a 
pixel by pixel basis in not feasible. The same joint measured at multiple timepoints under treatment 
therapy may change structurally, as the treatment may improve range and decrease pain. In this 
scenario, extracting the structural information to create a finger mesh would make the fitting to the 
  112 
previous time point difficult. The second reason is that the number of feature would be extracted 
if each pixel is considered a feature would larger than the number of unique samples. This would 
lead to over-fitting problems for data analysis. 
To this end we consider only a small number of image features that can be computed from all 
reconstruction images. After reconstruction of the 3D spatial distribution of ua and us’, a 3D region 
of interest (ROI) is determined for each finger. The mesh points used in the ROI is a center slice 
composed of voxels equidistant to the upper and lower bounds of the finger mesh. However, the 
mesh itself is an unstructured mesh, making the equidistant slice unique and ununiformed along 
the length of the finger. The ROI is created with the following steps. First, the unstructured mesh 
must be converted to a structured mesh using a custom built conversion algorithm [165]. Next, the 
center pixel position is computed according to the range of the upper to lower bounds of the finger 
while cycling through the finger length-wise, or sagittally (Figure 4.23). For each center pixel 
position found length-wise, a matrix of pixels is then extracted from the transverse plane of the 
finger. The pixels just above and below the center slice are extracted, and the top, center, and 
bottom pixels are averaged, creating a vector of pixels obtained from the transverse plane. Once 
all of the center pixel positions are cycled through and transverse vectors are extracted, the ROI 
then becomes a non-planer 2D slice of the transverse center of the finger. Finally, the 2D slice is 
cropped such that only mesh points that are at least 2mm away from the finger mesh boundary are 
removed. This helps eliminate any reconstruction boundary artifacts from being included in the 
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feature extraction process. The final ROI obtained produces a slice of the finger at the center of 
the finger joint, providing the best representation of the optical properties in the joint cavity [164].  
With the ROI extracted, visual inspection of the reconstruction results and the associated ROI may 
mislead false positive or missed diagnose. Instead, it is best to explore feature extraction and 
classification to quantify the state of the finger.  
 
Figure 4.23 A 3D rendering of the absorption coefficient from a finger joint. The center sagittal slice is shown 
with multiple transverse and coronal slices shown at a lower opacity. The center coronal slice is created by 
computing the midpoint of the central sagittal slice at all of the coronal positions.  
 
Features are extracted separately from the ua and us’ of the ROI that were produced from the 3D 
reconstruction images. Then the maximum, minimum, mean, variance, and the ratio of the 
minimum to maximum of each data set are calculated as features. Therefore 10 features in total 
are obtained for each finger. Although all features were evaluated, multiple features produced 
promising results for our one case study. In our research group’s previous studies, it has been 
shown that that the standard deviation of ua and the maximum us’ (stdev ua, max us’) are the two 
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most commonly significant features [40, 163, 164]. Because there are numerous clinical measures 
along with 10 optical features, the dimensionality of the feature comparison of this analysis 
requires a large number of subjects. Since we were only able to enroll one subject in this study, 
these two features were the only features analyzed in this work. 
 
4.6.7 Evaluating FDOT for Monitoring RA 
The features extracted from the finger reconstructions for our single subject over all time points 
were analyzed. From the clinical measurements, it was determined that the right PIP 2 and left PIP 
4 joints were the only joint severely affected by RA, while the remaining four joints were either 
moderately affected (Right PIP 2, Left PIP 2 and 3), or marginally affected (Right PIP 4).  
To test our first hypotheses, which was to differentiate the several affected joints from the moderate 
and mildly affected joints, the absolute values of our two features were analyzed. From previous 
work, it was shown that the lowest the value of these features, the higher the severity of RA. In 
Error! Reference source not found., the absolute values of the standard deviation of ua and max 
s’ are shown. Without any context of the values from the features to distinguish the severity of 
RA, the difference in the optical features at baseline show that right PIP 3 and left PIP 4 has the 
lowest standard deviation of the ua (Standard deviation of ~0.002 for both) and the lowest 
maximum us’ (Max us’ = 10.2 and 10.4 respectively). These results suggest that these two finger 
joints are the most affected by RA compared to the other PIP joints measured prior to the enhanced 
treatment. This finding correlates with the clinical scores, that suggested that these two finger 
joints were also the most affected by RA. Alternatively, the left PIP 2 joint showed the highest 
values from the two features, suggesting that this joint was the least affected by RA at baseline.  
This does not correspond with the clinical findings, in which the right PIP 4 as the least affected 
joint. Unfortunately, without any knowledge of the severity scale for the optical features, it is 
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difficult to postulate whether the four joints should be classified as moderate or mild. However, to 
examine the fDOT optical features even further between the two joints that were clinically 
determined to be severely affected and the remaining four joints, the mean and standard deviations 
of the optical features at baseline were computed (Figure 4.25). This figure demonstrates the 
difference of optical features of the joints are, and provides insight as to which joints may observed 
the highest effect to treatment over time.  
 
Figure 4.24 Graphical representation of feature results of stdev ua (TOP) and max us’ (BOTTOM). 
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Figure 4.25 Comparison of fDOT optical features between the two severely affected joints and the remaining 
four joints. Features of standard deviation of the ua (Left) and the maximum of the us’ (Right) are shown. 
To evaluate our second hypothesis, in which we expect a patient that will respond to treatment will 
observe a higher standard deviation of ua and higher max us’ over time in affected joints, the 
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interpretation is best delineated when the features are normalized to the baseline measures (Figure 
4.26).  
 
Figure 4.26 Graphical representation of normalized feature results of stdev ua (TOP) and max us’ (BOTTOM). 
Results shown are normalized to the baseline measurement, at week 0. The values in this column are 0. 
Here it is shown that although there are fluctuations in the optical features, the joints that showed 
an increase in the features over time were the most severely affected fingers. It may be deduced 
that the reason that the most severely affected joints showed the most improvement is because 
these joints had the most room for improvement compared to the other joints. In contrast, the 
relative changes in optical properties from the remaining four joints either had a marginal 
difference over time or worsened. Most notably, the right PIP 2 joint showed a 1% decrease in the 
standard deviation in ua and a 0.03% decrease in the max of us’. To examine the changes in optical 
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features over time even further, I have taken the mean and standard deviation of the two severely 
affected joints as well as the remaining four joints presumed to be moderately or mildly affected 
and displayed this calculation over time (Figure 4.27). This figure also validates our third 
hypothesis, which is that the mild or marginally affected joints will not observe any, or margin 
changes under treatment than the severely affected joints.  
 
Figure 4.27 Relative changes in optical features between the two severely affected joints (Red) and moderate 
or mildly affected joints (Blue) observed over time. The standard deviation of ua (TOP), and the maximum us’ 
(BOTTOM) both show that the severely affected joints had the most improvement during the clinical trial for 
this patient. 
 
4.6.8 Evaluating DOS Using the WHDD for Monitoring RA 
Although the fDOT system has shown its potential in discriminating healthy from RA affected 
joints [40], and has shown ability in monitoring treatment in our RA patient case study as shown 
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in the previous section, the system is large and is not easily transportable which makes its usability 
inside a typical exam room difficult. For example, the fDOT system had to be used in a small 
selection of available exam rooms at CUMC during our pilot study because the system simply 
could not fit in other exam rooms. Because of this, it was our goal to compare the already capable 
fDOT system to that of smaller scale version system. Thus, in addition to using the fDOT system 
to characterize the optical properties from finger joints, the wireless handheld DOS device 
(WHDD) was also used to assess RA progression in the PIP joints. In this section, I will compare 
the clinical imaging results from our RA patient to that of the WHDD. The WHDD hardware, 
along with the reconstruction algorithm, is a system that is designed to make point measurements 
of [Hb] and [HbO2] from human tissue.  
Although the PIP finger joint has vascularity from the synovial membrane, the primary 
composition of the finger joint is low vascular cartilage and ligaments, as well as the proteins, 
water, and monocytes from the synovial fluid. The synovial membrane, which a dense net of small 
blood vessels that provide nutrients not only for synovium but also for cartilage, becomes inflamed 
for people suffering from RA [166]. This phenomenon of increased thickness of the synovial 
membrane, and the subsequent invasion by the pannus of cartilage and bone, is caused by an 
increase in the vascular supply to the synovium to cope with the increased requirement for oxygen 
and nutrients. This formation of new blood vessels, or angiogenesis, is a key event in the formation 
and maintenance of the pannus in RA.  
Monitoring of increased vascularity due to angiogenesis has been monitored with power Doppler 
ultrasound is studies [167, 168]. Fukae et al discovered that the change of vascularity in response 
to DMARDs, defined as the percentage change in vascularity by the eighth week from baseline, 
was inversely correlated with radiographic progression in each MCP joint. Extending their work, 
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they also found that smouldering inflammation reflected by positive synovial vascularity under 
low disease activity was linked to joint damage. The damage progressed irrespective of the severity 
of positive synovial vascularity.  Their work concluded that using vascularity as a guide to consider 
a therapeutic approach would have benefits for patients with active RA. Although this group used 
power Doppler ultrasound to measure vascular flow to assess the overall vascularity of the joint, 
optical techniques such as DOS can also be used to quantify the level of vascularity in the finger 
joint.  
 
Figure 4.28 Example of the WHDD probe being placed on the palmer side of the second PIP joint. 
 
Using DOS with the WHDD system, it was our hypothesis that DOS will have similar outcome to 
the of the fDOT system. Specifically, we first hypothesize that vascularity due to angiogenesis in 
severely affected RA joints can be differentiated from the non- or marginally affected joints at 
baseline. Second, a patient responding to treatment will observe a lower HbT and a higher %StO2 
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over the course of the study in severely affected joints. Finally, our last hypothesis is that non- or 
marginally affected joints will not respond as highly to treatment than severely affected joints. 
To test these hypotheses, we employed the WHDD to scan the PIP finger joints at the palmar side 
of the hand to make point measurements of vascularity at the finger joint. Figure 4.28 shows an 
example of how the WHDD was placed on the joint. After measurements were taken from the 
finger joints, the probe was calibrated to a solid phantom cylinder with known optical properties 
(Table 4.7). Reconstructions of HbT and %StO2 were computed based on the calibration 




WL	(nm)	 575	 661	 757	 780	 905	 850	 808	
Measured	(ua)	 0.0693	 0.0606	 0.0512	 0.0484	 0.0359	 0.0414	 0.0456	
Measured	(us')	 9.3200	 9.2100	 8.7800	 8.6760	 8.2885	 8.4590	 8.5892	
Table 4.7 Optical properties of phantom cylinder used to calibrate the WHDD during the RA clinical study. A 
linear fit was made for wavelengths used in the WHDD. The wavelengths chosen for actual optical properties 
were based on fluorescence tomography calibration, and thus uses lower wavelengths.  
 
The WHDD reconstruction results of total hemoglobin (HbT), and oxygen saturation (%StO2) 
from this case study is shown in Figure 4.6.  From the absolute results, it can be interpreted that 
all finger joints had a low concentration of HbT prior to treatment which is expected of healthy 
finger joints, since normal joints have a small amount of vascularity. However, the joints observed 
an increase in HbT over the course of the treatment. As it was observed that the patient improved 
after treatment as measured by other imaging modalities, these results go against that trend. 
The %StO2 measurements at baseline were well below what is considered normal (normal>70%), 
suggesting that the joints were hypoxic during baseline measurements. Unfortunately, the StO2 
results during the course of the trial fluctuated negatively, which does not correlate with the results 
from the clinical and fDOT measures. The trends over time show that the right PIP 3 has the highest 
average HbT during the trial, which does correlate with what the severity of that joint observed. 
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The HbT results also suggest that the right PIP 2 joint worsened the most over time. The StO2 
measurements over the trial largely jumped between 20 and 70%, which is unreasonable in regards 
to consistency. However, the right PIP 3 and left PIP 2 demonstrated a more monotonic change, 
in which right PIP 3 showed that most improvement. This finding correlates with clinical and 
fDOT measurements.  
 
Figure 4.29 Absolute reconstruction results of total hemoglobin (TOP), and tissue oxygen saturation (BOT). 
The columns represent the number of weeks the patient has been under treatment and the rows represent the 
finger joints that were measured with the WHDD to make DOS measurements.  
 
With the absolute results largely inconsistent with the clinical and fDOT measurements, we 
examine this further by analyzing the percent change from baseline of the HbT and StO2 
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measurements (Figure 4.30). Here, it is clear that all joints observed an increase in HbT during the 
trial, which would correspond to increase vascularity due to angiogenesis. This also suggests that 
by an increase in vascularity, that the joints are worsening in severity of RA. Conversely while 
analysing the percent change from baseline of StO2, most joints either decreased in StO2 (Right 
PIP 2, Left PIP 3), or showed a marginal decrease (Left PIP 2, Left PIP 4). For these four joints, 
the changes in function parameters was not monotonic and would jump as much as -80% to +80% 
from baseline. Alternatively, the right PIP 3 did show consistent improvement in StO2 over the 
  124 
trial, which correlates with clinical and fDOT findings. In addition, the left PIP 2 joint only 
observed a marginal percent change in %StO2 (+/- 6.5%) during the trial.  
 
Figure 4.30 Relative reconstruction results of total hemoglobin (TOP), and tissue oxygen saturation (BOT). The 
columns represent the number of weeks the patient has been under treatment and the rows represent the finger 
joints that were measured with the WHDD to make DOS measurements. 
 
4.6.9 Discussion Comparing DOS and FDOT 
The optical imaging modalities DOS and fDOT were used to monitor the progression of RA in our 
single patient study. The fDOT system used is a highly sensitive tool to make localized 
measurements of absorption and reduced scattering coefficients at 660nm. The system size 
however makes it difficult to use in the exam room, as it was seen in our study, it could only fit in 
a select number of exam rooms. It was our secondary objective then to make additional 
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measurements using a handheld, transportable WHDD probe that uses continuous wave (CW) 
DOS imaging technology to make point measurements of total hemoglobin and tissue oxygen 
saturation.  
Comparing the two NIR optical imaging modalities, it was expected that the optical trends between 
the two would show similarities for individual finger joints, or demonstrate a difference in severity 
between the PIP joints.  Unfortunately, the WHDD measurements did not demonstrate either, 
disproving our hypotheses relating to the use of the WHDD for this case study. In this section I 
will discuss the potential shortcomings of using the WHDD to monitor the treatment of RA. 
The WHDD may have not produced similar results to that of fDOT based on three observations. 
First, making good contact with the finger joint was difficult, especially for finger joints that had 
severe structural damage. The WHDD, although is handheld, the device can be too wide for 
making point measurement on PIP joints. In addition, WHDD measurements are easier to make 
when the finger is extended, which is painful or not possible for RA patients with significant 
structural damage.  
The second potential reason for the shortcoming of the WHDD results is due to the configuration 
of the source-detector pairs. The WHDD uses a reflectance based configuration in which laser 
light is emitted at the tissue surface, light is then scattered and absorbed, and only reflected photons 
are acquired and measured. This configuration may be problematic because both the light 
illumination or detectors positions are not directly over the joint. Therefore, the scanning medium 
may be too small and heterogeneous to be measured accurately.  
The third potential reason for why there may have been a shortcoming using the WHDD is the use 
of the CW imaging modality over fDOT to make static measurements. The fDOT system, as well 
as fDOT technology has been shown to separate the absorption and reduced scattering coefficients 
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better than CW. Therefore, chromophore reconstructions of HbT and StO2 with CW may not be 
as effective compared to fDOT. This, along with the previous two issues, may be the reasons why 
the DOS measurements showed very little similarity with the fDOT results.  
For future considerations, I suggest that the interface of the WHDD be modified to a transmission 
based configuration, such that transillumination measurements can be made similar to that of the 
fDOT system. This will allow for laser illumination and measurements to be made directly above 
and below the finger joint, reducing the risk of not reaching the proper imaging medium. In 
addition, a physical finger clip placed at the joint can make the imaging procedure more 
comfortable for the patient. For this interface, the patient would be able to have their hand in a 
relaxed position, reducing the amount of pain that may be associated with the imaging procedure. 
Finally, in addition to making static measurements using CW, the imaging procedure can be 
modified to induce a venous or arterial occlusion at the upper arm, similar to using a blood pressure 
cuff for blood pressure measurements. Dynamic measurements using diffuse optical imaging such 
as DOS and DOT has been used in other projects [6, 169-171], and for RA imaging studies [151]. 
For dynamic measurements, the outcome results may be the rate of hemodynamic change, the rise 
time of the absorption measurements, or the change in the oxygen saturation over the time of the 
cuff occlusion. Additional design work towards a new interface is needed to explore these 
considerations. 
4.6.10 Study Discussion 
Rheumatoid arthritis is an inflammatory autoimmune disorder that causes chronic inflammation 
of the synovial membrane of small and large joints in 1% of the world’s population. The severity 
of RA can be associated with significant pain and disability. There is currently no cure for RA, but 
disease-modifying anti-rheumatic drugs (DMARDs), the key therapeutic agents, reduce synovitis 
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and systemic inflammation and improve function. In addition, biologics such as Humira and Enbrel 
target pro-inflammatory cytokines, chemokines and growth factors such as TNF have been used 
more in the past decade to further reduce RA progression. However, these biological agents may 
have considerable toxic effects, and infections and high costs restrict prescription of them. 
Therefore, it is vital for RA remission that the patient treat and determine the efficacy of the 
treatment early. 
Expanding on this group’s previous studies in which RA can differentiated from normal joints, we 
developed a protocol to monitor the progression, or remission of RA under treatment. Using a 
fDOT system specifically designed to make highly sensitive measurements of optical absorption 
and reduced scattering, we monitored the efficacy of treatment in a single-subject case study. We 
compared the fDOT technology, in which we created 3D absorption and scattering maps of PIP 
joints 2-4, to that of standard clinical and imaging measures, in which we used quantitative scoring 
methods to objectively determine which joints were most severely affected by RA, and which 
joints showed a positive response to treatment. Although the fDOT system can reliably make 
accurate measurements of absorption and reduced scattering, the system is large and can be 
difficult to access in a clinical setting. To address this problem, we incorporated the use of the 
WHDD probe to make point measurements of total hemoglobin and oxygen saturation at the 
palmer side of the PIP joints. The vascular measurements taken by the WHDD were intended to 
monitor to the level of angiogenesis associated with RA. Potentially, DOS from the WHDD could 
measure the severity of RA and provide a better understanding of the pathophysiology of RA.  
By using the fDOT and DOS techniques on a single patient case study, we have evaluated the 
capabilities of both methods and their abilities to accurately differentiate severity between joints 
and monitor RA progression as described by our gold standards of clinical examinations and 
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radiological imaging. Using features of standard deviation of ua and the maximum value of us’ 
within the 3D spatial maps of the optical properties, the fDOT modality demonstrated that the right 
PIP 3 and left PIP 4 were the most affected joints while the other joints were observed to be 
moderately or mildly affected by RA. In addition, fDOT was able to show these two joints 
improved over the 36-week study under additional DMARD treatment.  
Employing the WHDD, however, the vascular results from this modality exhibited inconsistent 
results from that of the fDOT and clinical measures. Since the clinical results showed an 
improvement from the treatment therapy, and with the fDOT results corresponding to same 
outcome, it was expected that the DOS measurements using the WHDD probe would show an 
increase in tissue oxygen saturation from a possible hypoxic state, as well as a decrease in the total 
hemoglobin concentration from the reduced amount of vascularity that stemmed from 
angiogenesis of the synovial membrane. Unfortunately, the trends that were hypothesized for the 
WHDD measurements were largely unobserved. Instead, the HbT measurements were shown to 
be at normal levels at baseline, suggesting that the joints were healthy. Over time, most joints 
observed an increase in HbT, suggesting that there was more vascularity in the joint. The %StO2 
also observed similar trends. However, the right PIP 3, which is clearly the most severely affected 
joint of the six measured, did observe an increase in %StO2 of 80% from baseline. This suggested 
that this joint did improve over the trial. This singular observation was the only positive correlation 
from the WHDD measurements.  
The potential limits of the use of the WHDD for monitoring RA may have been due to the 
reflectance geometry configuration used, in which transillumination measurements could not be 
performed as was done with the fDOT imaging system. In addition, interfacing issues with the 
finger joint may have prevented a reliable acquisition of DOS data. These potential limits can be 
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addressed with a new interface from the WHDD electronics to the finger. In addition, the use of a 
venous occlusion to create a dynamic change in the metabolic and hemodynamic state of the joint 
could be useful for future work. There are also limits to this study. First, the recruitment of patients 
was incredibly difficult and a result only one patient was enrolled into this study. More patients 
are required to make a sufficient analysis of the fDOT and DOS technology. In conclusion, we 
demonstrate that fDOT has the potential to aid in monitoring the progression and treatment 
efficacy of RA that can help in management decisions for rheumatologists.  
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5 Using DOS for Intraoperative Monitoring During Vascular Surgery 
In this chapter, I will provide details for a system design that can be used for intraoperative 
monitoring during vascular surgery to assist in improving the efficacy of arterial revascularization 
for patients suffering from PAD. Characterization of the device, including performance and 
measurement accuracy, and repeatability will be reported. To conclude, I will describe the initial 
results of a longitudinal study in which perfusion in the lower extremities of 20 subjects were 
measured before and after arterial revascularization using the designed. 
5.1 Peripheral Arterial Disease 
Peripheral arterial disease (PAD) is the narrowing of arteries due to plaque accumulation and in 
the vascular walls (atherosclerosis) in the lower extremities [172]. Plaque is made up of fat, 
cholesterol, calcium, fibrous tissue, and other substances in the blood. When plaque builds up in 
the body's arteries, the condition is called atherosclerosis. Over time, plaque can harden and narrow 
the arteries. This limits the flow of oxygen-rich blood to your organs and other parts of your body. 
While many people with PAD have mild or no symptoms, PAD typically manifests itself as 
claudication, which is defined as a cramping leg pain with ambulation to a set distance. As the 
disease progresses, this distance becomes progressively shorter, and in later stages the pain 
becomes severe and present even at rest [173]. The location of the pain depends on the location of 
the clogged or narrowed artery. The severity of claudication varies widely, from mild discomfort 
to debilitating pain. Severe claudication can make it hard to walk or do other types of physical 
activities. 
PAD affects approximately 12 million individuals in the United States and is associated with 
significant morbidity and mortality [174]. Every year, PAD is responsible for over 2,750,000 office 
visits, 10% of which result in hospital admissions. Approximately 45,000 PAD patients die from 
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this disease annually [175]. It is estimated that >200 million people have PAD worldwide, with a 
spectrum of symptoms from none to severe [176]. 
Risk factors for developing PAD include age, smoking, hypertension, hyperlipidemia, 
hypercholesterolemia, and diabetes. Although PAD is characterized by a slow and low rate of local 
symptoms and complications, it is also characterized by ongoing atherogenesis in other vascular 
beds and a very high rate of mortality (approximately 25%-30% within 5 years for patients with 
symptomatic PAD) due mainly to stroke and myocardial infarction (MI) [172]. 
If left untreated, the disease eventually leads to critical limb ischemia, a condition in which the 
formation of foot wounds or ulceration occur and don’t heal due to lack of perfusion. This 
subsequently can lead to infection of the wound and tissue loss (gangrene), and ultimately 
amputation. Furthermore, patients with PAD have an increased risk of stroke and myocardial 
infarction, and show a two-fold increase in the risk of death from cardiovascular disease [177].  
5.2 Treatment of PAD 
Patients with severe PAD will often require lower extremity percutaneous transluminal angioplasty 
or bypass surgery to fix the occluded blood to flow to the extremities. In angioplasty, an empty 
and collapsed balloon on a guide wire, known as a balloon catheter, is passed into the artery to 
narrowed locations and then inflated to a fixed size using water pressure. The balloon crushes the 
fatty deposits, opening up the blood vessel for improved flow; the balloon is then deflated and 
withdrawn.  
Stents are small steel mesh tubes that can be placed inside an artery during an angioplasty 
procedure. Stents "prop" open arteries to keep blood flowing. A stent is then usually placed at the 
same location to ensure that the vessel remains open. If this technique is ineffective, a vascular 
bypass is conducted. This is very invasive, as the surgeon has to make a large cut and move the 
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muscles and tissue to reach the artery, then re-route it by taking a segment of another artery or 
using synthetic tubing. 
 
 
Figure 5.1 Diagrams of balloon angioplasty (left) and stent placement (right) in a stenotic artery 
 
In addition to lifestyle changes such as smoking cessation and exercise programs, antiplatelet drugs 
(aspirin, clopidogrel), angiotensin-converting enzyme inhibitors, and statins are recommended for 
all persons with PAD. Lower extremity percutaneous transluminal angioplasty or bypass surgery 
is performed when advanced stages are reached and limb-threatening ischemia occurs. Once 
gangrene develops, amputation is necessary to prevent infected and dying tissues from causing 
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septicemia. Therefore, accurate and timely diagnosis of PAD is crucial in the prevention of further 
health consequences [8]. 
5.3 Current Diagnostic Techniques 
5.3.1 Ankle brachial Index 
The most widely accepted, objective definition of PAD is the ankle brachial index (ABI) [172]. 
The ABI is calculated by measuring the maximum systolic blood pressure at the ankle and dividing 
it by the systolic blood pressure in the brachial artery in the upper arm. In healthy individuals ABI 
values range between 0.9 and 1.2. Values less than 0.9 identify patients with some form of vascular 
occlusions or stenosis. Most patients with symptoms of claudication will have an ABI between 0.5 
and 0.8 and those with more severe symptoms such as rest pain will generally have values less 
than 0.5. 
 
Figure 5.2 Ankle brachial index being measured on the dorsalis pedis artery of the foot. 
  
Although the ABI is often useful in the diagnosis and determination of the severity of PAD, it has 
major shortcomings [178, 179]. The presence of distal emboli, micro-emboli and atherosclerotic 
plaques in the foot can lead to tissue breakdown, ulceration and amputation, even if the ABI is 
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close to 1. Furthermore, falsely elevated ABI readings occur in patients with medial wall 
calcification, which is a condition commonly seen in diabetic patients. In these cases, the ABI 
reflects the ability of the vessel wall to resist compression rather than being a true indicator of the 
blood flow and pressure within the vessel. In addition, diabetic patients with neuropathy showed 
that ABI’s inability to detect arterial disease resulted in false-negative results in one third of the 
limbs [179]. Consequently, physicians rarely employ this test in diabetic patients. Considering that 
between 120 and 140 million people suffer from diabetes mellitus (DM) worldwide and that 
diabetic patients are at excess risk of developing PAD, the implications of the problem are 
enormous [180]. 
 
5.3.2 Pulse-volume recordings 
Pulse-volume recordings (PVR) are conducted using segmental limb pressure cuffs along with the 
ABI measurement in an attempt to localize a stenosis or occlusion. Limb pressure cuffs are placed 
on the thigh, calf, ankle and the metatarsal region of the foot. These pressure cuffs are then inflated 
sequentially to 65mmHg and a plethysmographic tracing is recorded at the various levels (Figure 
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5.3). The pleth recording is typically performed using Doppler ultrasound but laser Doppler 
systems also exist to perform the same function [181, 182].  
 
Figure 5.3 Example of a patient undergoing a PVR measurement 
 
The shape of the tracing should consist of a systolic upstroke and a rapid down stroke with a 
prominent dichrotic notch during the downs stroke period. With increasing severity of PAD, the 
waveforms become more attenuated with wider slopes until eventually the waveforms are absent. 
Figure 5.4 below represents PVR waveform recordings conducted at a vascular lab. As one can 
see, the severity increases as the amplitude decreases and the shape of the waveform loses its 
higher frequency content. 
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5.3.3 Duplex ultrasound 
Imaging methods are usually used as second line diagnostic tests, to confirm initial diagnostic 
results and to assess for a potential surgical intervention [182]. Typically, lower limb Duplex- 
ultrasound (DUS) examinations are initially performed first to determine the location of stenosis 
or occlusions in the legs. DUS is a combination of B-mode and Doppler ultrasound and is useful 
in detecting lesions along the lower extremities.Duplex Doppler ultrasound is another clinical tool 
used for functional assessment of blood flow in large vessels. Changes in a cross-sectional area of 
the vascular lumen can be determined by means of peak systolic velocity (PSV) at the site of a 
stenosis, the ratio of PSV at the site of the stenosis and its immediate normal vicinity, end diastolic 
velocity, and more subjective criteria such as number of phases in the Doppler waveform and 
degree of spectral broadening [183]. Although this technique is excellent for measuring flow in 
large vessels, it has difficulty in probing small vessels [e.g., diameter less than 100 µm] in the 
lower extremity muscles. Current non-invasive techniques for the evaluation of microvascular 
blood flow include Doppler optical coherence tomography [182] and laser Doppler.  
 
Figure 5.5 Duplex ultrasound scan being conducted along the lower extremities. 
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The imaging technician will look for occlusions and listen for bruits (“wooshing” sounds) resulting 
from blood flow through narrowed arteries. DUS is used to identify lesions within the leg (Figure 
5.5), however the arteries below the knee are small, which makes the DUS assessment difficult. 
As the arteries decrease in size the results become heavily user dependent. Furthermore, 
identifying lesions does not provide direct information on the perfusion of the foot [184]. 
5.3.4 Angiography 
The current gold standard in PAD diagnosis is called digital subtraction angiography (DSA) [185]. 
DSA provides images of the blood vessels in the lower extremities to detect a problem with blood 
flow. These images are used in the operating room to assess the precise location of one or more 
occlusions in the lower arteries. Vascular surgeons use this information to place stents or balloons 
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and continue using DSA during the angioplasty procedure to ensure proper placement and verify 
that blood flow through the artery is improved. 
 
Figure 5.6 DSA image of the vasculature in thigh. The main vessel in this image is the femoral artery. The 
contrast dye used is passing through the femoral towards the tibial arteries. 
 
The procedure involves inserting a catheter (a small, thin tube) into an artery patient (usually 
through the femoral artery) and passing it down to the blood vessels towards the foot. A contrast 
dye is injected through the catheter and X-ray images are taken to obtain an image of the 
vasculature in the lower extremities. DSA is conducted on all patients being considered for 
amputation to determine whether revascularization is an option.  DSA is invasive and also requires 
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nephrotoxic contrast media. In addition, it also requires ionizing radiation, which limits DSA’s 
frequency of use. 
DSA has been used for intraoperative verification of bypass graft patency. Limitations of this 
technique include inability to measure flow dynamics, violation of graft integrity, risks of ionizing 
hazard, contrast injection, and arterial puncture.  
 
5.4 Use of Diffuse Optical Imaging for Diagnosis of PAD 
Monitoring techniques to directly quantify tissue hemodynamic and metabolic responses to the 
revascularization in local ischemic muscles of a lower extremity would describe a critical feature 
of treatment success and lead to a better understanding of the treatment mechanisms. Use of diffuse 
optical spectroscopy (DOS) to monitor PAD in the lower extremities during surgical interventions 
has the potential to objectively assess the success of arterial revascularization.  
Optical imaging techniques has been used by many groups to evaluate muscle vascularization in 
the calf [186-190], even during surgical intervention of PAD [186]. Although results in [186] 
showed a significant improvement in relative blood flow (rBF) in the affected limb, measurements 
on the control side largely varied. Additionally, changes in Hb and HbO2 did not show significant 
changes.  
To expand on this research, our group has made a significant effort to utilizing optical tomographic 
imaging to measure perfusion in the foot for PAD patients [191-195]. In our group’s initial pilot 
study, we used vascular optical tomographic imaging (VOTI) on 40 individuals (20 healthy 
volunteers, 10 non- diabetic PAD patients, and 10 patients with PAD and diabetes) were presented 
to quantify VOTI’s sensitivity and specificity at detecting PAD, its ability to assess the severity of 
the disease and localize the perfusion response in the foot. The VOTI system is a optical fiber 
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based system with a total of 34 fibers encompassed the foot, forming a coronal cross section at the 
mid-metatarsal level (Figure 5.7). These fibers shine light through the foot and capture the back-
reflected and transmitted light. It was shown that the VOTI system was capable of quantifying the 
blood volume changes within the foot during the thigh cuff occlusion and outputting diagnostic 
parameters, such as change in hemoglobin concentration, enabling the assessment of foot 
perfusion. The study resulted in a statistically significant difference between the healthy cohort 
and both the non-diabetic and the diabetic PAD cohorts [194].  
  
Figure 5.7 The VOTI system with its sandal shaped measuring probe provides cross sectional images of 
hemoglobin concentrations in the foot. 
 
From these results, our group has looked to expand this work into monitoring of tissue perfusion 
during the angioplasty procedure. Unfortunately, the VOTI system was shown to be too large to 
be integrated into an operating room setting. In addition, the use of optical fibers from VOTI or 
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use of non-contact imaging [193] was intended to be used in a clinical exam room setting, where 
the patient is sitting down.  
To make DOS measurements more appropriate for the OR setting, I present work towards creating 
a multi-channel DOS system based on the technology of the WHDD (Chapter 2) to monitor 
haemoglobin concentrations during surgical intervention. However in DOS, measurements are 
performed in a reflection-based geometry at isolated points on the surface of the tissue, which 
makes the technique heavily dependent on the location of the probe. Because of this, I have 
employed a system with four channels to capture vascular information at the foot where blood is 
supplied from various major arteries at or below the knee.  
 
5.5 Vascular Optical Spectroscopic Measurement (VOSM) System Design for 
Intraoperative Use During Vascular Surgery 
This section will provide a technical overview and characterization of a DOS device designed for 
intraoperative monitoring device during revascularization of arteries of the lower extremities, 
which I have named the vascular optical spectroscopic measurement or VOSM system. This design 
is a portable multi-channel DOS system that can be easily integrated in the OR. Previous studies 
that have used DOS for intraoperative use only used DOS on the calf muscle to measure 
improvement in tissue perfusion [186-190]. This placement however does not provide vascular 
information at the foot, where ulcers and gangrene is more prevalent. Placement of DOS probes 
on the foot may not be sensitive to revascularization to specific arteries due to the angiosome 
concept. Angiosomes are vascular territories are called angiosomes (Figure 5.8), and are defined 
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as five distinct zones in the lower legs as fed by the medial sural artery, lateral sural artery, 
posterior tibial artery (PTA), anterior tibial artery (ATA), and peroneal artery (PA).   
 
Figure 5.8 Diagram of different angiosomes in the lower extremity. 
 
Because this angiosome concept can separate which ulcerations can affect specific zone, it has the 
potential to help surgeons choose whether a bypass or an endovascular procedure has the best 
chance of healing an existent ischemic ulcer. The design of the multi-channel system intends to 
provide perfusion measurement at various vascular territories that lie through the foot. By 
monitoring multiple angiosomes, our hope is to provide immediate feedback to the surgeon as to 
the efficacy of the revascularization to the ulcers.  
 
5.5.1 Design Overview of the VOSM Device 
A technical overview of the vascular optical spectroscopic measurement (VOSM) system is 
described here. This VOSM system will be an extension of the design from the handheld wireless 
probe from Chapter 1. In the first chapter, the WHDD contained a single channel device that could 
  143 
only provide data for a single vascular volume. For the VOSM system, I have expanded the WHDD 




Figure 5.9 Outline of intraoperative system for vascular surgery. A PC controls the system via USB. The 
motherboard will relay an experiment profile to the multiple DOS channels. Each channel has an interface 
patch that is placed on the foot of the subject according to the angiosome concept. 
 
The VOSM system consists of three main components. (1) a laptop with a MATLAB graphical 
user interface (GUI) that controls the VOSM system electronics. (2) The VOSM system that 
contains a central processing board, or motherboard to be used for communication to and from the 
GUI, and two acquisition boards that contain the lasing and detection circuitry to perform the DOS 
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measurements. Each of the electronics boards has connectors for USB connectivity to the PC, 
power, inter-board connectivity, and DOS measurement cabling. (3) The interface cabling and 
interface patches that are placed on the subject’s foot. The cabling is made up of leads that power 
the laser diodes as wells as leads for detection of reflected light from the DOS measurements. Each 
of the four interface patches contains four laser sources and two photodetectors. A photo of the 
entire system is shown in Figure 5.10. 
 
 
Figure 5.10 VOSM system for vascular measurements on the lower extremities. The VOSM system consists of 
a laptop with a MATLAB GUI that controls the VOSM hardware via RS-232. There are 4 DOS channels 
consisting of 3 patches and 1 toe clip.   
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The main system electronics consists of the motherboard and two acquisition boards that are 
stacked and screwed on top of one another using standoffs (Figure 5.11) and enclosed in a plastic 
enclosure (Figure 5.12).  
 
 
Figure 5.11 VOSM system enclosure with system electronics. There are three electronics boards in the 
enclosure, with the motherboard on top (A), and two acquisition boards below (B, C). In addition, there is an 
expansion connector to control a legacy optical switch (D). 
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5.5.2 Motherboard 
The motherboard in the VOSM system is a central control board that processes measurement 
instructions to and from the PC/laptop and instructs the acquisition boards to perform single 
measurements (Figure 5.13). At the heart of the masterboard is a central microcontroller 
(PIC32MX695F512H, Microchip) to perform and communicate tasks.  The microcontroller 
performs these tasks by utilizing its multiple UART ports to communicate with peripheral devices.  
One of the UART ports is converted to RS-232 for communication with the PC connected to the 
VOSM hardware. Through this port, the PC is able to send measurement instruction profiles and 
acquisition settings for the acquisition boards to the motherboard, while during acquisition of data, 
the motherboard bundles all of the measurement data from the acquisition boards to create a data 
packet containing one frame of data. A second UART port from the motherboard microcontroller 
communicates with the acquisition boards by sending information packets to the microcontrollers 
on one of the two acquisition boards. These information packets contain information about gain 
settings and a flag on whether to perform a measurement. When the acquisition board acquires a 
new frame of data, this data is sent back to the motherboard microcontroller on the same UART 
bus. A third UART port can be used for communcations with an optical switch used in another 
imaging system, for special experimentation purposes.  
The communication between the PC and microcontroller is perform via RS-232. The UART bus 
on the motherboard microcontroller sends and receives information through RS-232 by using a 
converting chip that will take the 0V to +3.3V UART signal and converts it into the -5V to +5V 
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RS-232 signal. The structure of the data packets between the motherboard and the PC and the 
motherboard and the acquisition boards will be discussed further in section 5.5.6.  
Although this current motherboard is set up to communicate with two acquisition boards, the 
motherboard allows for scalability, allowing up to 4 acquisition boards to be connected at one 





Figure 5.13 Photo of the master board used in the VOSM system. The board contains a RS-232 connection to 
a PC (A), connections to the two acquisition boards (B), a USB connector used power the VOSM system and 
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5.5.3 Acquisition Board 
Along with the motherboard, there are two acquisition boards that are enclosed in the VOSM 
system. Each acquisition board consists of two DOS channels (which correspond to two DOS 
patch probes), connectors to the interface cables and patches, an ADC to sample the DOS 
measurements, and a microcontroller for DOS signal demodulation and communication between 
the acquisition board and motherboard. Figure 5.14 shows a diagram of an acquisition board, 
containing DOS channels 1/2 or channels 3/4 for the two respective acquisition boards.  
 
Figure 5.14 Diagram of an acquisition board used in the VOSM system. Each acquisition board contains two 
DOS channels and a microcontroller. The microcontroller accepts instructions from the motherboard and 
acquires data according to the gain settings and scanning profile. Modulation signals control the output power 
that the laser drivers provide to the laser diodes. Cabling from the laser driver to the interface supplies power 
to the lasers. Lasers emit light into tissue and photodetectors sense the reflected light. The current from the 
photodetectors is amplified and filtered for signal conditioning into the MUX. The resulting signal is sampled 
and processed for demodulation using our digital lock-in detection scheme. 
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Each DOS channel consists of sections for laser modulation and laser driving circuitry for source 
illumination, as well as current amplification, signal conditioning, and sampling for the detection 
electronics. Once the signal is properly conditioned, an analog multiplexer (MAX4518, Maxim) 
selects which detector channel should be sampled and the acquisition board’s ADC (LTC1865L, 
Linear Technology). Addition processing of the detected signal is performed through the board 
microcontroller to compute the amplitude of the detected signal. Once an entire frame from the 
acquisition board is obtained, the data is sent back to the master board. The following subsections 
describe the functionality of the DOS channels in further depth. A photo of an acquisition board is 
shown in Figure 5.15. 
 
 
Figure 5.15 Photograph of one of the two acquisition boards in the VOSM system.  
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5.5.3.1 Light Illumination Unit 
The input light is generated by 5 mW 5.6 mm-diameter laser diodes at wavelengths of 780 nm, 
808 nm, 678 nm, and 904 nm (L780P010, L808P010, HL6748MG, L904P010, Thorlabs). The 
wavelengths are selected to provide a range of spectral information to reconstruct oxygenated 
hemoglobin ([HbO2 ]), deoxygenated hemoglobin ([Hb]) and scattering while working within the 
limited selection of wavelengths available in this small package. The laser diodes are driven by 
the 15 V Laser Diode Driver (iC-WKN, iC Haus). Each wavelength has the ability to modulate the 
amplitude at a programmatically controllable frequency ranging from 1 to 5 KHz. The modulation 
signal is generated using a combination of a 1 kHz–33 MHz Oscillator (LTC6903, Linear 
Technology), a binary counter (M74HC4820, STMicroelectronics) and a SPI-controllable low-
pass filter (LTC1569-6, Linear Technology) that was typically set to a 72kHz. This creates a 1k-
5kHz sinusoidal signal that has a range from 0 to 3.3V. To control the output laser power on the 
laser driver, the sinusoid must be conditioned for a specific mean and amplitude. Therefore, an 
adjustable gain and offset amplifier stage was applied before the modulation set pin on the laser 
driver. The laser power of the driver is set by a POT resistor such that the laser output power is 
5mW. The modulation of the input light provides several advantages including superior noise 
rejection (including ambient light) as well as the ability to illuminate the tissue simultaneously 
with multiple wavelengths.  
 
5.5.3.2 Detection Unit 
The light is absorbed and scattered as light passes through the sample to two silicon photodiodes 
(SiPD) (Hamamatsu S1337-33BR) on an interface adapter board that is placed on the foot of a 
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subject. The maximum source detector distance for the first PD (PD1) is 16mm and the 25mm for 
the PD2. Current from the two SiPD travels down a 3 foot cable and is converted to voltage using 
a single-supply transimpedance amplifier (Op-Amp: AD8606, Analog Devices) that utilizes a 
bandwidth-extension technique previously implemented in [57]. The gain for the TIA is fixed at 
20k V/A for PD1 and 50k V/A for PD2 with a bandwidth of 74kHz and 30kHz respectively. The 
operational amplifier (op-amp) used for the TIA is specifically chosen for this application due to 
its low bias current and noise. The bias current of this device is ~1 pA which allows us to measure 
photodiode currents in the tens of picoamps. In addition, the AD8606 has excellent voltage noise 
performance of 6.5 nV/Hz-1/2 and 0.01 pA/Hz-1/2 which means that with a 20 kΩ resistor the noise 
generated from the op-amp is: 
 
 𝑉hiE<ji,kh@=. = 𝐼kh@=.R = 	 0.01𝑝𝐴𝐻𝑧 5.1𝑘𝐻𝑧 50𝑘Ω = 35.7𝑛𝑉 (5.1) 
 
Whereas the thermal noise of the 50kΩ resistor is: 
 
𝑉,u.vj<w = 	 4𝑘𝑇𝑅𝑓 = 	 4 1.38 ∗ 10E3{𝑚3𝑘𝑔𝑠E3𝐾E2 298𝐾 20𝑘Ω 5.1𝑘𝐻𝑧= 1.3𝜇𝑉 (5.2) 
The noise generated by the op-amp is still well below the thermal noise of the resistor. In both Eq. 
(5.1) and (5.2) the frequency used is 5.1 kHz which is the bandwidth of our acquired signal, as 
specified by the cutoff frequency of the low-pass anti-aliasing filter. Notice that in Eq. (5.2) it is 
important that temperature be controlled as it can lead to an unwanted increase in the thermal noise. 
Additionally, a 3-bit programmable gain amplifier (PGA) (LTC6910, Linear Technology) stage is 
used to optimize the signal to the scale range of the ADC which is 0 to 3.3V. These PGAs were 
selected because they are low noise that are easy to use and occupy very little PC board space. are 
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low noise digitally programmable gain amplifiers (PGAs) that are easy to use and occupy very 
little PC board space. The highest voltage noise performance of the PGA (Gain =1V/V) is 24 
nV/Hz-1/2 which means that 5.1kHz bandwidth the noise generated from the PGA is 54.2nV. 
Following the TIA and PGA gain stages, the signal is filtered with a 4th order Butterworth anti-
aliasing filter that removes high frequency components and whose primary purpose is to ensure 
there are no frequencies present above the Nyquist frequency prior to digitization. The signal is 
sampled by the ADC at 50 kSamples/s which establishes a Nyquist frequency of 25 kHz. As a 
result, we choose a cutoff frequency of 5.1 kHz and a Butterworth filter that has a flat passband 
for the 5 kHz signals, while also providing strong attenuation of any higher frequency noise at risk 
of aliasing into the passband. The 4th order Butterworth filter is implemented using a single filter 
chips (LTC1563-2IGN, Linear Technologies). The filter, in combination with a number of 
resistors, form an 4th order low-pass Butterworth filter with a 5.1kHz cutoff frequency that has 
<0.1% attenuation at our upper core frequency of 5 kHz, but still offers over 50 dB of noise 
suppression in our aliasing range.  
Once the signal has been properly filtered for sampling, the resulting signal goes into a 4 by 1 
analog multiplexer (MUX) (MAX4518, Maxim) that selects which detector to sample. A 4 by 1 
MUX was selected because there are two detectors per DOS channel and there are 2 channels 
resulting in four total detectors per acquisition board. This Maxim MUX is a precision, low-voltage 
chip that is suitable for this application.   
 
5.5.3.3 Data Sampling and Amplitude Detection 
Finally transitioning from the analog domain to the digital domain, the signal is quantized using a 
16-bit ADC (LTC1865, Linear Technology) that provides speeds up to 150kps. To do this we must 
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convert a continuous, smoothly varying signal, into a finite number of samples that adequately 
capture the shape of the signal. Resolution in both x (time) and y (amplitude) are both important. 
Resolution in time is determined by the sampling rate of the ADC, fs (or inversely, the sampling 
period Ts=1/fs), while the resolution of the amplitude is determined by the number of bits that the 
ADC can capture in its digital sample. More bits allow for more resolution in approximating the 
analog signal. The 16-bit ADC used in our design provides 216=65536 levels of quantization, and 
given that we have a supply range of 3.3V, the ADC provides a resolution of 50.4 µV. The ADC 
uses a successive approximation (SAR) architecture to sample the signal. For this architecture, the 
conversion starts with the internal D/A converter (DAC) set to midscale. The comparator 
determines whether the SHA output is greater or less than the DAC output, and the result (the 
most-significant bit (MSB) of the conversion) is stored in the successive-approximation register 
(SAR) as a 1 or a 0. The DAC is then set either to 1⁄4 scale or 3⁄4 scale (depending on the value of 
the MSB), and the comparator makes the decision for the second bit of the conversion. The result 
(1 or 0) is stored in the register, and the process continues until all of the bit values have been 
determined.   
With the ADC sampling rate set to 50kHz for a 5kHz modulated signal, 100 samples are acquired 
to precisely acquire exactly 10 cycles. Using our digital lock-in detection scheme [58] that was 
discussed in section 2.2.3, this vector of data will be converted to represent the amplitude for one 
of the 8 source-detector pairs for a single channel/patch. A single frame of channel data is acquired 
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once all combinations of four lasers and two detectors are illuminated/sampled. Once the frame is 
collected, the data is formatted into a packet and is transmitted via UART to the motherboard. 
 
5.5.4 Interfacing and Cabling 
Each DOS channel interface contains 4 laser sources and 2 PDs that fit onto a single patch interface 
or toe clip. The condition of the feet of many PAD patient can largely vary, with some exhibiting 
a substantial amount of pain, ulceration, and/or gangrene. To this end, careful consideration was 
taken into account for cabling and interfacing of the DOS channels to the foot to prevent further 
discomfort while undergoing the DOS measurements. The ideal patch interface design must be 
non-intrusive, lightweight, and durable. In addition, the interface would ideally have a disposable 
adhesive contact to easily stick the interface patches to the various angiosomes of the foot. The 
cabling requires 15 leads in order to operate and must be have good electrical isolation to prevent 
noise. Although these attributes for the interface would be ideal, many compromises were made 
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for the initial prototype for time consideration and potential redesigns of the opto-electrical 
components that may be costly to make for a custom designed interface.  
 
Figure 5.16 Front face of a patch interface, containing 4 laser sources and 2 photodetectors, with a laser cut 
cover made of acrylic (A). The back face of the patch interfaces shown with a phantom block interface used for 
calibration of our measurements (B). The toe clip shown with a silicone calibration bar in the toe chamber (C).  
Photo of a patch interface on a patient’s foot, alongside the toe clip (D). 
 
The initial patch interface design for the VOSM prototype was made on a low-profile PCB board 
that was enclosed in a 3D printed back casing and had its opto-electric components protected using 
laser cut acrylic (Figure 5.16A,B,D). The PCB design underwent several iterations to improve the 
form factor and the cross-talk between the laser sources and the photodetectors. To maximize the 
SNR of the acquisition, the interfacing DOS channels have the illumination and detector circuitry 
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isolated from each other. In addition, the enclosure of the patch interfaces was 3D printed to 
minimize the volume and to ensure a compact and tight fit for the PCB board. The patch interface 
probes contain 8 SD pairs from 4 laser source and 2 detectors. The illumination wavelengths, SD 
distances and other patch dimensions are shown in Figure 5.17. Although artery depth in the foot 
can be up to 3cm into the foot and the optimum SD distance to measure arterial changes would be 
6cm, the largest SD distance in this design is 25mm while the smallest is 10mm. These SD 
distances were chosen by an experimental process, in which laser cut acrylic of varying sizes were 
made and placed on the feet of volunteers to determine placement and size constraints that would 
arise from imaging patients. Through this process, it was determined that a 25mm SD pair distance 
would be the largest distance possible before interface placement issues on the subject became 
problematic. This maximum SD pair distance was further justified by the reconstruction processing 
performed by Khalil et. al. [195], in which the fiber-based imaging system largely used a 
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combination of reflectance measurements of 1, 2, and 3 cm SD pair distances for the image 
reconstruction of optical properties. 
 
Figure 5.17 The top view of the PCB layout for the patch interface board. Lasing and detecting interfaces are 
facing into the page. Dimensions of the board and SD distances are shown.    
The fourth channel for the VOSM system is a toe clip that fits on the big toe. This custom-made 
design was inspired by the numerous pulse-ox monitors that fit on the finger. The DOS topology 
differs from that of the patch design, as its measurement design is transmission based, where the 
4 laser sources are placed on the plantar side of the toe and the two photodetectors are placed on 
the dorsal side. The toe clip is made up of four 3D printed parts, two clip parts that house the toe, 
and opto-electronics, two covers that protect and hold the PCB boards and connectors, screws, and 
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a self-adjusting spring to create a snug fit in the toe chamber (Figure 5.16C,D). The toe clip 
chamber distance from the illumination sources and the detectors is 17mm. The size of toe clip is 
80mm x 27mm x 25mm. The Solidworks CAD model is shown in Figure 5.18 
 
Figure 5.18 A CAD drawing of the toe clip design. The design consists of four 3D printed parts including the 
toe chamber and covers for the opto-electronic enclosures, a hinge to hold the chamber, and a spring to apply 
closing pressure onto the toe being measured. 
 
In order to connect the opto-electronics, the two PDs require 3 leads while the four laser sources 
require a total of 12 leads from the main VOSM electronics to the interfacing. The Chapter 1, the 
WHDD interface was connected directly to the rest of the device, which is not feasible for this 
application. The interface must be connected to cabling from the main device to a small PCB board 
that will embody the laser and photodetector components. Previous iterations of the cabling 
consisted of a single cable solution, where all 15 leads were enclosed in the cable. Although a 
single cable solution is less cumbersome, the cross-talk between the illumination and detector leads 
dominated the actual measurements (Not shown). For the current VOSM system design, the 
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detector cable used is a shielded audio stereo cable, that contains two signal leads (Left and Right, 
corresponding to PD1 and PD2) and a ground lead. The custom-built illumination cable consists 
of two 6-lead cables, that make up the necessary 12 leads required to illuminate the 4 laser sources. 
The illumination cables are connected through a VGA connector at the VOSM system end and a 
micro rectangular connector (SM12B-ZPDSS-TF, ZPD Connectors) at the interface end (Figure 
5.19). 
 
Figure 5.19 VOSM system with interface cabling. VGA connectors are used to connect the illumination leads 
to the main VOSM system electronics. A stereo cable is used for the detector leads. Dual cables consisting of 6 
leads each are used to power the laser diode. 
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5.5.5 Graphical User Interface 
A MATLAB based graphical user interface (GUI) was designed to control, collect, and display 
data streaming from the VOSM system (Figure 5.20). The GUI can connect to the VOSM system 
using a virtual COM port, in which a USB to RS-232 cable is used to send and receive data to the 
VOSM system. Similar to the GUI used for the WHDD described in Chapter 1, the Graphical User 
Interface Design Environment (GUIDE) module was used to create point-and-click control of 
software applications, eliminating the need to learn a language or type commands in order to run 
the application.  
The GUI that was created has the ability to control the VOSM system using connect, stop, start, 
and calibration of gain, save the data to a specified location, load previous gain settings, and 
display incoming data from the multiple channels from VOSM in real time. The data received by 
the GUI is saved to a text file at a user specified location. The interface also has the ability to 
manually adjust and send individual gain settings to the device using sliders for each source 
detector pair by pressing the “Send Configuration” button. The DOS channels can be manipulated 
by selecting the corresponding radio buttons, and with 4 sources and 2 detectors, there are a total 
of 8 source-detector pairs that can have the gain adjusted for a given DOS channel.  
The user can load previous gain information by clicking on the “Browse” button on the “Open 
Config. File” section and selecting a “*_config.txt” file and pressing the “Load” button. Once 
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loaded, the sliders for the gain configuration will update accordingly. The user must then press the 
“Send Configuration” button to send the loaded gain settings to the device.   
 
Figure 5.20 A screenshot of the GUI used to control the VOSM system. The user can select up to 4 channels for 
a measurement (Channel Selection). Data can be saved and a gain configuration profile can be loaded 
(Load/Save Data). Radio buttons can select the gain profiles of the corresponding DOS channel, sliders are used 
to control gain settings of individual SD pairs, and a table of the returned signal of all 32 possible SD pairs are 
displayed (System Configurations). Incoming data from a selected DOS channel is displayed (Acquisition 
Display). 
 
Once the gain configuration is sent, the user can press the “Start” button to begin acquiring data. 
The start data will send a command to the device to begin imaging. Once the imaging is initiated, 
the VOSM will continually collect frames from the user selected DOS channels. Each frame of 
data is sent in a packet via USB/RS-232. Each packet contains a header with the packet size, the 
SD pair data with an adjustable size of significant digits of raw (voltage) data, and the gain of the 
SD pair. For each frame, the GUI parses the packet by computing the size of the packet from the 
header. The GUI then separates the data from the packet and writes the frame to the text file. In 
addition, the frame of data is displayed on the GUI screen for real-time visualization of the data 
acquisition. Although this GUI can be natively used with a Windows PC, this GUI has the ability 
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to be used with the Mac OSx operating system as well with the installation of the Prolific PL2303 
USB to RS232 driver (PL2303_MacOSX_1.6.1_20160309.pkg). 
 
5.5.6 Data Flow and Commands 
A diagram of the flow of commands and data is shown in Figure 5.21. 
 
Figure 5.21 Diagram of the instruction and data flow between laptop containing the MATLAB GUI, the 
motherboard in the VOSM system hardware, and the two acquisition boards. 
 
The VOSM instructional commands of ASCII strings are sent from the PC GUI to the main VOSM 
system to be processed there or are relayed to the appropriate acquisition board for further 
processing (Table 5.1). Each instruction packet begins with a 5-character header that contains the 
function command character (A, G, D, Y, S), 3 characters for the packet size (000-999), and an 
end of header character (!). The remaining packet contains channel and/or gain information for the 
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VOSM firmware.  The commands that are executed by the motherboard are used to initialize all 
of the system electronics and to execute user feedback information such as LEDs lights.  
 
GUI	Commands	to	VOSM	System	Hardware	
Function	 Commands	 Packet	Size	 Example	 Note	










D	 #Ch	*	2	 D004!2	3		 Read	Gain	for	Ch	2	and	3,	ready	LED	on	
Start	
Imaging	 Y	 #Ch	*	2	 Y004!2	3		
Being	Imaging	on	Ch	2	and	3,	imaging	LED	
on	
Stop	Imaging	 S	 0	 S000!	 Stop	all	imaging,	ready	LED	on	
Disconnect	 A	 0	 A000!	 Initialize	VOSM,	ready	LED	off	
Table 5.1 Command functions and packets sent from the GUI to the VOSM system hardware to control the 
device. 
 
All instruction packets are parsed in with the firmware of motherboard processor. The “channel 
number” info contained in the instruction packets is relayed to the proper acquisition board. For 
example, packets containing channel 1 and 2 information will be sent to acquisition board 1 to 
manipulate DOS channel 1 and 2, while packets containing information for channel 3 and 4 will 
be sent to acquisition board 2.  Commands processed by the acquisition boards are only related to 
setting gain bit information and obtaining data from a specific DOS channel only (Table 5.2). 
Commands	from	Motherboard	to	Acquisition	Boards	












D	 ChNumber	*	2	 D002!1	 Get	data	from	local	channel	1	
Table 5.2 Command functions and packets sent from the motherboard to the one of the two acquisition boards 
to either relay gain settings for a local DOS channel, or obtain a frame of data from the local DOS channel. 
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For each command sent to an acquisition board, the associated local DOS channel for that 
command will send back to the motherboard 8 data value readings for each SD pair, which is a 
single frame of data. If a measurement profile includes all four channels, the motherboard will 
send 4 commands to the acquisition boards, and will receive back 1 frame of data (data packet) 
from each of the 4 DOS channels that the VOSM system contains. The motherboard will parse the 
data packets and will build a new data packet that is sent back to the PC. Since the RS-232 buffer 
is limited in size, the VOSM system will transmit the measurement data one DOS channel at a 
time sequentially. The structure of the data packet that the PC receives from a single DOS channel 







Table 5.3 An example data packet from a single DOS channel 
  
 
5.5.7 Reconstruction of Optical Properties 
The measurement data collected from the VOSM system contains the reflectance information of 
the three patch channels, and the transmission information from the toe clip channel, all of which 
have units of volts. The voltage range of the DOS channels is 0 to 3.3V. Once the measurement 
data acquired, a DCT filter with a filter size of 200, which corresponds to the cutoff frequency of 
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the cuff occlusion protocol described later in this chapter. This filter will smooth the data, 
suppressing noise that may have been due to motion of the patient. 
In addition to pre-processing of the measurement data, calibration measurements must be taken to 
reconstruct the voltage data into concentrations of [HbO2], [Hb], and the reduced scattering 
coefficient us’. The calibration for the patch channels is performed by placing the interface patches 
onto the solid phantom cube described in section 3.5.4 (Figure 5.16B). With the calibration data 
acquired with the patch channels, the optical properties from each frame of the measurement data 
is reconstructed using the spatially resolved spectroscopy (SRS) constrained evolution strategy   
algorithm as described in section 2.2.6. 
The transmission based toe clip data undergoes a separate reconstruction procedure, where the 
calibration measurement is performed by placing an in-house made solid phantom in the chamber 
of the toe clip and measuring it at the same gain settings as the measurement data. Next, the 
measurement and calibration data is applied to the modified Beer-Lambert law (mBLL) model to 
reconstruct the concentrations [HbO2], [Hb], and the reduced scattering coefficient us’. The 
modified Beer–Lambert law (mBLL) [196-198], assumes (1) the absorption of the medium 
changes homogeneously, and (2) the scattering loss is constant [199]. The mBLL model is stated 
as: 
 𝐴 = 𝑙𝑛 𝐼@k&𝐼%., = 𝐿𝜇< + 𝐺 (5.3) 
where A is the attenuation (defined here as log base e), Iinc is the incident light intensity, Idet is 
the detected light intensity, L is the total mean path length of detected photons, µa is the absorption 
coefficient of the tissue and G is a geometry-dependent factor, which is independent of absorption 
and represents intensity loss caused by scattering. The differential form of the MBLL (dMBLL) 
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also holds for relatively small changes of attenuation, if G can be regarded constant, and the 
absorption changes homogeneously in the illuminated tissue volume: 
 Δ𝐴 = 𝑙𝑛 𝐼%.,,2𝐼%.,,3 = 𝐿Δ𝜇< (5.4) 
 
The latter is the weighted sum of the change in the concentration of tissue chromophores, mainly 
oxy- and deoxyhemoglobin: 
 Δ𝜇< = 𝛼NF\]Δ𝑐NF\] + 𝛼NFΔ𝑐NF (5.5) 
where the α weights denote the specific (molar) absorption coefficients of the chromophores. 
When the changes of attenuation are measured at more than two wavelengths, concentration 
changes can be determined by linear least-squares fitting [198]. To obtain the tissue chromophore 
concentrations with our calibration based setup up, Idet,1 is equal to an experimental measurement 
frame while Idet,2 is equal to the median of the phantom measurements for each SD pair. 
 
5.5.8 System Characterization 
The VOSM system requirements consists of a small form factor and ease of interfacing to a foot 
for a patient with PAD. In addition, the system must be fast enough the observe vascular changes 
from an angioplasty during intraoperative use, or from a venous occlusion as performed in our 
group’s diagnostic measurements [194, 195], and must have enough sensitivity and stability to 
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observe these changes.  Here we discuss the characterization of the system with the following 
parameters: Speed, Sensitivity and Dynamic Range, Linearity, Stability, Size.  
5.5.8.1 Speed 
The speed of acquisition is an essential parameter for dynamic measurements. The temporal 
response of the VOSM system is limited by the communication speed of the data from the VOSM 
sytem to the PC and the digital lock-in detection scheme applied in microcontroller of the 
acquisition board. Since we measure the tissue perfusion of the foot from one or more DOS 
channels, the imaging rate also depends on the number DOS channels used in an experiment. 
Consequently, the fastest the system can measure with one DOS channel, consisting of 4 
wavelengths and 2 detectors is (10.23 Hz). Or, with two DOS channels, VOSM can acquire data 
at 5.12 Hz). Finally, the slowest configuration is to use all 4 DOS channels, which operates at a 
framerate of 2.56Hz. For dynamic measurements applied by either angioplasty or induced venous 
occlusion by a pressure cuff, this framerate is more than adequate. 
5.5.8.2 Sensitivity and Dynamic Range 
The dark noise is the measured signal when no incident light is present, and thus represents the 
smallest measurement that can be reliably performed with the system. Figure 5.22 shows the dark 
noise measured for each gain setting with the standard deviation of the measurements across all 
detectors indicated by the error bars. By increasing amplification in the PGA stage, we do not see 
an increase of until a gain of 100. At the lower gain stages, we see noise levels below 100 µV, but 
as the gain increases we see increasing noise until at the highest gain stage of 100 (25.9MV/V) we 
have an RMS dark noise of 108 uV. Although the highest gain settings results in a much higher 
dark noise measurement compared to the lowest, the RMS dark noise only results in a noise of less 
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the 1% of the optimal return for a foot measurement, which is 2.8V. That is 108uV/2.8V = 0.003%, 
or 88dB of SNR.  
The largest light signal that can be detected uses the full detector range for the lowest gain setting, 
which in this case is to detect a 3.3 V peak-to-peak voltage on the 20kV/V gain setting. Using 
these values, we can calculate the dynamic range of the system to be 89.7 dB. 
 
Figure 5.22 Plot of the root mean squared (RMS) dark noise for each detector gain setting. Error bars represent 
the standard deviation of all detectors. 
 
5.5.8.3 Coefficient of Variation and Long Term Stability 
The coefficient of variation (CoV), shown in Equation (5.6) is calculated here for a static block 
phantom used section 2.3.4 in with optical properties shown in Table 2.3 over a period of 5 minutes 
(800 frames) with the full number of sources and detectors. 
 CoV =  , SNR = 20𝑙𝑜𝑔2 2h  (5.6) 
Figure 5.23 shows the mean of the CoV calculated for all SD pairs at the given gain setting for 
each channel. At the highest gain setting (PGA Gain = 100) the CoV is as low as 0.24% for the 
ATA and LPA channels. For the PTA and MPA channels, the CoV is above 1% at PGA gain = 5 
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and at the highest gain setting it increases to approximately 10%. It is speculated that the MPA has 
a high CoV due to its transmission based topology. The SNR for each of these settings can be 
calculated according to equation (5.6) giving us an average SNR of 71.8 dB for the lowest gain 
setting and 33.8 dB for the highest gain setting. 
 
Figure 5.23 The mean CV of the source-detector pairs at each gain setting for each channel. Errors bars 
represent the standard deviation across source-detector pairs. 
 
5.5.8.4 Linearity 
System linearity was examined by measuring the detected voltage from the solid block phantom 
and the toe clip phantom simultaneously across all possible PGA chip gain settings (LTC6910-1, 
Linear Technology) for each channel. The linearity experiment was repeated four times in order 
to cover all gain settings. The PGA chips used in the detector channels are 3-bit controlled with 
gain settings (0, -1, -2, -5, -10, -20, -50, -100V/V). The results are plotted in Figure 5.24, where it 
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is demonstrated that a linear relationship across the gain settings is generally maintained. For the 
curves below, linearity with R-squared measures of R=0.973 (ATA), R=0.949 (LPA), R=0.936 
(PTA), and R=0.859 (MPA). It is hypothesized that the MPA channel did not have as good a 
regression fit due to its transmission based topology compared to the reflection based channels.  
 
Figure 5.24 Linearity across all gain settings measured through an INO phantom block. Each facet represents 
the channels of the VOSM system. 
 
5.5.8.5 Physical Dimensions 
The VOSM electronic components and software interface described in the previous sections are 
combined into a single system that is easy to transport, as shown in Figure 5.10. The computer that 
contains the control GUI is currently a MacBook Pro 15” with a 2.3 GHz Intel Quad-Core i7 but 
the VOSM system can be easily controlled with most laptops containing MATLAB and a USB 2.0 
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port. All of the VOSM system electronics are completely encased by a 6.6” x 6” x 3.5” enclosure 
(1598ESGYPBK, Hammond Manufacturing). The VOSM system has four DOS interface 
channels, with each channel connected by 3 cables extending 3ft long. The interface patches that 
connect to the cables are 35mm x 25mm x 7mm in size while the dimensions of the toe clip is 
80mm x 27mm x 25mm. Table 5.4 provides a summary of the dimensions of the VOSM system 
components. 
VOSM	System	Dimensions	(cm)	
		 L	 W		 H	
System	Enclosure	 16.8	 15.2	 8.9	
Interface	Patches	 3.5	 2.5	 0.7	
Toe	Clip	 8.0	 2.7	 2.5	
Cabling	 152.4	 		 		
Laptop	 36.3	 24.9	 2.4	
Table 5.4 Dimension of the VOSM system and its components 
 
5.6 Monitoring of Peripheral Arterial Disease in the lower extremities after surgical 
intervention using Dynamic Diffuse Optical Spectroscopy  
To investigate the performance of the VOSM system in a clinical setting, we gathered preliminary 
measurement data from 22 PAD subjects before and after surgical interventions aimed to improve 
tissue perfusion in the lower extremities. The goal of the study is to explore the use of dynamic 
imaging techniques to detect and characterize PAD. In a previous 40 patient study examining the 
dynamic response of blood parameters to a venous occlusion, our group had shown that DDOT 
can distinguish between healthy subjects and patients with PAD, even in the diabetic PAD patients 
with calcified incompressible arteries [194, 195]. Although it was a future consideration, we did 
not examine the longitudinal outcomes of patients that underwent treatment to improve PAD. Here 
we aim to use DOS to examine its ability to track the severity of PAD before, and up to 12 months 
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after a PAD patient has undergone surgical intervention to fix the occluded blood to flow to the 
extremities.  
In this section, the initial results from a longitudinal study are presented to quantify VOSM’s 
ability of monitoring the perfusion effects of surgical intervention for PAD patient, its ability to 
assess the severity of the disease based on the perfusion response in the foot. 
 
5.6.1 Methods 
5.6.1.1 Clinical Study 
We have employed a 100-patient longitudinal study to monitor PAD patients at six time points 
over a one year period before and after surgical intervention of PAD, where currently 22 PAD 
patients are enrolled for this cross-sectional analysis. IRB approval was obtained from Columbia 
University Medical Center (CUMC) Investigational Review Board (Protocol# IRB- AAAK6702), 
and patients are recruited in the pre-operative area for vascular surgery at CUMC. Any patient 
undergoing surgical intervention are to be asked to enroll in the study. The inclusion/exclusion 
criteria do not have any restrictions based on race or gender. Recruitment of a greater proportion 
of minorities in keeping with the demographic makeup of patients seeking treatment at Columbia 
University Medical Center is anticipated. As this technique is still under investigation, the patients 
are not informed of any results that come from their VOSM monitoring.  
Once a patient has been enrolled and has signed the appropriate consent forms, the patient will be 
monitored before undergoing surgery, immediately after the procedure, and during follow-up 
examinations 1 month, 3 months, 6 months, and 12 months after the surgery. Standard clinical 
measures, are performed during examinations prior to the intervention, and during follow-up 
examinations. Because this report is based on an early cross-section of the study, results from the 
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pre- and post-operative measurements, as well as the 1 month follow-up are the only timepoints 
examined.  
 
5.6.1.2 Study Devices 
We propose the use of dynamic diffuse optical spectroscopy (DDOS) to monitor PAD before and 
after surgical intervention through the VOSM system as described in section 5.5. The VOSM 
system uses DDOS, which is a non-invasive, non-ionizing, contrast-free, fast imaging modality 
that allows for the measurement of blood volume changes in the foot. With VOSM, up to four 
DDOS channels made up of small patches are placed onto the lower limb and foot, where light is 
shone onto the surface of the tissue of interest. The light will illuminate various positions on the 
surface of the lower limb and foot. The reflected light intensities are recorded and the 
measurements are further processed to display the temporal changes of concentrations of oxy 
[HbO2], deoxy [Hb] and total hemoglobin ([HbO2] + [Hb] = [HbT]), which is proportional to the 
total blood volume (BV) in that limb. 
The VOSM system measurements are compared to the current standard for PAD measurements, 
the ankle-brachial index (ABI). ABI is used to monitor PAD within the lower extremities by taking 
the systolic blood pressure in the arm and dividing it by the systolic blood pressure in the foot. An 
ABI level that is less than 0.9 is indicative of affected vasculature, while a level above 0.9 and 
below 1.2 is considered normal. Falsely elevated ABI readings (>1.2) occur in patients with medial 
wall calcification, which is a condition commonly seen in diabetic patients. 
In addition to the ABI measurements, pulse-volume recordings (PVR) are conducted using 
segmental limb pressure cuffs along with the ABI measurement in an attempt to localize a stenosis 
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or occlusion. The PVR waveforms obtained for each segment are categorized in four categories: 
Normal, mildly abnormal, moderately abnormal, and severely abnormal. 
 
5.6.1.3 Angiosome Concept and DOS Channel Placement 
The four DDOS channels will be placed in various regions in the lower extremities according to 
the angiosome theorem [200-211]. An angiosome is defined as a three-dimensional anatomic unit 
of tissue fed by a source artery. The angiosome concept was initially described in plastic and 
reconstructive surgery papers and was intended to provide the basis for a logical planning of 
incisions and flaps [200, 201]. Adjacent angiosomes are bordered by choke vessels, which link 
neighboring angiosomes to one another and demarcate the border of each angiosome. Stenosis in 
arteries can affect the entire limb, but the degree of effects can be localized. This concept of 
perfusion delineates vascular territories that are supplied by specific arteries. Tissue defects caused 
by PAD can be treated by targeting arteries according to the location of foot ulcers.  
The angiosome model for the revascularization of the foot was followed by several authors who 
confirmed its relevance for ulcer healing and consequent limb salvage [202-205, 208]. This model 
includes 5 angiosomes (Figure 5.25) that we have used as a guide for our placement of VOSM 
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system channels, to monitor revascularization in arteries of the lower extremity for patients 
suffering from PAD.  
 
 
Figure 5.25 Diagram of the angiosome concept for the lower extremities [202]. Angiosomes are defined as three-
dimensional anatomic units of tissue (from skin to bone) fed by a given source artery. 
 
The VOSM system, which includes four DOS channels, were placed on four of the five 
angiosomes regions. The VOSM patch channels were placed on the regions that are supplied by 
the anterior tibial artery (ATA, dorsal side of foot), the lateral plantar artery (LPA, plantar side of 
foot), and the posterior tibial artery (PTA, calf muscle). In addition, the toe clip was placed on the 
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hallux, or commonly known as the big toe, to monitor the perfusion from the medial plantar artery 
(MPA). Example of the placement is shown in Figure 5.26 
 
Figure 5.26 VOSM patch and toe clip placement on a PAD subject. Each channel monitors perfusion on an 
angiosome. 
Although the PTA channel of the VOSM system is not located on the foot as the other channels 
are, we decided to place this patch on the calf for two reasons: (1) the tissue perfusion at the calf 
is still considered in the region of the angiosome associated with the PTA [212-218] and (2), many 
studies on exercise oxygenation use pulse oximetry or spectroscopic probes on the calf muscle. 
For these reasons, we examine the change in perfusion via the PTA from the calf location [219, 
220]. 
One compromise we made to perfusion monitoring was the lack of a VOSM channel at the 
angiosome related to the peroneal artery. Although the angiosome concept states that a region is 
primarily associated with an artery, sufficient cross branching from other arteries may allow us to 
monitor the peroneal artery’s effect on tissue perfusion. Thus, we believe that the four VOSM 
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channels measuring perfusion from 4 of the 5 angiosomes in the foot will provide sufficient 
information on the overall perfusion changes from the surgical intervention.  
 
5.6.1.4 VOSM Imaging Protocol 
A five stage dynamics imaging protocol was employed to measure the individuals with the VOSM 
system, who were lying flat on a surgical bed or adjustable exam chair while up to 4 of the VOSM 
channels were placed and strapped to the foot and calf using Velcro strips (Figure 5.27). To illicit 
a controlled vascular response a pressure cuff was applied to the thigh. The protocol consisted of 
(1) rest phase, (2) 60 mmHg thigh cuff occlusion phase, (3) release and recovery phase, (4) 100 
mmHg thigh cuff occlusion phase, and (5) release and recovery phase. Initially, the patient was 
imaged at rest for 1 minute. Then in the second phase, a pressure cuff was inflated to 60 mmHg to 
induce venous occlusion for 1 minute. The thigh cuff prevented the blood from leaving the leg 
through the veins, while arteries continued to supply blood to the foot. This pressure caused the 
blood to pool in the leg, which absorbed the light as it propagated through the foot, decreasing the 
intensity of the detected signal. In the third phase, the pressure was released allowing for 1 minute 
of recovery time. In the fourth phase, the thigh cuff was reapplied at 100 mmHg for 1 minute, 
inducing a greater venous occlusion. Finally, the cuff was released and the patient was imaged for 
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1 minute. This protocol was selected because it focuses on arterial flow, while avoiding the arterial 
compression required by blood pressure based measurements. 
 
Figure 5.27 A five stage dynamics measurement protocol was employed to measure the individuals with the 
VOSM system. Diagram of the measurement protocol (TOP). Raw traces of the returned signal normalized to 
the first “rest” period. 
 
5.6.1.5 Feature Extraction 
VOSM can provide multiple measurements per second of these blood parameters, allowing for the 
observation of temporal variations in these parameters. For example, by applying a pressure cuff 
at 100mmHg around the thigh, we induce venous occlusion in the leg and can use the VOSM 
system to observe the blood pooling in the foot and then returning to rest state upon release of the 
thigh cuff. In order to quantify the temporal changes in [HbT] from blood pooling during a venous 
occlusion, we have developed 3 features (Figure 5.28) that can provide a measure of the status of 
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the vascularity. All features extracted are normalized measurements relative to the baseline (rest) 
phase. These are: 
1. The percent change in [HbT] from the “rest” phase to the end of the occlusion phase. This 
feature will measure the overall all change of blood pooling due to the thigh cuff occlusion. 
2. The rise time of the [HbT] curve during the venous occlusion, which is calculated as the 
time duration, in seconds, from 10% to 80% of the peak [HbT]. The rise time feature is a 
measure of how fast the blood pooling occurs to reach 80% of it maximum value. 
3. The normalized pooling rate of [HbT] into the lower extremity, as defined as the amount 
of [HbT] that is pooled from the start of the venous occlusion to the point of the cuff release, 
normalized to the level of [HbT] at the cuff release. This measure of blood pooling will 
provide information of the amount of blood that was pooled over the occlusion interval. 
The area under the time traces is highly proportional to this measure. 
 
 
Figure 5.28 Normalized data of HbT during a venous occlusion on a patient. There are 3 features extracted 
from this time trace. (1) Percent change of HbT from baseline to cuff release. (2) Rise time, defined as the time 
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from 10% to 80% of the maximum HbT measured. (3) Normalized pooling rate, defined as the amount of HbT 
pooled during a venous occlusion, normalized to the peak HbT. 
 
5.6.1.6 Surgical Interventions 
Patients with severe and moderate PAD, as measured by ABI, PVR, and Duplex US, underwent 
exploratory angiograms in order to visualize the stenosis of the arteries in the lower extremities. 
During the angiogram imaging, patients that demonstrated clear stenosis immediately underwent 
surgical intervention. Procedures that were performed include angioplasty, stenting, atherectomy, 
or a combination of the three. If necessary, multiple lesions that were contained in the same or 
different arteries were treated at the discretion of the attending surgeon.  
In order to perform our angiosome analysis, the arteries that were treated were grouped into zones 
that corresponded with one or multiple angiosomes, as was initially explained in section 5.6.1.3. 
The diagram in Figure 5.29 shows the major arteries that primarily affect perfusion to the foot. 
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Table 5.5 provides a list of arteries that may be treated, its corresponding “zone”, and the 
angiosomes or VOSM channels that are hypothesized to be primarily affected by the treatment. 
 
Figure 5.29 Diagram of major arteries in the leg. During revascularization, one or more arteries were treated 
in order to improve tissue perfusion in the foot. The arteries treated were grouped into zones, and each zone 
treated corresponded to one or more angiosomes that should observe a large improvement compared to other 








Table 5.5 Designated intervention zones that separate major arteries that were treated for patients undergoing 
revascularization 
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5.6.1.7 Statistical Methods 
The three features extracted from the VOSM time trace measurements were analyzed. In order to 
verify linear independence between features, principle component analysis was performed for 
dimensionality reduction. The data were in the form of mean and standard deviations unless 
otherwise stated. To quantify VOSM’s ability to measure changes in tissue perfusion over time, 
comparisons between pre-op, post-op, and 1 month follow-ups (FUs) were made using a repeated 
measure analysis of variance (RM-ANOVA). Verification of the covariance structure between 
time points was performed by implementing a linear mixed effects regression model. The use of 
RM-ANOVA however, only tests the global hypothesis about any number of treatments whose 
effects are measured repeatedly in the same subjects. Since it is possible to observe each 
experimental subject before, after, and at multiple points after a single treatment, the paired t-test 
was used to identify the average change the treatment produces over time. To correct for multiple 
time-point comparisons, a Holm-Sidak p-value correction was applied. For a 95% confidence 
interval, and three measurements a1=0.0167, a2=0.025, a3=0.05 were obtained as significance 
cutoffs. To quantify the repeatability of the system, a Bland and Altman diagram was created and 
the coefficient of repeatability was calculated. 
Comparisons of VOSM parameters were compared to the gold standard measurements of ankle 
brachial index (ABI). The continuous variable ABI was analyzed between pre-op and FU 
measurements using the RM-ANOVA and post-analysis using the paired t–test, with a set to 0.05.  
Repeatability is a crucial measure of VOSM’s efficacy in demonstrating that the procedure is 
objective. The test must produce consistent results among a control group with a single assessor 
(test-retest reliability). To establish test-retest reliability, it is necessary to show minimal variance 
in the interaction of the subject and the tasks (thereby indicating that there is no statistically 
significant effect in the replicate trials). An appropriate method to determine whether the data have 
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test-retest reliability is by the repeated measures analysis of variance (RM-ANOVA) based on the 
null hypothesis that no significant difference exists between replicates. This hypothesis was tested 
in the present study at an α level of 0.05 based on a 95% confidence interval to prove that the null 




5.6.2.1 Study Population 
Twenty-two individuals were recruited for this IRB approved diagnostic pilot study in the Division 
of Vascular Surgery at New York Presbyterian Hospital - Columbia University. The 
inclusion/exclusion criteria did not have any restrictions based on race or gender. The physicians 
and researchers involved in the study recruited patients that were scheduled for exploratory 
angiograms. The patients enrolled in this study have access to all of the treatment, counselling and 
support services offered through the CUMC Division of Vascular Surgery.  
The patients recruited were 59% male and 41% female, with a mean age of 74.4 +/- 13.5 years. 
The mean weight of the patients was 175.2 +/- 39.9 lbs. Of the patients recruited, 7.4% were current 
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smokers and 80% were diabetics. The ethnic make-up was 5% Hispanic, 45% Non-Hispanic 
White, 9% Black, and 9% Asian (Figure 5.30). 
 
Figure 5.30 Ethnic makeup of the PAD monitoring study. 
 
Patients with severe PAD will often require surgical intervention to fix the occluded blood to flow 
to the extremities. This pilot study attempts to measure tissue perfusion in the lower extremities 
affected vasculature from these patients to monitor improvement or disease progression. To 
correlate vascular improvements according to angiosome regions, we also collected information 
regarding the arteries that were treated during surgical intervention (Figure 5.31).  This analysis 
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was only completed on PAD patients to see how the VOSM readings correlate with current 
techniques.  
 
Figure 5.31 Number of subjects separated by their “treatment zones” as described in section 5.6.1.3. Treatment 
zones SFA is related to the arteries above the knee (SFA, Illiac, Popliteal), ATA is for the anterior tibial artery, 
PTA is the posterior tibial artery, and PERO is the peroneal artery. 
 
5.6.2.2 Example Case Study 
We present a case study to demonstrate the efficacy of detecting PAD within the lower extremities 
with the VOSM system. Two patients were selected: a PAD patient with diabetes and a PAD 
patient without diabetes. The physician recommended that the subjects undergo a diagnostic 
angiogram with the potential of intervention based on a combination of the patients’ ABI readings, 
segmental ultrasound waveforms, physical symptoms and medical history. The patients were 
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enrolled just prior to their procedure and the imaging protocol was performed before and after the 
procedure, as well as one month after intervention.  
Example Case 1: Diabetic PAD 
Using the traditional ABI measurement, it is possible to discern between the healthy control and 
the PAD patient, however the diabetic PAD patient is not distinguishable. Diabetic patients often 
have incompressible arteries due to calcifications which result in elevated ABI readings and leads 
to false negative diagnoses. This patient, denoted as PAD02, was enrolled as a 59-year-old white 
male, who is an active smoker and was diagnosed with severe PAD prior to intervention. The 
VOSM imaging protocol was performed and the time trace of HbT was acquired (Figure 5.32 blue 
trace). The LPA showed a curve similar to that of a healthy subject, but the ATA and PTA channels 
demonstrated a slower pooling and rise time of HbT.  
During the diagnostic angiogram, it was observed that the patient had three major plaque lesions 
at his popliteal, peroneal, and the posterior tibial artery (PTA), all of which underwent angioplasty 
intervention to improve tissue perfusion in the lower right extremity. After the procedure, the 
VOSM measurement was taken again and an improved % change in HbT, rise time and pooling 
rate was observed (Figure 5.33).  
Measurements were taken at 1 and 6 months after the procedure, at which time gold standard ABI 
measurements were taken (ABI=1.01 and 1.18 respectively). However, VOSM measurements 
demonstrated a 14% decrease in perfusion after one month, and further decreased at 6 months (Not 
shown). Furthermore, this patient was unable to complete the study, as he underwent a second 
angioplasty before the 1 year of VOSM measurements.  
  




Figure 5.32 HbT(%) measurement data from a diabetic PAD patient before and up to 6 months after 
intervention. 
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Figure 5.33 Feature results from the first three measurement points for PAD02, our diabetic PAD patient case.  
This indicates that although the ABI measurements showed a normal reading, VOSM was able to 
detect a decrease in perfusion related to stenosis in the arteries. 
 
Example Case 2: Non-Diabetic PAD 
In this example, we demonstrate that VOSM has the ability to track ABI measurements with 
patients without diabetes. Here, we present an 89-year-old Asian male, who was diagnosed with 
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moderate PAD prior to intervention. The VOSM imaging protocol was performed and the time 
trace of HbT was acquired (Figure 5.34 blue trace). All curves at intervention were indicative of a 
subject with PAD, particularly the PTA and MPA channels, as the response of pooling was about 
20 seconds later than that of the LPA channel. The patient underwent an angioplasty of the right 
peroneal, which should create an increase in perfusion primarily in the LPA and PTA channel. 
 
Figure 5.34 Time traces of HbT for PAD17, a non-diabetic PAD subject with moderate PAD at the time of the 
procedure.  
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Using the extracted features form the time traces, it was determined that there was an increase in 
perfusion immediately after intervention for all channel, but at measurements taken at the 1 month 
follow-up indicated that there was still improvement in two channels, but a decrease in perfusion 
in the ATA and LPA channels. ABI measurements showed that the patient went from a moderate 
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to a mild level of PAD severity 1 month after intervention. These results illustrate that the VOSM 
may be able to detect mild changes of severity to PAD, as also indicated with ABI measurements.  
 
Figure 5.35 Feature results from the first three measurement points for PAD17, our non-diabetic PAD patient 
case. 
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It is important to note that with 29% of PAD patient over the age of 50 being also diabetic, it is 
important that the diagnostic measures be accurate for these patients, as they make a up a large 
sum of the PAD population.  
5.6.2.3 ABI Measurements 
ABI readings were collected from medical records of the patient enrolled in the study before and 
at 1-month after revascularization. In total, 9 ABI measurements taken prior to patient 
revascularization and 11 measurements were made at their 1-month follow-up. The PAD patients 
prior to intervention had an average ABI of 0.88 +/- 0.14 indicating moderate disease, while 
measurements made during the 1-month follow up had an average ABI of 0.95 +/- 0.36, which 
could be misinterpreted as healthy vasculature, as 80% of the subjects were diabetic. Although 
arterial calcifications render the arteries incompressible and falsely elevate the ABI readings, a 
statistical significance (p=0.013) is observed between the pre-operative and 1-month follow-up 
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ABI readings. In general, this is indicative of an improvement of vascular flow to the lower 
extremities. 
 
Figure 5.36 Comparison of ABI measurements taken from subjects before and 1-month after revascularization. 
A statistically significant change in the ABI was observed (p=0.0129) 
 
5.6.2.4 VOSM Measurements up to 1-Month After Intervention 
The three features extracted from the time traces were analyzed (Percent change, HbT Rise time, 
and normalized pooling rate) and boxplots were created for each feature and thigh cuff pressure 
associated with the measurement (Figure 5.37, Figure 5.38, Figure 5.39, and Figure 5.40). The 
boxplots show a general trend that the percentage change feature increases between the pre- and 
post-operative measurements and then decreases after one month. This pre-, post-op, and 1 month 
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measurement trend is also observed for the pooling rate. Conversely, the rise time of HbT between 
pre- and post-operative measurements decreases, and then again increases between post-op and 1-
month follow up measurements. The basis of these results indicate that features indicate that there 
is an increase in perfusion after the intervention but generally shows a decrease in perfusion 1-
month after the intervention.  
To quantify these observations, a RM-ANOVA test was used for each VOSM channel to compute 
global difference between optical vascular measures. With 3 features, 2 thigh cuff pressures, and 
4 VOSM channels, there were a total of 24 RM-ANOVA tests that were performed. Table 5.6 
shows the p-values computed from the hypothesis testing, where the null hypothesis is rejected if 
the p-value is below 0.05. A rejection of the null hypothesis indicates that a significant difference 
is present in at least one of the repeated measures. From these results, it is shown that rise time 
provides a strong measure for vascular differences in the ATA and LPA channels. The Pooling 
rate feature also demonstrates significant changes with the LPA channel for both thigh cuff 
pressures. In addition, the percent change feature shows no significant differences between 
measurements for any channel or thigh cuff pressures. Furthermore, there are no differences 
between measurements with PTA and MPA channels for any of the features, which may indicate 
that there is a lack of sensitivity at these physical locations.  
Channel 60mmHg 100mmHg 60mmHg 100mmHg 60mmHg 100mmHg
ATA	Channel 0.401 0.106 0.040 0.005 0.063 0.156
LPA	Channel 0.053 0.116 0.001 0.000 0.006 0.012
PTA	Channel 0.984 0.945 0.274 0.337 0.168 0.666




Table 5.6 Computed p-values from the repeated-measure ANOVA tests. The null hypothesis was rejected if the 
p-value was computed to be less than 0.05. 
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Despite the lack of global significance in these 24 groups using the RM-ANOVA, post-hoc testing 
was performed to quantify specific changes between measurement pairs. Within subject 
comparisons were made between pre-, post-operative, and 1 month follow-up measurements using 
a paired t-test. Difference in measurements in the ATA Channel (Figure 5.37) show that the there 
is a significant difference between the pre- and post-operative measurements for all features and 
thigh cuff pressures. Furthermore, there are no other significant differences between any other 
group, which signifies that the patient may be worsening one month after revascularization, albeit 
it is to a lesser degree than the vascular state as measured pre-operation.  
There are many observations that can be made from these pair-wise comparisons. The most notable 
difference is that out of 24 channel/feature/cuff pressure combinations, with a total of 72 
measurement comparisons, there were 13 significant differences observed, with 11 of those 
calculations observed between pre- and post-operative measurements, and the other 2 calculations 
observed between post-operative and 1-month follow measurements. This trend may indicate that 
although the patient improves after intervention, tissue perfusion in the lower extremities may 
worsen after only 1 month.  
The ATA channel shows significant differences between the pre- and post-operative measurements 
across all features and cuff pressures, while the LPA channel also has differences between pre- 
and post-operative measurements, expect in the percent change category at 100mmHg. As 
indicated by the RM-ANOVA results, comparison made within the PTA and MPA channels were 
largely insignificant, with only the MPA channel showing a change between pre- and post-
operative VOSM measurements for the 60mmHg normalized pooling rate feature. There are no 
significant differences between groups from the PTA channel, which may indicate that there is not 
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enough sensitivity from the calf location. In addition, there is only two significantly different 
comparisons outside of the pre- and post-operative measurements, which are between post-
operative and 1-month follow ups (LPA-percent change-60mmHg thigh cuff pressure, and the 
MPA-rise time-100mmHg).  
 
Figure 5.37 Comparisons between pre-op, post-op, and 1 month follow-up measurements from the ATA patch 
channel using a paired t-test. Calculations were made against all three features (Percent change, HbT Rise 
Time, and the Normalized Pooling Rate), and for both thigh cuff pressures (60 and 100mmHg).  
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Figure 5.38 Comparisons between pre-op, post-op, and 1 month follow-up measurements from the LPA patch 
channel using a paired t-test. Calculations were made against all three features (Percent change, HbT Rise 
Time, and the Normalized Pooling Rate), and for both thigh cuff pressures (60 and 100mmHg). 
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Figure 5.39 Comparisons between pre-op, post-op, and 1 month follow-up measurements from the PTA patch 
channel using a paired t-test. Calculations were made against all three features (Percent change, HbT Rise 
Time, and the Normalized Pooling Rate), and for both thigh cuff pressures (60 and 100mmHg). 
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Figure 5.40 Comparisons between pre-op, post-op, and 1 month follow-up measurements from the MPA toe 
clip channel using a paired t-test. Calculations were made against all three features (Percent change, HbT Rise 
Time, and the Normalized Pooling Rate), and for both thigh cuff pressures (60 and 100mmHg). 
 
Table 5.7 provides a list of the Holm-Sidak adjusted p-values of the multiple comparisons. Based 
on these p-values from the 3 features and 2 cuff pressures, it can be deduced that the rise time 
feature at 60mmHg provides the highest sensitivity in measuring changes in perfusion across 
repeated measurements. It should be emphasized that the PTA and MPA channels did not observe 
statistical significance in the RM-ANOVA test and as such the significant changes in paired t-test 
from the MPA channel may be a result of a type I error. 
  

















Pre - Post 0.049 0.007 0.021 0.037	 0.011	 0.023	
Pre - 1 Mo. 0.682 0.139 0.266 0.476	 0.171	 0.239	
Post - 1 Mo. 0.682 0.355 0.842 0.476	 0.011	 0.488	

















Pre - Post 0.102	 0.002	 0.003	 0.135	 0.006	 0.009	
Pre - 1 Mo. 0.481	 0.130	 0.237	 0.979	 0.145	 0.180	
Post - 1 Mo. 0.042	 0.058	 0.237	 0.247	 0.006	 0.090	

















Pre - Post 1.000	 0.150	 0.348	 1.000	 0.761	 1.000	
Pre - 1 Mo. 1.000	 0.774	 0.571	 1.000	 0.261	 1.000	
Post - 1 Mo. 1.000	 0.230	 0.143	 1.000	 0.261	 0.597	


















Pre - Post 0.739	 0.658	 0.033	 0.416	 0.877	 0.747	
Pre - 1 Mo. 0.219	 0.658	 0.906	 0.888	 0.750	 0.747	
Post - 1 Mo. 0.739	 0.418	 0.181	 0.627	 0.025	 0.747	
Table 5.7 Computed Holm-Sidak adjusted p-values comparing repeated measures for all channel, feature, and 
thigh cuff pressure combinations.    
 
Within the ATA and LPA channels, there were features that showed statistically significant 
differences, largely between pre- and post-operative measurements. Although establishing the 
general trend of the effect from the surgical intervention is important, quantifying the percentage 
change of the features between time points is also important, as the inter-measurement reliability 
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may affect the overall outcome of the VOSM measurements. Figure 5.41 and Figure 5.42 show 
the vascular response according to the VOSM features from pre- and post-intervention and post-
intervention vs. 1 month follow-ups. The features show an 18 to 50% increase perfusion based on 
these features from before and after intervention, with the LPA channel demonstrating a larger 
change in response compared to the ATA channel. Furthermore, these results show that the 
perfusion decreases again after 1 month. The magnitude of these changes range from 8 to 38%, 
with the normalized pooling rate showing the minimal amount of change at -8%.  
 
Figure 5.41 Percent change in response between time points (Pre- vs. Post-intervention and Post-Intervention 
vs. 1 Month F/U) from the VOSM features used to measure perfusion. Data displayed is from cuff 
measurements made at 60mmHg. 
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Figure 5.42 Percent change in response between time points (Pre- vs. Post-intervention and Post-Intervention 
vs. 1 Month F/U) from the VOSM features used to measure perfusion. Data displayed is from cuff 
measurements made at 100mmHg. 
 
5.6.2.5 Angiosome Analysis 
Angiosome theory is a topic of great interest in vascular surgery. The primary use of the four 
VOSM channel patches is to localize perfusion changes to these angiosome according to the artery 
or arteries treated during surgical intervention. The four angiosomes captured from the lower 
extremities include regions that are supplied by the anterior tibial artery (ATA, dorsal side of foot), 
the lateral plantar artery (LPA, plantar side of foot), and the posterior tibial artery (PTA, calf 
muscle). In addition, the toe clip was placed on the hallux, or commonly known as the big toe, to 
monitor the perfusion from the medial plantar artery (MPA). Due to the vast number of arteries in 
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the lower extremity, treatment locations were divided into zones for which angiosomes are 
expected to observe a change (Table 5.5).  
In order to quantify the interaction between the treated artery and the perfusion response of the 
angiosome, the VOSM measurements were separated by each defined treatment zone. For 
example, surgical treatment to the ATA (Zone 2) is expected to primarily improve perfusion in the 
dorsal region of the foot, and should be measured as such by the ATA VOSM channel. However, 
the treatment of the femoral artery, which supplies blood to all of the angiosome regions, is 
expected to improve perfusion to all angiosome regions and all VOSM channel measurements 
should observe this change.  
Vascular changes to the angiosome regions according to the treatment locations were quantified 
by using the paired t-test to analyze the differences in the feature data before and after the surgical 
intervention. Since the differences in vascular results between pre-op and 1 month VOSM 
measurements are not statistically significant (Section 5.6.2.2), measurements taken at 1 month 
were not included in this analysis. Furthermore, because the differences in the pre- and post- 
operation data are maximized, the sensitivity of vascular response from the angiosomes according 
to the treatment locations are also maximized. Significant changes in perfusion after 
revascularization according the treatment zones were evaluated using a p-value < 0.05 for thigh 
cuff pressures at 60mmHg (Error! Reference source not found.) and at 100mmHg (Error! 
ference source not found.). The significant changes between angiosome and treatment zone are 
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highlighted in yellow, while NA values denotes that a comparison measure was not possible due 
to the small number of the patients that underwent treatment at that location. 
 
 
HbT	perc	change	 SFA	 ATA	 PTA	 PERO	
ATA-	Cuff:60mmHg	 0.009	 0.978	 NA	 NA	
LPA-	Cuff:60mmHg	 0.087	 0.994	 NA	 NA	
PTA-	Cuff:60mmHg	 0.588	 NA	 NA	 NA	
MPA-	Cuff:60mmHg	 0.857	 NA	 NA	 NA	
	     
HbT	Rise	time	 SFA	 ATA	 PTA	 PERO	
ATA-	Cuff:60mmHg	 0.03	 0.174	 NA	 NA	
LPA-	Cuff:60mmHg	 0.029	 0.311	 NA	 NA	
PTA-	Cuff:60mmHg	 0.502	 NA	 NA	 NA	
MPA-	Cuff:60mmHg	 0.6	 NA	 NA	 NA	
	     
Norm.	Pooling	Rate	 SFA	 ATA	 PTA	 PERO	
ATA-	Cuff:60mmHg	 0.088	 0.046	 NA	 NA	
LPA-	Cuff:60mmHg	 0.086	 0.107	 NA	 NA	
PTA-	Cuff:60mmHg	 0.615	 NA	 NA	 NA	
MPA-	Cuff:60mmHg	 0.456	 NA	 NA	 NA	
Table 5.8 Calculated p-values between pre- and post-operative VOSM channel measurements according to the 
subject’s defined treatment zone. These measurements are only made for cuff occlusions at 60mmHg 
 
HbT	perc	change	 SFA	 ATA	 PTA	 PERO	
ATA-	Cuff:100mmHg	 0.026	 0.012	 NA	 NA	
LPA-	Cuff:100mmHg	 0.086	 0.923	 NA	 NA	
PTA-	Cuff:100mmHg	 0.924	 NA	 NA	 NA	
MPA-	Cuff:100mmHg	 0.121	 NA	 NA	 NA	
	     
HbT	Rise	time	 SFA	 ATA	 PTA	 PERO	
ATA-	Cuff:100mmHg	 0.002	 0.323	 NA	 NA	
LPA-	Cuff:100mmHg	 0.005	 0.184	 NA	 NA	
PTA-	Cuff:100mmHg	 0.743	 NA	 NA	 NA	
MPA-	Cuff:100mmHg	 1	 NA	 NA	 NA	
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Norm.	Pooling	Rate	 SFA	 ATA	 PTA	 PERO	
ATA-	Cuff:100mmHg	 0.02	 0.058	 NA	 NA	
LPA-	Cuff:100mmHg	 0.126	 0.21	 NA	 NA	
PTA-	Cuff:100mmHg	 0.114	 NA	 NA	 NA	
MPA-	Cuff:100mmHg	 0.502	 NA	 NA	 NA	
Table 5.9 Calculated p-values between pre- and post-operative VOSM channel measurements according to the 
subject’s defined treatment zone. These measurements are only made for cuff occlusions at 100mmHg 
As these tables show, the number of treatment measurements in zone 3 and 4 are too low to make 
a quantitative comparison using the paired t-test. Also, due to poor signal quality at the PTA and 
MPA channels, a paired t-test for the Zone 2 (ATA) could not be computed. For treatment above 
the knee (SFA, Popliteal, Iliac), measurements taken at the PTA and MPA are not significant 
(P>0.114). Finally, there are more significant differences in the angiosome-to-treatment zone 
comparisons with the cuff measurement at 100mmHg than 60mmHg. This may signify that a cuff 
pressure at 100mmHg provides a more sensitive measurement to changes. 
 
5.6.2.6 Repeatability  
To assess the reliability of VOSM, the imaging protocol described in section 5.6.1.4  is performed 
in two trials during each patient visit, and the 3 features that are extracted from the VOSM time 
traces are compared from the initial and repeated reading. To quantify the differences between the 
features of the repeated measures, a Bland-Altman diagram was created to visualize the mean and 
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difference of the repeated measure of the percent change, rise time, and pooling rate features 




  207 
 
Figure 5.43 Bland-Altman plots demonstrating the reliability of the VOSM system through three of the 
extracted features. TOP: percent change of HbT from the baseline measurement, MIDDLE: Rise time of the 
pooling from 10% to 80% of the maximum HbT, BOTTOM: Normalized pooling rate of HbT. 
 
These figures demonstrate that the repeated measures have a mean variation of 18.1% for “Percent 
change HbT”, 9.9% for “Rise time”, and 7.1% for “Normalized pooling rate”. However, 
computing the mean of the difference of the repeated measurements is heavily weighted on 
potential outliers that may occur due to physical factors such as motion artifacts during acquisition, 
ulcerations at the toe, or physiological changes that may be caused by repeated thigh cuff 
occlusions. To substantiate the weight of the outliers on the repeatability measurements, a boxplot 
of the percent variation from the initial and repeated reading for all VOSM channels are shown in 
Figure 5.44. Here it is shown that there are outliers that reach up to 54% variation between initial 
and repeated measure (Percent change HbT). Despite the range of variations from repeatable 
measures, 70.5% of the instances fall below the mean difference in repeated measures for the 
normalized pooling rate and 61% for the rise time feature. By using boxplots, the median of the 
difference is shown to be lower than the mean variation (HbT % Change = 11.2%, “Rise time” = 
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7.7%, “Normalized pooling” = 4.2%). The mean and median differences in repeated measures in 
summarized in Table 5.10.  
 
Figure 5.44 Boxplot the percent change from initial and repeated measurements for all measurements from all 
channels.  
In addition to computing the percent change between the repeated measures, an RM-ANOVA test 
was performed for each of the three features. Using this metric, the null hypothesis is desired, as 
it demonstrates there is no significant difference between the first and second measurement. The 
p-values from the RM-ANOVA are shown in Table 5.10. These results show that the “Rise time” 
and “Normalized pooling rate” have no significant differences between the first and second 
measurement. However, the “Percent change in HbT” feature has a p<0.05, signifying that the first 
and second measurements is significant. This suggests that the percent change feature may not be 
a reliable feature for tracking  
	 VOSM	Feature	
		 %	Change	HbT	 Rise	Time	 Normalized	Pooling	Rate	
Mean	Variation	 18.1%	 9.9%	 7.1%	
Median	Variation	 11.2%	 7.7%	 4.2%	
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RM-ANOVA	p-Values	 0.002	 0.545	 0.051	
Table 5.10 Summary of the repeatability error from the 3 VOSM features.  
 
5.7 Discussion 
The VOSM system is a non-invasive, non-ionizing, contrast-free imaging modality that uses 
diffuse optical spectroscopy (DOS) in which red and near-infrared light to is used to measure 
changes in blood perfusion in tissue. The DOS technology has been applied to image PAD in the 
foot. Using our imaging protocol to simulate hemodynamic changes in the lower extremities, 
optical changes due to blood pooling is observed. For large vessel disease, the plaque buildup 
increases the resistance and reduces compliance of the vessels. This leads to a reduction in the 
blood pooling into the foot, resulting in lower pooling rate of [HbT]. In small vessel disease, the 
same effect can be caused by arterial stenosis. 
In order to quantify the level of perfusion in the lower extremeties, multiple features were extracted 
from these VOSM time traces as described in our imaging protocol (Percent change HbT, HbT 
Rise Time, and Normalized Pooling Rate). Based on these features, VOSM shows statistically 
significant differences in blood perfusion in PAD patients before and after surgical intervention to 
improve affected vasculature in the foot.  
Measurements to quantify repeatability were taken at each imaging session with VOSM. During 
each session, the imaging protocol was performed twice and were compared to each other with 
respect to channel and thigh cuff pressure. It was found that the rise time and normalized pooling 
rate feature were repeatable within 7 and 5% respectively. There were outliers that were observed 
for these repeatability measurements, which caused the mean variance to increase. It is believed 
that the high level of variance in for these measurements are due to physiological changes in the 
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leg after multiple thigh cuff occlusions, motion artifacts, or patch placement was moved out of the 
a region with high vasculature.  
Measurements of perfusion were made at four separate points on the leg, with two of the channels 
(ATA, LPA channels) demonstrating the most sensitivity between pre- and post-operative 
measurements, based on statistically significant differences between the measurements. The most 
sensitive feature extracted from the VOSM times traces to monitor increase of blood pooling 
during the cuff occlusion is from the HbT rise time feature at a thigh cuff pressure of 100mmHg 
(RM-ANOVA p<0.001). The normalize pooling rate was also determined to be a suitable measure 
of blood perfusion in the foot, but did not demonstrate a statistically significant difference between 
measures for the ATA channel. This analysis was also completed for 60 mmHg thigh cuff 
occlusions, which was not as effective as the 100mmHg pressure. We suspect this is because of 60 
mmHg may not be a sufficient cuff pressure to produce a full venous occlusion. In addition, the 
PTA and MPA channels on the VOSM system did not demonstrate statistically significant changes 
between measurements based on the RM-ANOVA. This may indicate that the position of these 
channels should be adjusted in order to acquire more sensitive measurements on these arteries. 
VOSM measurements performed one month after surgical interventions displayed an increase in 
the HbT rise time, and did not have any statistically significant changes with the pre-operative 
measurement for any of the feature and thigh cuff combinations. This suggests that the blood 
perfusion after only one month is worsening and further treatment may be required to maintain 
proper perfusion to the foot otherwise risk of ulceration, gangrene, or amputation may be 
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imminent. For example, of the 22 subjects enrolled, there have been 3 that have required a second 
intervention before completing the 12 months of monitoring as described in our study protocol.  
Conversely, the ground truth measure of ABI taken one month after intervention suggests 
otherwise, as these diagnostics demonstrated an improvement at the 1 month mark (p=0.013), 
suggesting that perfusion is improved compared to pre-operative measurements. Unfortunately, 
this cross-sectional analysis cannot provide insight into when and if the gold standard 
measurements indicate additional intervention is needed. Furthermore, our continuation of the 
study is necessary in providing insight as to if the VOSM measurements provide an earlier 
indication into changes in tissues perfusion as compared with ABI measurements.  
There is currently no gold standard for assessing angiosome perfusion, making statistical analysis 
on tissue perfusion in the various angiosome regions difficult. Future studies involving animal 
models or angiographic foot analysis in patients with distal arterial disease may help to validate 
angiosome analysis using VOTI. Although more data is required for an in-depth angiosome 
analysis, it was shown in this analysis that the VOSM ATA channel could show the most sensitive 
measurements for cases in which the AT artery was treated. These results suggest that the use of 
the VOSM system may aid in treatment planning, where a physician can intervene to improve 
perfusion to the most compromised areas of the foot. Unfortunately, there were only 1 case each 
for treatment of peroneal and the PT artery, and our angiosome analysis could not be done for 
these cases. 
VOSM provides a direct measurement of the perfusion to multiple angiosome regions, serving as 
a measure of the effects of the lesions or stenosis on the foot. The DOS technology that VOSM 
utilizes can be used to non-invasively monitor patients with PAD, without needing to inject 
contrast into the patient’s bloodstream. These cross-sectional results of this 100-patient study 
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indicate that a physician can effectively monitor patients with PAD independently of arterial 
calcifications using VOSM, despite the ABI measurements not being accurate. Future studies will 
involve greater enrollment to account for multivariate risk factors including smoking, age, 
hypertension, weight, and demographics to understand their effects on tissue perfusion as 
measured using the VOSM system. 
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6 Conclusion and Future Directions 
This dissertation investigates the ability and clinical functionality of DOS as a compact system to 
monitor various diseases such as infantile hemangiomas (IH), rheumatoid arthritis (RA), and 
peripheral artery disease (PAD). We began by creating a second-generation handheld wireless 
probe, so that it would easy to use in the clinic and capable of accommodating the various tissue 
types and sizes observed in the clinic. Upon completing the new probe, we began a 15-patient pilot 
study to show that the WHDD was capable of monitoring the stages of IH to provide a proof 
concept that DOS technology could provide a quantitative measure to assess the highly vascular 
IH lesions.  
In order to verify the accessibility of the WHDD system, we hoped to demonstrate that its 
sensitivity to vascular changes could be applied to measuring optical changes of the finger joint 
with patients suffering from RA that are undergoing treatment therapy. In a case study, ehe optical 
measurements from the WHDD were compared optical changes from our proven fDOT system 
and a sensitivity analysis was performed. Unfortunately, the sensitivity of the WHDD could not 
match that of the fDOT system from this single case. I believe that an improvement to the optical 
interfacing to the finger joint would make for more reliable measurements. In addition, the ability 
of fDOT to make accurate measurements of reduced scattering in comparison to the continuous 
wave topology of the WHDD system increases the sensitivity of monitoring RA. I suggest if a 
smaller form factor device is created for monitoring RA, future work must incorporate these two 
attributes.  
Finally, in our study investigating the use of DOS to monitor blood perfusion in the foot in PAD 
patients before and up to a year after surgical intervention, a portable system was designed based 
on the hardware designs from the WHDD system. This system, called vascular optical 
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spectroscopic measurement (VOSM) system, has four DOS channels capable of making vascular 
measurements on the lower extremities of PAD patients. We demonstrated that the VOSM system 
is capable of displaying the increase in blood pooling associated with the intervention. We have 
also provided evidence that tissue perfusion vastly decreases only a month after the intervention, 
despite what the reading from the gold standard measures of ABI and PVR indicate. The cross-
sectional analysis performed suggests a correlation between the location of the arteries treated and 
tissue perfusion improvement within the associated angiosome region. This feature may be able to 
guide vascular surgeons in how to approach revascularization for their patients. Future work for 
this project includes the completion of the 100-patient clinical study to perform a complete 
analysis. Furthermore, improvements should be made on the system’s interfacing such that 
usability in a clinical setting is not an issue. 
DOS has plenty of applications within the vascular realm. In the future, we hope to see DOS in a 
small form factor such as the WHP used by physicians to assess diseases. Furthermore, DOS can 
be used in 3rd world nations where technology is scarce or standard technology is too expensive 
for monitoring diseases such as breast cancer.  
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Appendix A 
Guide to processing and reconstructing 3D optical property maps of finger joints for monitoring 
treatment of rheumatoid arthritis. 
First, follow all post processing procedures as described in the TOPOscan manual. 
When creating a surface mesh, be sure that the element size length is <1mm 
http://geuz.org/gmsh/doc/texinfo/gmsh.html#Specifying-mesh-element-sizes 
 
Mesh creation (Gmsh): 
• File > Open > .stl file 
• Geometry > Elementary entitites > Add > Volume 
• Select volume > (popup) Create new .geo file > 'e' 
• Mesh > 3D 
• Geometry > Edit File 
• Edit file in TextWrangler.  
o Add 'Mesh.CharacteristicLengthFactor = 0.01;' to beginning of file. Higher the 
number, the larger the elements. 
o Add 'Mesh.CharacteristicLengthExtendFromBoundary = x;' to change density at 
surface boundary (<1 more dense at surface, >1 more dense in the center) 
o Save File.  
• Geometry > Reload 
• Mesh > 3D 
• Tools > Statistics 
• Nodes on surfaces + Nodes in volumes = Total Nodes (Max nodes for reconstruction is 
10,000 - shoot for 8,000) 
• Tetrahedra = Number of elements 
• Other 
o Save Model Options - saves a .opt file with all the options 
Find marker locations 
• Using meshlab, use the PickPoints tool and click on select point (Right click).  
• Select a point and the coordinates will appear in the pop-up window. 
• Save the point as a .pp file 
• If FVM algorithm needs to be reconstructed, use: g++ -o GID2FVM GID2FVM.cpp 
 
How data is preprocessed: 
• 16 (usually) images are taken within a modulation cycle, at one source position.  
• To calibrate images  
  233 
o "beamspot" files are produced from experiment or an old one is called  
§ These 16 images are demodulated to find phase and amplitude of the beam 
spot 
§ After demodulated, a 45x45 pixel AOI is taken at the beam spot  
§ Phase value is averaged over that area - call this phase of system 
o A calibration file is loaded  
§ This file contains data from a diffused image of a sheet of paper binned at 
the specified parameter 
§ Demodulated as well 
o Calibration amplitude  
§ Calibration file * max(beam spot amplitude) / Calibration file amplitude at 
beam spot location 
o Calibration phase  
§ Calibration file - Calibration file amplitude at beam spot location + phase 
of system 
o Calibration intensity (DC)   
§ Same method as calibration amplitude 
• Raw finger data is demodulated into its amplitude in phase  
o Demodulation steps  
§ 16 images at 1 pixel will look like a sinusoid 




§ This results in a complex number (abs- amplitude, angle(M)*180/pi+180) 
o Resulting calibrated images  
§ Amplitude  
§ 1/F*(Ameasure/Acal) 
§ F = 9.437 
§ Similarly with intensity (DC) 
§ Phase  
§ PHImeasure-PHIcalibrate 
§ However if PHI<0 then add 360 to it 
§ PHI will be between 0 and 360  
To change a batch file: 
chmod a+x Filename.sh  
  
  234 
Appendix B 
 
Publications Resulting from This Work 
 
PATENTS 
• A.H. Hielscher, Y. Li, A. Bur, M. Flexman, J. Masciotti, C.J. Fong, Systems and methods for 
dynamic imaging of tissue using digital optical tomography, 20100292569 (2010). 
• A.H. Hielscher, and C.J. Fong, Imaging interfaces for full finger and full hand optical 
tomography, 20150150458 (2015). 
• A.H. Hielscher, and C.J. Fong, Dynamic diffuse optical spectroscopic measurement system 
for monitoring blood perfusion, (Application filed - 2016). 
JOURNAL PAPERS 
• C.J. Fong, J.W. Hoi, L. Geller, H.K. Kim, J. Wu, M. Garzon, A.H. Hielscher, 
“Assessment of Infantile Hemangiomas Using a Handheld Wireless Diffuse Optical 
Spectroscopic Device,” Pediatr. Dermato., 34, 3, (2017). 
• M.L. Flexman, H.K. Kim, R. Stoll, M.A. Khalil, C.J. Fong, A.H. Hielscher, “A 
wireless handheld probe with spectrally constrained evolution strategies for diffuse 
optical imaging of tissue,” Rev. Sci. Instrum. 83, 033108 (2012). 
• M.L. Flexman, M.A. Khalil, R. Al Abdi, H.K. Kim, C.J. Fong, E. Desperito, D.L. 
Hershman, R.L. Barbour, A.H. Hielscher “Digital optical tomography system for 




• C.J. Fong, J.W. Hoi, H.K. Kim, L. Geller, N. Antonov, M.L. Flexman, M. Garzon, 
A.H. Hielscher, “Infantile Hemangiomas Assessment with a Handheld Wireless Near-
  235 
Infrared Spectroscopic Device,” Biomedical Optics OSA Technical Digest, Miami 
USA, (2014). 
• C.J. Fong, L. Geller, J.W. Hoi, M.L. Flexman, C. Lauren, H.K. Kim, M. Garzon, A.H. 
Hielscher, “A Near-Infrared Spectroscopic Handheld Wireless Device for Assessing 
Infantile Hemangiomas,” Britton Chance Centennial Symposium on Metabolic 
Imaging and Spectroscopy, Philadelphia, PA. (2013) 
• C.J. Fong, M.L. Flexman, J.W. Hoi, L. Geller, M. Garzon, H.K. Kim, A.H. Hielscher, 
"A handheld wireless device for diffuse optical spectroscopic assessment of infantile 
hemangiomas ", Proc. of SPIE 8578 (2013). 
• M.L. Flexman, M.A. Khalil, C. J. Fong, R.M. Al Abdi, R.L. Barbour, B. Reig, D. 
Hershman, E. Desperito, A.H. Hielscher, "Optical tomographic imaging of the 
hemodynamic response to a breath hold in breast cancer patients," Proc. SPIE 7896, 
78962J (2011). 
• Y. Li, A. M. Bur, C.J. Fong, M.L. Flexman, R.A. Abdi, R.L. Barbour, A.H. Hielscher, 
“Design of a Digital Optical Tomography System for Dynamic Breast Imaging,” 
Biomedical Optics OSA Technical Digest, BSuB5 (2010). 
 
